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Abstract 
 
The purpose of this project was to determine the interaction between dietary protein and the 
gut microbiome in the production of genotoxic metabolites, with a particular focus on the 
poorly characterised metabolite 4-cresol.  
 
The thesis describes, in the first instance, data from a large human observation study (n=205 
healthy Omani adults). In which dietary records and urinary nitrogen excretion were used to 
estimate protein consumption in relation to urinary 4-cresol excretion. The study observed 
positive correlations between excreted 4 cresol and protein intake and then sought to explain 
the inter-individual variance in this by evaluating the influence of the colonic microbiota.  
 
Then the study focused on predicting 4-cresol exposures in the colon using in vitro gut 
fermentation models. The microbiota composition and metabolic profiles from these models 
are evaluated against different substrates, including comparisons of animal and plant proteins. 
We show that the total production of 4-cresol is dependent both on the host microbiota and also 
upon the dietary nitrogen source. The metabolite profiles of these fermentations may be used 
to predict DNA damage, with 4-cresol emerging as the greatest correlate of fermentation 
supernatant mediated genotoxicity.  
 
Finally, the study explored whether specific tumour isolates of F. nucleatum produce 4-cresol, 
or other genotoxins, that could drive intestinal carcinogenesis. At this stage the study is unable 
to conclude whether or not these isolates are passengers or drivers of intestinal disease. This 
work suggests the need for better models of the effects of the tumour environment on microbial 
growth. 
The most significant aspect of this thesis is that it evidences both the potential genotoxic 
contribution of 4-cresol in the colonic milieu, but also that urinary 4-cresol sulfate may be used 
as a biomarker of genotoxic colonic fermentation and thus, may be of use as a cancer risk 
endpoint in future dietary intervention study.  
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1. Gut bugs and colorectal carcinogenesis 
 
1.1 Abstract 
In this review we evaluate current thinking on the role of the gut microbiota in colorectal 
carcinogenesis. We argue that the microbiota plays an important role in colorectal 
carcinogenesis. Saccharolytic fermentation yields short chain fatty acids which may protect 
against adenocarcinoma formation, although its role in other tumour pathways is less certain. 
Some beneficial bacteria may also inhibit tumour formation through the suppression of 
inflammation and/or the enhancement of immune surveillance. In contrast, the collective 
proteolytic biota yield toxic metabolites including hydrogen sulphide, ammonia, cresol and 
phenol which enhance colonic genotoxicity and promote tumorigenesis. Further, we consider 
the tumour associated biota as a source of oncogenic peptides or inflammatory stimuli. The 
current literature supports interventions with pre or probiotics intended to optimise the balance 
of microbial activity in the colon, although efficacy in relation to carcinogenesis has not been 
demonstrated in man. Going forward, there is a need to integrate advances in microbiology 
with the different molecular pathways observed in colorectal carcinogenesis.     
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1.2 Introduction 
The comparative incidence of colorectal to oesophageal and stomach cancer is approximately 
30:1:2 [1, 2] making the colon the primary anatomical location of gastrointestinal tumours. A 
distinguishing characteristic of the colon is the relative abundance of a resident microbiota, 
with microbial populations present in much higher numbers than elsewhere in the GI tract.  
In gnotobiotic (germ free) mice, the colon architecture is visibly aberrant, there is an under-
developed immune system [3]. Furthermore, there is a reduction in epithelial cell 
differentiation , mediated potentially through impaired wnt signalling [4] leading to a 
functionally impaired epithelial barrier [5]. These models clearly demonstrate the importance 
of host-microbe interactions to normal host physiology. Further, the incidence of chemically 
induced tumours in mice models varies dependent upon the presence or absence of a functional 
microbiota [6] suggesting a role for the microbiota in neoplastic transformation. Experimental 
intervention studies in non-germ free animal models, with both probiotics and prebiotics have 
been shown to potentially suppress tumour development (reviewed previously) [7]. 
Epidemiological evidence indicates a protective role for dietary fibre in CRC in meta-analysis, 
which may be coupled to favourable microbial metabolism. Several meta-analyses show that 
consuming a high-fibre diet reduces CRC risk [8-10]. These strands of evidence point to roles 
for the microbiota in both tumour development and perhaps suppression. Understanding these 
host microbiome interactions in cancer is of continuing interest. The emergence of microbial 
culture independent technologies is beginning to bring some clarity to the complex interactions 
between the gut microbiota in neoplastic disease, the purpose of this review is to assess this 
current literature.    
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1.3 The healthy microbiota 
In a healthy host, the colonic microbiome is typically dominated at the phyla level by 
Bacteroidetes and Firmicutes, with a smaller but sizable abundance of Actinobacteria and 
Verrucomicrobia [11, 12]. The proportions of these phyla are not fixed, and different phyla 
and/or species may compete to fulfil distinct ecological niches, thus there is considerable inter-
individual variation between phenotypically similar and healthy individuals [13]. Furthermore, 
age, gender, genetics, diet, and disease may all influence the composition of the microbiome 
through the life-course, potentially to the benefit or detriment of the host.  
 
1.4 Colorectal cancer  
Genetic analysis of colorectal tumour samples reveals inter tumour pathogenic heterogeneity; 
at least 4 distinct common CRC molecular subtypes have now been established [14]. Broadly 
speaking, the descending colon and rectum demonstrate high levels of chromosomal instability 
(CIN) and a strong upregulation of wnt signaling [15], in contrast, the microsatellite instability 
(MSI) subtype shows a higher prevalence in the ascending colon as do cancers developing 
through the serrated sessile polyp (CIMP phenotype) pathway. Thus the favoured anatomical 
distribution of these tumour subtypes hint at distinct aetiologies [16]. From a developmental 
perspective, the right and left side of the colon have different embryological origins. 
Physiologically, these portions of the colon may be characterised as having distinct microbial 
activities, and distal and proximal colonocytes may be exposed to diverging metabolite 
exposures. Saccharolytic fermentation dominates in the ascending colon, where the high fluid 
volume make the luminal contents quite dilute [17]. Microbial metabolites, including short 
chain fatty acids (SCFA), may be absorbed, with water and electrolytes, in situ and through the 
transverse colon, such that the contents of the descending colon are more concentrated. In in 
4 
vitro models at least, microbial activity may be decreased in the latter portions of the bowel but 
proteolysis becomes favoured [18, 19]. Mechanisms have been proposed through which the 
gut microbiota may influence the cancer process including, via eliciting chronic inflammation 
in the host, potentially by disrupting the epithelial barrier [20], or through the production of 
genotoxic metabolites [21]. Similarly, mechanisms of protection mediated through a healthy 
microbiota are proposed [22], notably through the production of beneficial SCFA, and through 
the competitive inhibition of pro-carcinogenic genera. Mechanisms have similarly been 
proposed to explain the role of diet in CRC. However, to this point, these mechanisms and 
aetiologies have been poorly considered in relation to the diversity in tumour sub-type. 
 
1.5 The saccharolytic microbiota in protection against cancer 
Meta-analysis of prospective cohorts show dose-dependent protection against CRC with 
increasing dietary fibre intake, corresponding to a 10% decrease in risk per additional 10g 
consumed per day [9]. Suggested mechanisms underpinning this protection include the 
displacement of other foods from the diet, the co-linearity of fibre with phytochemical intakes, 
and decreasing colonic genotoxin exposure (via both hastening bowel transit times and the 
diluting of stool) [23, 24]. Of note, in the small intestine fibre chelates both iron and bile acids, 
and the delivery of these to the colon could feasibly increase genotoxicity in the gut.  
An additional protective mechanism involving the colonic fermentation of fibre has been well 
characterised; SCFA are produced as a consequence of microbial fermentation with fibre as a 
substrate. Predominantly acetate, propionate and butyrate are produced in ratios which may 
vary according to diet and microbial composition, but are often approximately 3:1:1 [25]. The 
SCFAs are natural ligands for free fatty acid receptors 2 and 3 (FFAR 2/3), which activate 
MAPK; this pathway is suggested to exert direct downstream anti-inflammatory and gut barrier 
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function enhancing responses [26, 27]. Conversely an increase in the permeability of tight 
junctions is associated with translocation of bacteria and a subsequent pro-inflammatory 
response which may represent an independent risk pathway for CRC [28].  
Of the colonic SCFAs, butyrate is the preferential energy source for normal colonocytes [29]. 
In addition, in healthy cells, butyrate may confer some protection against genotoxins via the 
induction of glutathione-S transferases (GST) [30]. Moreover, in colorectal cancer cell lines, 
butyrate has consistently been observed to induce cell cycle arrest, differentiation and apoptosis 
[31]. Tumour cells are inherently glycolytic; butyrate is therefore not oxidised and its 
accumulation inhibits the activity of histone deacetylases in favour of histone 
acetyltransferases, thus transcriptionally activating regions of the genome that were otherwise 
silent, and which favour apoptosis [32] Figure 1.1. In vitro these effects on tumour cells are 
concentration dependent; in vivo, there exists a concentration gradient through the bowel, with 
the highest concentrations likely to be present in the caecum where saccharolytic activity is at 
its greatest, and the lowest concentrations in the sigmoid colon/rectum where the upregulated 
wnt/canonical signalling subtype of cancer predominates [33, 34]. The potential relationship of 
butyrate in the caecum to the development of right side tumours is also not well explored; at 
high concentrations, butyrate provides the cell with an abundance of acetyl groups, which may, 
if not oxidised or shuttled into lipogenesis,  potentially be utilised by histone acetyltransferases 
[35] in a region of the colon characterised by a susceptibility to epigenetically sensitive serrated 
polyps and tumours.   
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Figure 1.1: The effects of butyrate accumulation on histone deacetylases in glycolytic neoplastic cells. Here two models of butyrate-induced 
histone acetylation mechanisms. In addition to acting as an HDAC inhibitor (at the left side), butyrate can act as an acetyl-CoA donor and 
stimulate HAT activity (at the right side).
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As a consequence of the observed biological responses to butyrate in vitro, dietary 
interventions have been explored utilising prebiotics to enhance the production of butyrate in 
situ. In in vivo models, with animals fed experimentally high doses of prebiotics, chemically 
induced tumour and development and pre-neoplasia can be suppressed Table 1.1. These 
interventions show greatest efficacy when the dietary prebiotic is given to the test animals prior 
to tumour induction. In addition to changing microbiota composition, post-tumour induction 
the prebiotics suppress inflammation which might help explain their anti-cancer action.   
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Table 1.1: Intervention studies in rodent models evaluating the anti-cancer effects of prebiotic supplements 
Intervention Rodents Carcinogenesis protocol Treatment Outcome Ref. 
Resistant starch in a 
colitis-associated 
colorectal cancer 
model 
4 week old 
Male 
sprague-
Dawley rats 
(n=100, 25 
per group)   
2 weeks of tests diets, then 2 
injections of Azoxymethane (AOM) 
(10mg/kg) 1 week apart, then 2% 
dextran sodium sulphate indrinking 
water for 7 days. Test diets 
maintained for a further 20 weeks 
20 week 
intervention with 
diets containing 
10% Resistant 
starch and/or 0.5% 
Green tea extract. 
 
 
 
RS and RS + GTE but not GTE diets 
decreased tumour multiplicity and 
adenocarcinoma formation compared 
to control diet (p<0.05). RS changed 
microbial composition, increasing 
Parabacteroides, Ruminococcus, 
Marvinbryantia and Bifidobacterium. 
RS increased SCFAs and decreased 
inflammation markers  
 
[36] 
Galacto-
Oligosaccharides 
and biomarkers of 
Colorectal Cancer 
in Wister Rats 
Six-week 
old male 
Wister rats 
(n=90, 15 
per group) 
40 mg/kg body weight 1,2-
dimethylhydrazine dihydrochloride 
(DMH) given twice a week for two 
weeks prior to intervention with 
(GalOS) 
16 week 
intervention diets 
with GalOS at doses 
equivalent to 4, 6 or 
GalOS reduced ACF formation, 
increased SCFA and decreased the 
activity of microbial β-glucuronidase, 
β-glucosidase, azoreductase and 
nitroreductase.  
[37] 
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 8 g per day in man 
by weight 
 
Inulin type fructans 
and a colitis 
associated murine 
model 
Five-week 
old male 
BALB/cAn
Nhsd mice 
(n-105, 15 
per group) 
Azoxymethane (10 mg/kg i.p.) plus 
aqueous DSS 2% for 4 days given 
either before or after (or both) the 
dietary intervention  
1 month inulin prior 
to induction then 8 
months without 
inulin  
Or 1 month inulin 
prior to induction 
then 8 months with 
inulin  
Or induction then 9 
months inulin 
 
Inhibition of colitis, and a reduction in 
polyp number with Inulin type 
fructans.  
Reduction in inflammatory markers 
was greater in animals fed the inulin 
pre AOM:DSS exposure than post 
exposure.  
[38] 
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High-amylose CS, 
high amylose-
octenyl succinic 
anhydride-modified 
CS, and a novel 
RS, high amylose-
stearic acid-
complexed CS. 
1/ 5-week-
old male 
F344 rats 
(n=90) 
2/ 5-week-
old male 
A/J mice 
(n=120) 
1/ Rats- Azoxymethane (15 mg/kg 
i.p) twice over two weeks 
2/ Mice- Azoxymethane (7.5 mg/kg 
i.p.) weekly for 4 weeks 
Control diet (corn 
starch) for two 
weeks, then 
induction with 
AOM, then 
transition to 
treatment diets for 
10 weeks 
Resistant starch did not inhibit ACF 
formation                                                 
 [39] 
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Dietary intervention studies in high-risk cohorts with cancer endpoints in man using high fibre 
diets and/or prebiotics have shown less efficacy. The Polyp Prevention Trial was a polyp 
recurrence dietary intervention study initially involving 1905 participants, enrolled on a high 
fruit and vegetable/low fat arm (~18 g fibre 1000 kcal-1) or a control diet. Based on intention 
to treat analyses, there were no observed differences in polyp recurrence at either 4, or 8 years 
[40]. Adherence to a long term high fibre intervention is difficult to achieve in a large cohort, 
in a post hoc analysis only 210 individuals from this study were identified as being ‘super 
compliant’, these individuals did show a 35% reduction in the risk of recurrence [41]. The 
production of butyrate was not quantified in this intervention study, and it is not possible to 
determine the contribution of microbial metabolism to this observation.   
In mixed culture in vitro gut fermentation models, resistant starch stimulates the growth of 
Ruminococcus bromii, Faecalibacterium prausnitzii, Eubacterium rectale and Eubacterium 
hallii and induces a significant increase in the concentration of butyrate in supernatant   [19, 
42-45]. It was selected therefore as a potential butyrate delivery vehicle for use in the CAPP1 
and 2 polyp prevention trials. The Colorectal Adenoma/Carcinoma Prevention Programme 
(CAPP 1) study involved a 30g day-1 dietary intervention with resistant starch (n=30), or with 
resistant starch plus aspirin (n=31) or with placebos. The study was conducted amongst very 
high risk adolescents with familial adenomatous polyposis (FAP) for period of 17 months. At 
the end of the study the resistant starch elicited a reduction in the length of the crypts of 
Lieberkühn relative to placebo but it did not suppress polyp formation (RR 1ꞏ05, 95% CI 0ꞏ73–
1ꞏ49). In follow up, CAPP2 used the same intervention arms to evaluate chemoprevention in 
individuals with Lynch syndrome over almost 4 years. Lynch syndrome has a slightly lower 
absolute risk of CRC than FAP, and the resultant colonic changes are characterised by 
mismatch repair as opposed to APC mutation; this evaluation of different subtypes of tumour 
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is a strength of the collective CAPP programme. However, again they observed no anti-cancer 
effects of resistant starch consumption in this genetically high risk cohort [46].  
A common critique of CAPP and indeed of all polyp recurrence studies is that subjects have 
already progressed quite far along the cancer former phenotype, and accordingly that 
chemoprevention needs to begin earlier.  
Evidence from short term dietary interventions using high fibre diets, or prebiotics, in healthy 
volunteers with the earlier, and poorly validated against neoplasia, end-point that is faecal 
genotoxicity, suggest an alternative butyrate-independent mechanism through which these 
saccharolytic fermentation substrates might protect against cancer Table 1.2. 
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Table 1.2: Human prebiotic dietary intervention studies with faecal genotoxicity as an endpoint.  
Intervention 
food 
Subjects  Protocol  Faecal water genotoxicity Reference 
 
β-glucan  in a  
bread product 
versus β-glucan  
free control 
bread 
 
Polypectomised 
patients (n = 69) 
recruited in 
Greece. (Mean age 
63) 
 
 
Double blind randomised control 
trial in which participants consumed 
breads containing 3 g/day β-glucan  
or control over 3 months   
 
Faecal water induced DNA damage assessed against 
Caco-2 cells via the comet assay decreased significantly 
in the treatment group 
 
[47] 
Wheat bran 
extract (AXOS) 
or oligofructose 
or placebo in a 
sucrose drink 
Healthy Belgian 
adults (n=19)  
 
Double-blind, randomized cross-over 
trial. 2 week intervention periods 
with 15g day in week 1 and 30 g day 
in week 2. 2 week washout period 
Both WBE- and oligo-fructose tended to reduce faecal 
water induced DNA damage in Ht29 cells compared to 
placebo but the effect was not quite statistically 
significant (WBE: p = 0.060; oligofructose: p = 0.057) 
(Comet assay) 
 
[48] 
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Polydextrose 
versus 
maltodextrin  
Healthy British 
adults  
(n= 31)  
 
Double blind placebo-controlled, 
crossover study polydextrose PDX; 
8g/d and placebo 8g/d, or control for 
three weeks then crossover after a 3 
week wash out 
 
Faecal water induced DNA damage assessed against Ht29 
cells (Comet assay) was significantly lower following 
consumption of PDX versus the maltodextrin 
[49] 
Galacto-
oligosaccharide
(GOS) in an 
orange juice vs. 
a juice control 
Healthy older 
British volunteers 
aged 50+,  (n=37) 
(Comet analysis 
n= 5)   
Randomised, double-blind, placebo-
controlled crossover trial with a juice 
containing 4 g GOS or a placebo. 
With a three week treatment and 
three week wash out. 
DNA damage against Ht29 cells assessed pre and post 
treatment for five volunteers (Comet assay). No change in 
faecal water genotoxicity reported, although the study 
may be underpowered.  
[50] 
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Saccharolytic ‘probiotic’ bacteria are also prepared as dietary supplements; and in rodent 
models of cancer, with animals fed experimentally high doses of the probiotic, they are shown 
to strongly inhibit tumorigenesis but with significant strain and species variability (Table 1.3).  
The probiotics most commonly demonstrating anti-cancer effects in experimental models are 
of the lactate producing lactobacillus genus; Lactobacilli do not directly produce large 
quantities of butyrate, they do temporarily shift the metabolic activity of the intestinal biota, 
through both competitive inhibition and the production of hydrogen peroxide and bacteriocins 
[51]. The activity of microbial enzymes implicated in the activation of intestinal carcinogens 
may therefore be attenuated; a double blind placebo control human feeding trial with combined 
Lactobacillus rhamnosus LC705 and Propionibacterium freudenreichii ssp. shermanii JS led 
to a reduction in the activities of both beta-glucosidase and urease [52] in recovered stool. 
Whilst a separate intervention, this time in elderly volunteers, with the same probiotic 
combination reduced the activity of faecal azoreductase [53]. 
The lactobacilli may also inhibit DNA damage directly, by binding and potentially 
metabolising genotoxins [54], or alternatively through the induction of the DNA repair [55] 
apparatus of the colonocytes. This anti-genotoxicity is not just shown against experimental 
carcinogens; the genotoxicity of human faecal samples may be significantly reduced by post 
collection in vitro incubation with viable probiotic bacteria [56].  
In randomised control trials supplemental lactobacilli and/or selected other probiotic strains 
reduce inflammatory markers in healthy volunteers [57-59] and may induce remission and 
maintenance of remission in ulcerative colitis [60, 61] though not in Crohn’s. This suppression 
of inflammation may be mediated through interaction with toll like receptors, and their 
subsequent influence on the intestinal barrier [62]. Lactobacilli mediated suppression of the 
pro-carcinogenic enzyme COX-2, which activates pro-inflammatory prostaglandins has been 
shown in in vivo and in vitro models of carcinogenesis [63, 64].   Conversely, in interesting 
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tumour xenograft or implantation models Lactobacillus casei BL23, Lactobacillus plantarum 
are shown to strongly suppress the subsequent development of initiated non GI tumours [65, 
66], presumably through activation of the immune response. Indeed enhancement of NK 
(Natural Killer) cell activity has been shown in dietary interventions in both animal models 
and in human volunteers [67-69]. Thus it seems that select probiotics downregulate systemic 
inflammation whilst potentiating immune surveillance through NK cell activity, thus targeting 
different phases of cancer development. We are unaware of studies demonstrating the anti-
cancer benefits of chronic probiotic ingestion on these systems. The observed responses may 
well be transient as the host adapts to novel intestinal antigen, with adaptation these anti-
cancer immune effects may or may not persist.  
As with the prebiotics, human data proving efficacy in cancer prevention is lacking. 
Epidemiological studies have not assessed probiotic intake in any detail, and to our knowledge, 
aside from those interventions showing amelioriation of inflammation in UC, there are no 
experimental intervention data in healthy volunteers with probiotics using a well validated 
colorectal cancer endpoint such as polyp recurrence. As with prebiotic intervention trials 
researchers have had to use poorly validated endpoints in probiotic feeding studies; for 
example, a 4 week randomised crossover trial in 17 volunteers with Bifidobacterium lactis (and 
resistant starch) induced no significant changes in crypt cell kinetics or DNA methylation 
patterns [70] in colonic biopsy material. In contrast, a 12 week dietary intervention with a 
synbiotic (Inulin, Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb12) decreased 
DNA damage in intestinal mucosa and reduced faecal water genotoxicity [71]. The animal 
experimental data are highly promising and well controlled dietary interventions in high cancer 
risk human cohorts with probiotics are now perhaps justified.   
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Table 1.3: Probiotic treatments in experimental models of tumorigenesis  
Intervention Rodents Carcinogenesis 
protocol  
Treatment  Outcome Reference 
Lactobacillus 
rhamnosus GG 
CGMCC 1.2134 
(LGG) 
 
 
 
64  four week 
old female 
Sprague Dawley 
rats (16 per 
treatment group) 
 
1,2-Dimethyl 
hydrazine 
(40 mg/kg i.p) 
weekly for 10 
weeks  
1 x109 CFU Lactobacillus 
rhamnosus GG CGMCC 1.2134 
(LGG) given daily from initiation 
of carcinogenesis through 25 
weeks. Or DMH control, LGG 
control, or -/-control.  
~40 % reduction in tumour incidence 
in L.GG/DMH group versus DMH 
group. And a relative suppression of 
TNFα, NF-kβ, iNOS and VEGF 
versus DMH group.  
[72] 
Activia(R) 
(Bifidobacterium 
animalis lactis 
DN-173 
010/CNCM I-
2494) 
70 Swiss (Mus 
musculus) male, 
sexually mature 
mice, in 
7 experimental 
groups (n = 10)  
Four doses of 1,2-
DMH (20 mg/kg 
b.w., ip), two 
doses per week. 
Given to relevant 
treatment arms 
during weeks 3 
Activia® groups received the 
Activia® product by oral gavage 
(0.1 mL/10 g b.w., vo) either just 
prior to initiation with DMH, just 
post initiation, or simultaneously 
with DMH, or pre and post 
initiation every day until the 12th 
The numbers of aberrant crypt foci 
were reduced by up to 79% in mice 
given the activia relative to DMH 
alone. The reduction in ACF was 
greatest in the mice pretreated with the 
probiotic, suggesting suppression of 
the initiating DNA damage.  
[73] 
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and 4 of the 
intervention 
week, plus relevant controls. 
Sacrifice at week 12.  
Lactobacillus 
rhamnosus GG ( 
ATCC 53013)  
Seven week old  
Apc Min/+ mice 
(n=24) 
Sporadic polyp 
development in 
this model, Ad 
libitum sulindac  
(180 ppm in 
drinking water) 
used as a 
protective control. 
1 × 108 CFU LGG in dried form 
as part of the experimental diet 
every day for 8 weeks  
LGG reduced the polyp burden in this 
genetically post initiation model, but 
not quite as well as sulindac.  
[74] 
      
Synbiotic 
preparation  LBB 
(oligofructose- 
Lactobacillus 
acidophilus, 
Bifidobacterium 
bifidum, and 
Three week old 
Sprague Dawley 
rats (n=40) ten 
per group  
Ampicillin 
(75 mg/kg), daily 
for five days,  
Relevant 
treatment arms 
then received 1,2-
DMH sub- 
cutaneously 
weekly for 10 
weeks  
LBB in chow at 0.9 g/ kg body 
weight daily equivalent to   
6.4 × 1011 cfu Lactobacillus 
acidophilus and 1.9 × 1010 cfu 
Bifidobacteria spp. for 23 weeks 
alongside initiation 
 
20% reduction in tumour burden with 
rats co-administered the probiotic 
versus the DMH alone. It also 
preserved epithelial integrity and 
suppressed β catenin.  
[62] 
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Bifidobacterium 
infantus) 
 
Lactobacillus 
casei BL23 
Or  L. lactis 
MG1363   
6 week old 
Balb-c mice 
(N=30-35 per 
group) 
Sub cutaneous 1,2 
DMH weekly for  
10 weeks 9 (20 
mg/kg bw) 
(1 × 109 CFU) Lactobacillus casei 
BL23  or  L. lactis MG1363 daily 
in chow beginning the day of first 
DMH injection.  
~40 % reduction in multiple plaque 
lesions in mice fed  Lactobacillus 
casei BL23  but not  L. lactis MG1363 
relative to DMH positive control.  
[65] 
      
Lactobacillus 
salivarius Ren  
Five-week-old 
male F344 rats 
(n=24, 8 per 
treatment group) 
Subcutaneous 1, 
2-DMH weekly 
for 10 weeks   
5 × 1010 CFU/kg bodyweight per 
day Lactobacillus salivarius Ren 
for 32 weeks beginning 2 weeks 
prior to DMH initiation  
 
~62 % reduction in tumour burden 
amongst the probiotic treated animals 
relative to DMH alone.   
[75] 
Lactobacillus 
plantarum  and  
Lactobacillus 
rhamnosus 
6-8 week old 
female BALB/c 
mice (n=30, 10 
per group) 
Tumour induction 
via subcutaneous 
implantation of  
CT26 tumour 
cells 
Probiotics administered via oral 
gavage at  1×108 CFU per day for 
two weeks prior to implantation 
and then weekly at 1×109 CFU for 
three weeks post implantation 
The mean implanted tumour volume 
was significantly suppressed in the 
mice fed L. plantarum, relative to the 
no probiotic group. It also 
significantly increased survival, L. 
[66] 
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rhamnosus did not have any effect on 
survival 
 
Lactobacillus 
plantarum 
(AdF10)  or 
Lactobacillus 
rhamnosus GG 
(LGG) 
Female sprague 
dawley rats in 6 
groups (n=6 per 
group) 
Subcutaneous 1,2 
DMH  30 mg/kg 
body weight twice 
a week for four 
weeks, then once 
a week for 16 12 
weeks 
 
Probiotics administered at 1010 
CFU per day for 16 weeks by oral 
gavage beginning at the same time 
as the tumour initiation treatment. 
50 % reduction in the tumour burden 
with the Lactobacillus plantarum 
relative to DMH control.  
34% reduction in tumour burden for 
the Lactobacillus GG 
[76] 
Lactobacillus 
salivarius Ren  
50 male F344 
rats aged 5 
weeks. (n=10 
per group) 
Subcutaneous 
1,2-DMH (30 mg 
Kg BW) once a 
week for 10 
weeks 
Probiotic given orally at high 
(1x1010 CFU per day) 
or low doses (5x 108 CFU per 
day) for two weeks prior to 
initiation and then continuously 
until week 15 
 
~35% reduction in aberrant crypt foci 
numbers in rats given either the high 
or low dose probiotic at week 15 
relative to DMH control  
 
[77] 
Lactobacillus 
delbrueckii UFV-
Eight week old 
male Swiss mice 
were distributed  
1,2-DMH  (25 
mg/kg) 
Each probiotic prepared at 3x108 
CFU mL-1, and given ad libitum 
Both the lactobacilli and the 
bifidobacterium reduced the numbers 
of ACF by ~50% relative to DMH 
[78] 
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H2b20 or 
Bifidobacterium 
animalis var. 
lactis Bb12; or a 
combination of 
the two, or  
Saccharomyces 
boulardii 
 
five treatment 
groups 
(n=10/group) 
subcutaneously 
beginning 1 week 
after first 
treatment with 
probiotic and then 
once weekly for 6 
weeks 
 
in the drinking water from one 
week prior to initiation through 14 
weeks 
control. Interestingly in combination 
they were not effective.  
Lactobacillus 
rhamnosus GG 
MTCC #1408, or  
Lactobacillus 
casei 
MTCC#1423, 
Lactobacillus 
plantarum MTCC 
#1407, or 
Sprague Dawley 
rats, (n=6 per 
group with 12 
treatment 
groups) 
1,2-DMH intra-
peritoneal (20 
mg/kg bw) 
weekly for 6 wk. 
1 × 109 CFU daily for 1 week 
prior to initiation then daily for 
six weeks   
Significant decrease in ACF formation 
with all probiotic regimens relative to 
DMH control. Notably L.GG induced 
a 99% reduction in ACF numbers   
[79] 
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Lactobacillus 
acidophilus 
NCDC #15 or 
Bifidobacterim 
bifidum NCDC 
#234 
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1.6 The proteolytic gut microbiota in colorectal cancer causation 
1.6.1 Proteolytic fermentation 
The epidemiological evidence implicating total protein intake in colorectal cancer is weak [80], 
there are however suggestions of differential risk according to protein source; plant protein 
consumption, from sources such as soy, may be associated with a decrease in risk [81] and 
animal protein intake, particularly from red and processed meat, associated with an increase in 
risk [82]. It has variously been proposed that the increased risk associated with animal protein 
intake is due to higher fat and haem intake, or that contaminants from processing or cooking 
of meat are the cause, or that meat is simply a proxy for an otherwise energy rich diet. More 
recently it has been suggested that animal proteins are a stronger stimulator for mitogenic 
hormones such as IGF-1 [83]. These mechanistic hypotheses remain generally poorly 
evidenced and somewhat neglect the potential involvement of the resident microbiota.   
With a western diet somewhere between 6 g and 18 g of protein per day is thought to reach the 
colon [84, 85]. Saccharolytic fermentation is favoured in the caecum, but as a substrate it can 
be quickly utilised. With decreasing availability of fermentable carbohydrate in the distal 
colon, there is a shift towards the production of proteolytic end products in this slightly more 
cancer prone location [86]. In in vitro mixed culture models of gut fermentation, the addition 
of protein to media increases the concentrations of an assortment of metabolites, including 
phenolic compounds, amines, ammonia and hydrogen sulfide, these metabolites can be 
leveraged as nitrogen sources for bacterial growth, or they may be taken up by colonocytes and 
transported into the bloodstream [87]; their accumulation in the colonic lumen is associated 
with increasing toxicity [21, 88].  
The amino acid composition of the protein substrate influences the overall composition of this 
potentially genotoxic fermentation supernatant. For example, methionine and cysteine may be 
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used as substrate by the sulfate reducing bacteria (SRB) (most notably Desulfovibrio, 
Desulfotomaculum, Desulfobacter, Desulfobulbus [89]), leading to the generation of H2S [89, 
90] Table 1.6.  Hydrogen sulphide inhibits butyric acid oxidation  [91-93], it increases cell 
proliferation in vitro [94] and is shown to be genotoxic [95]. In in vitro batch-culture 
fermentation with faecal inoculate, the rate of H2S production differs according to whether 
albumin or casein is used as a substrate [96]. In human observational studies the sulfate 
reducing bacteria may be associated with inflammatory bowel disease [97], and are putatively 
implicated in its pathogenesis through the ability of H2S to compromise barrier function [90, 
98]. In both animal and human dietary intervention, diets high in protein increase the recovery 
of sulfide in faeces [99].  
Additionally, fermentation of the aromatic amino acids leads to the production of phenols, 
indoles and 4-cresol. These are not well recovered in stool, but rather enter the hepatic 
circulation to be detoxified in the liver and eventually excreted in urine [100]. Studies have 
shown that with high protein intake, metabolites of 4-cresol and phenol appear in the urine  
[101]. Phenol and 4-cresol are toxins and may be associated with disease, however due to their 
low concentration in stool they have not been thoroughly investigated as contributors to the 
colonic genotoxic load. 
In contrast to the epidemiological data, the carcinogenicity of higher protein diets is 
consistently demonstrated, particularly in relation to colonic inflammation, in experimental 
animal models [102]. Higher protein dietary interventions in human volunteers do lead to 
increased excretion, in urine, of markers of amino acid fermentation, but the appearance of 
these metabolites in urine does not necessarily correlate with increased faecal genotoxicity 
[103, 104]. Colonic fermentation and absorption is dynamic, and stool can vary considerably 
in water content, therefore faecal samples may be poorly representative of colonic exposures; 
better biomarkers of cancer risk for human dietary intervention study are certainly needed to 
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bridge the gap between the lack of associations between protein intake and cancer in human 
subjects versus the mechanistic and animal experimental evidence to the contrary.      
1.7 Towards a colon cancer specific microbiota  
Perhaps the first specific bacteria implicated in the pathogenesis of colon cancer was 
Streptococcus gallolyticus (Sg). Endocarditis and bacteraemia associated with SG infection is 
associated with increased risk of colorectal neoplasia in observational studies [105, 106]. 
Similarly, case-control studies show an increased risk of colorectal cancer associated with 
serological evidence of previous exposure to (Sg) antigen [107-109]. Faecal samples from 
volunteers with colorectal cancer were found to be more likely to score positively for Sg, and 
tumour tissues show higher Sg counts than adjacent normal mucosa [110].  
There is also good experimental evidence demonstrating the carcinogenicity of Sg; pre 
exposure of cultured HCT116 cells to Sg resulted in greater tumour mass in a mouse xenograft 
model, whilst oral gavage with Sg increased the tumour burden in an AOM mouse model of 
tumourigenesis [111, 112], From a mechanistic perspective the exacerbation of tumour 
development in the presence of Sg may be mediated via inflammation, indeed Abdulamir et 
al., [113] observed a higher expression of Nf-KB and IL-8 mRNA in tumour tissues from 
individuals seropositive for Sg antibodies versus Sg negative patients, indicating increased 
inflammation in the tumour environment which may influence cell turnover. Alternatively Sg. 
might also influence cell behaviour independently of inflammatory pathways, Kumar et al., 
[114] observed increased cell proliferation in cultured colon cancer cell lines (HT29, HCT116 
and LoVo) exposed to Sg and demonstrated that this was driven by an increase in nuclear β-
catenin.  
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The emergence of Helicobacter pylori as a risk factor in gastric cancer in the 1980s meant that 
it too has been considered as a candidate in CRC causation. Routine clinical screening for 
Helicobacter pylori infection facilitates opportunistic observational study into its role in CRC; 
a 2013 meta-analysis of 28 of these studies suggested an approximate 40% increase in CRC 
risk with H. pylori infection [115]. Separately Wang et al. analysed 27 studies to conclude that 
H. pylori infection increases risk of colonic adenocarcinoma by ~24%, adenoma by ~87%, 
tubular adenoma by 3 fold and villous adenoma by 2 fold [116], thus implying a role for H. 
pylori early in the disease process. In the stomach, strains of H. pylori secrete CagA which can 
be absorbed by the mucosa locating itself inside the cell membrane and presenting as antigen 
thus initiating systemic inflammation. Independently the CagA protein also aberrantly activates 
SH2 and the Ras-Erk MAP kinase signalling pathway [117] thus driving gastric carcinogenesis 
via different mechanisms. The potential mechanisms of action of H. pylori in the colonic 
mucosa have not been well investigated, however. Curiously Sonnenberg et al. recently 
reported an inverse association between H. pylori infection and the incidence of serrated polyps 
in a large US cohort [118]. In a DSS-induced murine colitis model CagA+H. pylori infection 
significantly increased the number of dysplastic lesions observed at 48 days relative to DSS 
alone, via a process seemingly mediated through deregulated wnt signalling [119]. Whilst 
further mechanistic work is needed, the findings to date associate H. pylori infection with the 
adenocarcinoma pathway of CRC. In northern European populations about a third of the 
population screen positive for gastrointestinal H. pylori, levels of infection may be much higher 
in the developing world; given its already well established role in gastritis and gastric neoplasia, 
it may be singled out as a desirable target for elimination from the intestinal tract.  
Other bacteria capable of capable of secreting oncogenic peptides include Escherichia coli and 
Bacteroides fragilis. Raisch et al. studied the abundance of E. coli by phylogenetic subgroup 
in mucosal biopsies from colorectal cancer versus mucosal samples from patients with 
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diverticular disease as a control. They report a much higher abundance of E. coli from the 
phylogenetic subgroup B2 in the cancer specimens (positively identified in 73.7 % of cancer 
specimens versus 41.9 % of controls) [120]. The phylogenetic B2 sub group is home to 
enteropathogenic E. coli strains; it may also be characterised by the presence of genes encoding 
cyclomodulins and genotoxins such as colibactin. Cycle inhibiting factor (CIF) is a 
cyclomodulin capable of blocking mitosis independently of DNA damage, at least in vitro 
[121]. Colibactin is a poorly characterised genotoxic polyketide-peptide synthesised in the gut 
by polyketide synthase (PKS) positive Escherichia coli [122]. These PKS positive bacteria 
have been identified in up to 20 % of healthy volunteers. In animal models of carcinogenesis, 
exposure to PKS may induce DNA strand breaks [123]  and tumour formation [124, 125]. 
Transient infection of cultured epithelial cells with PKS positive E.coli induces chromosomal 
aberrations and increases the mutation frequency rate [123], in addition to influencing cell 
cycle behaviour [126]. Further, repeat infection of cultured intestinal cells with non-pathogenic 
E. coli abundant in the intestinal lumen are also shown to influence cell behaviour, enhancing 
cell survival and upregulating the B catenin apparatus consistent with a carcinogenic 
phenotype.   
Strains of Bacteroides fragilis produce a metalloprotease toxin (BFT) which has been 
associated with inflammatory bowel disease  [127] and which may be more abundant in 
samples from cancer patents than in controls [128] . Importantly an increased presence of BFT 
producing Bacteroides fragilis has been associated with pre-cancerous lesions suggesting its 
involvement early in the cancer pathway [129] . Chung et al. inoculated APCMin mice with B. 
fragilis to promote tumorigenesis via an inflammatory cascade involving Stat3 and Nf-kB 
[130], which might explain the ability of BFT+ B. fragilis to induce colitis in gnotobiotic mice 
[129]. This pro inflammatory effect suggest a tumour promoting role for BFT.   
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Recent advances in culture independent technologies for characterising microbial communities 
have facilitated a shotgun approach towards the identification of tumour specific microbes 
through comparisons of tumour tissue and adjacent healthy tissues in the same individual 
(Table 1.4), or by comparing healthy mucosa or faecal samples between cases and controls, 
(Table 1.5 and 1.6) respectively. These approaches identify microbial communities which may 
be preferentially successful at utilising the tumour environment; it does not, of itself, well 
evidence causality. The tumour environment may be characterised by a disruption to the 
colonic stream, aberrant mucin production coupled to a depleted mucosal barrier, 
inflammation, potentially blood, and host derived lactate as a glycolytic metabolic by-product. 
Specialists within the biota could well thrive in this niche, however the potential of a tumour 
associated microbiome to influence the carcinogenic process is worthy of investigation. That 
said there is little consensus across studies, bacteria within the genera Prevotella, Bacteroides, 
Roseburia  and Faecalibacterium are variously reported as being enriched in tumour tissue 
relative to normal mucosa, whereas between individuals Escherichia coli, Actinomyces 
odontolyticus, Bacteroides fragilis, Clostridium nexile are reported as being more abundant in 
cases but not consistently so across studies.  Few of these studies to date have taken into account 
or had the power to well consider the microbiota by CRC subtype or location, and given the 
common methodologies there may now be scope for meta-analysis, the one stand out candidate 
tumour associated microbe emerging from these analyses appears to be Fusobacterium 
nucleatum.   
Fusobacterium nucleatum are most commonly associated with the oral mucosa but they have 
been identified in, and cultured from, intestinal tumours [131, 132] Table 1.4. Evidence is 
emerging to suggest that this species may contribute to the tumour process. Yu et al. report an 
increased likelihood of tumour recurrence post treatment with a positive score for F. nucleatum 
[133]. Several groups report attenuation of the host immune response with the presence of F. 
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nucleatum [134-136], others suggest that these bacteria may increase cell proliferation and 
enhance wnt signalling through diverse cell mediated interactions [137-139]. Conversely, in 
recent work Amitay et al. were unable to identify F. nucleatum in pre-neoplastic adenomas, 
suggesting that this strain is more a passenger in advanced disease than a driver of early disease 
[140]. However others suggest F. nucleatum may be more strongly associated with serrated 
adenomas [141, 142] which are often characterised by aberrant CPG island methylation and 
microsatellite instability, and analysis of colonic tissue from patients with both ulcerative 
colitis and colorectal cancer shows hyper-methylation associated with the presence of 
fusobacteria [135].  
Experimental proof of the potential role of F. nucleatum in human carcinogenesis is lacking, 
and a satisfactory mechanistic explanation is still needed [139]. In one experimental study 
APCmin/+ mice gavaged with F. nucleatum, developed significantly more tumours than non-F. 
nucleatum treated controls, and in the same study, colorectal cancers were more likely to form 
tumorous grafts after injection into nude mice when the cells were pre-treated with F. 
nucleatum [139]. In contrast, Tomkovich et al. noted no increase in either inflammation or 
cancer risk in tumour susceptible APCMin/+;Il10−/− and APCMin/+ germ free animals colonised with 
F. nucleatum [124, 143] suggesting involvement in neither inflammation nor Wnt stimulating 
pathways of tumour promotion. 
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Table 1.4: A comparison of the adherent mucosa in colorectal cancer tissue versus adjacent normal mucosa    
Study population Characterisation Method Findings Reference 
 
46 CRC patients  
 
 
Pyrosequencing V1-V3 region of 
bacterial 16 S rDNA 
 
Lower microbial diversity in tumour versus non 
tumour tissues from the same patient. 
The cancerous tissue had higher numbers of Bacilli 
and Ochrobactrum and lower numbers of 
Phascolarctobacterium, Ruminococcaceae and 
Feacalibacterium than the adjacent normal tissue.  
 
 
[138] 
6 CRC patients 454 pyrosequencing V1-V3 region of 
bacterial 16 S rDNA 
Significant inter-individual differences in the normal 
mucosal microbiome and between normal and tumour 
tissues. Fusobacterium, Roseburia and 
Feacalibacterium were enriched in tumour specimens 
whilst the Enterobacteriaceae, Citrobacter, Shigella, 
Cronobacter, Kluyvera, Serratia and Salmonella spp. 
were decreased in the CRC samples relative to the 
normal tissue 
  
[144] 
65 colorectal 
cancer patients 
V4 16 S RNA pyrosequencing At the phylum level, the relative abundances of 
Bacteroidetes. Proteobacteria and Fusobacteria were 
[145] 
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more abundant in the tumour than the adjacent 
mucosa. 
At the genus level Fusobacterium, Prevotella, 
Alloprevotella, Porphyromonas, Peptostreptococcus 
and Parvimonas were enriched in the tumor tissue. In 
contrast, the relative abundances of the Bacillus, 
Lactococcus, Acinetobacter, Pseudomonas and 
Parabacteroides genera were significantly lower in 
tumour than in the adjacent non-tumour tissue 
 
52 CRC patients 
without 
symptoms of 
bacteraemia 
 
qPCR targeted at Streptococcus 
gallolyticus -specific primers 
 
33% of tumours versus 23% of matched normal colon 
tissues were Sg-positive  
[146] 
NGS 9 colorectal 
cancer patients.  
qPCR in samples 
from 95 patients 
454 sequencing of the 16S gene, 
qPCR pyrosequencing and 
quantitative  
PCR specific to pan-Fusobacterium 
and Fluorescent in situ hybridisation 
with the Fusobacterium 
Fusobacterium was the most differentially abundant 
taxon in colon tumour versus normal specimens via 
NGS.  
Fusobacterium nucleatum identified as the sub 
species most commonly enriched via qPCR. 
 
[136] 
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targeted probe (pB-00782) 
 
148 tumours and 
128 adjacent 
matched normal 
tissues from 
patients without 
bactereamia 
qPCR targeted using a Streptococcus 
gallolyticus -specific primer 
4% of tumour tissues versus 47% of the normal 
tissues were positive for Sg 
[77] 
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Table 1.5: Comparisons of the adherent mucosa microbiota in normal tissue from cancer patients versus mucosa from healthy controls 
Study population Characterisation Method Findings Reference 
 
46 CRC patients  
56 controls 
 
Pyrosequencing V1-V3 
region of bacterial 16 S 
rDNA 
In swabs taken from the normal mucosa Porphyromonas), 
Fusobacterium, Peptostreptococcus, and Mogibacterium were more 
in CRC patients, whereas in the control patients Faecalibacterium, 
Blautia, and Bifidobacterium were more abundant.  
 
[138] 
6 CRC patients 
6 serrated adenoma patients 
6 advanced colorectal 
neoplasia patients 
6 controls 
 
16S RNA 454 
pyrosequencing 
The normal mucosa from the control group was characterised by a 
predominance of Proteobacteria with significant numbers of 
Firmicutes and smaller numbers of Bacteriodetes and Actinobacteria. 
The normal mucosa of the CRC group was less diverse with a very 
dominant Proteobacteria The ACN group had a much higher 
abundance of fusobacteria than controls or CRC.  
The serrated adenoma group showed a slightly higher abundance of 
Bacteriodetes and Firmucutes. 
At the genus level the proportion of Eschericia coli was markedly 
increased in the mucosa of CRC patients. 
[142] 
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Table 1.6:  Comparisons of the microbiota in stool samples from healthy volunteers versus cancer patients 
 
Study population Characterisation Method Findings Reference 
 
 
46 CRC patients  
56 controls 
 
 
Pyrosequencing V1-V3 
region of bacterial 16 S 
rDNA 
 
The abundance of Erysipelotrichaceae, Prevotellaceae, 
Coriobacteriaceae (Collinsella), Peptostreptococcus, and 
Anaerotruncus (Clostridiales) was higher in cases than in the 
controls. 
 
[138] 
    
46 CRC patients 56 
controls 
454 pyrosequencing of the V3 
region of the 16S ribosomal 
RNA gene 
At the phylum level there was a slightly higher proportion of 
Firmicutes and a lower proportion of Bacteriodetes in the CRC 
patient stool samples relative to control. 
At the genus level Enterococcus, Streptococcus Escherichia/Shigella 
were enriched in the samples from the CRC patients 
 
[147] 
144 carcinoma patients 
73 serrated polyp patients 
323 polyp-free controls  
16S rRNA sequencing Lower diversity microbial diversity in CRC with reductions in the 
proportions of Ruminococcaceae, Clostridiaceae, and 
Lachnospiraceae and increases in the numbers of Actinomyces and 
Streptococcus 
 
[148] 
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28 patients with malignant 
gastrointestinal disease 
27 with non- malignant 
disease 
50 controls 
Identification of S. bovis (sic 
Galloctycus) by traditional 
culture methods 
(poorly defined) 
The prevalence of S. bovis in stool samples from patients with 
malignant disease 36% 
In non-malignant gastrointestinal disease 18%, and in healthy 
controls 0% 
[149] 
 
50 colorectal adenoma 
patients 
9 carcinoma patients 
49 healthy controls 
 
T-RFLP of all samples for 
genus level characterisation. 
NGS using V3–V4 region of 
16S rDNA for species level 
characterisation in six CRC 
cases versus six controls 
 
At the genus level cancer patients had higher numbers of 
actinomyces, fusobacteria, haemophilus and lower numbers of 
slackia than controls.   
At the species level, cancer patients had higher numbers of 
Actinomyces odontolyticus, Bacteroides fragilis, Clostridium nexile, 
Fusobacterium varium, Heamophilus parainfluenzae, Prevotella 
stercorea, Streptococcus gordonii, and Veillonella dispar 
 
 
[150] 
47 CRC case subjects and 
94 control subjects 
16S rRNA genes, sequenced 
by 454 FLX technology 
CRC case subjects had decreased overall microbial community 
diversity, a lower relative abundance of Clostridia (68.6% vs 77.8%) 
and an increased abundance of Fusobacterium 
[151] 
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1.8 Conclusions 
Colorectal cancer constitutes at least four distinct molecular subtypes of disease, the precise 
roles of bad diet, unfortunate genotype, chance, an unfavourable microbial metabolome, and 
the presence of specific detrimental microorganisms, in the aetiology of these diseases is far 
from resolved. Here we have considered current evidence regarding the involvement of the 
intestinal microbiota. We have presented evidence to show that constituents of the microbiome 
may be oncogenic and/or protective. There are several candidate ‘oncogenic’ bacteria which, 
if appropriate technologies were available, might be selectively targeted for elimination from 
the gut due to their roles in inflammatory disease as well as cancer. Interventions with 
probiotics show promise as a cancer prevention approach, at least in experimental models, 
although human trials are needed. Pressingly there is a need to better understand the unique 
drivers of carcinogenesis in different colonic compartments; microbial activities that are 
potentially protective in recto-sigmoid disease may not be beneficial in the caecum and vice 
versa. A more precise grasp of these aetiologies would better enable dietary or 
chemoprevention strategies to optimally balance the microbiota through the gut. Better 
experimental models of the now well-defined colorectal tumour sub-types would help. Other 
important research questions remain; driver-passenger relationships are not well determined 
for the tumour associated microbiome. The particular carcinogenicity of red and processed 
meat is still inadequately explained from a mechanistic perspective given the similarity in 
composition with white meats and fish. And, despite the emerging field of nutrigenetics, there 
is a relative absence of studies integrating the microbiota, genetics and diet.  
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 1.9 General hypothesis  
4-cresol, derived from the gut microbial breakdown of meat is a carcinogen. Variation in the 
functionality of the microbiome is modifiable by dietary substrates and can modulate host 
exposure to this carcinogen and therefore influence the risk of CRC. 
Objectives: 
 
1. To identify healthy free living upper and lower quartile 4-cresol excretors 
2. To characterise and determine differences in their dietary exposures and gut 
microbiome composition 
3. To compare microbial fermentation profiles from high and low excretors in simulated 
human gut models in order to: 
a/ assess the likely exposures to 4-cresol for the gut epithelia.  
b/ study the potential effects of nutrients and prebiotics on the microbiota and 
the production of 4-cresol in vitro.  
c/ assess the effects of faecal slurries generated from in vitro models on the 
cancer process 
 
1.10 Rationale 
Diet influences the metabolic activity of the gut microbiota with the potential to affect 
colorectal cancer. High levels of protein reaching the gut may increase the genotoxic load of 
the colonic milieu. Specific fermentation metabolites may be utilised as biomarkers of 
genotoxicity.  
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1.11 Thesis structure 
Firstly, the study has considered the current literature on the role of the gut microbiota in 
colorectal cancer.  
This thesis then describes the relationships between diet and microbial metabolism in an 
Omani cohort. The aim of the Omani study was to identify the dietary intake of and physical 
activity levels of in Omani population and consider associations with CRC risk.  
Methods: A cross sectional study was carried out on 205 healthy study subjects (91 males and 
114 females). Participants were aged between 19-60 years. Validated semi-quantitative food 
frequency questionnaires were collected. Anthropometric measurements and physical activity 
were assessed. Blood pressure was recorded and serum analysed for biochemical analysis. 24 
hours urine samples were used to measure 4-cresol levels using nuclear magnetic resonance 
(NMR) analysis. Within faeces the microbial population of selected volunteers was ascertained 
using fluorescent in situ hybridisation attached to flow cytometry (flow FISH). 
Afterwards, the study report on the in vitro fermentation of different protein sources and 
subsequent production of metabolic end products which were subsequently tested for 
genotoxicity in HT29 and Caco-2 cell lines models. We hypothesised that microbial 4-cresol 
is a colonic carcinogen and set out to model potential exposures in the colon and the effects 
of these exposures on colonic cells.   
Methods: Batch culture fermentations with faecal inoculate were used to determine the 
synthesis of 4-cresol and other metabolites in response to various substrates. The microbiota 
was monitored and fermentation supernatants were evaluated for genotoxicity and the 
independent effects of 4-cresol on colonic cells were studied in vitro. 
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Finally the study explore whether specific tumour isolates of F. nucleatum produce 4-cresol 
and or other genotoxins that could drive intestinal carcinogenesis. Here, the aim was to assess 
the genotoxicity of culture supernatants from F. nucleatum samples isolated from CRC tissue 
and further, we assess the influence of these supernatants on the cell cycle activity of the 
intestinal HT29 cell line. 
Methods: 18 F. nucleatum strains were isolated from tumour tissue and anaerobically cultured 
in a modified tryptic soy broth for 24 hrs. For the purity of these strains, these were isolated on 
selective agars, and the type strain were identified. The isolated fermentation supernatants were 
analysed for metabolite composition, and then used to treat HT29 cells, with assessment for 
DNA damage via comet assay, cells proliferation via DAPI, and cell cycle kinetics via 
propidium iodide staining with flow cytometry.  
 
1.12 Impact 
This work will establish gastrointestinal concentrations of a meat related carcinogen; it will 
shed new light on mechanisms linking diet and the gut microbiota to CRC. It may justify 
experimental and later, public health, interventions designed to beneficially modify the 
composition of the microbiota and/or sources of dietary protein for CRC prevention.  
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2. General Methodology 
 
This chapter provides an overview of all the methods used to investigate the research aims/ 
objectives. The merits of specific procedures or techniques used have been considered. This 
will aid in critically evaluating the overall validity and reliability of the data generated. 
2.1 Food frequency Questionnaire (FFQ) 
 
The semi-quantitative food frequency questionnaire (FFQ) consists of lists of foods and 
beverages with response categories to indicate usual frequency of consumption over the time 
period queried (e.g. times per day: daily; weekly and monthly). It is also used to obtain 
information on portion size; as standardised portions or as a choice of listed sizes [1]. 
Subsequent estimates for nutrient intake can be calculated via computerised software programs 
that multiply the reported frequency of each food by the nutrient quantities in the serving. FFQ 
are also used to describe a population's intake in cross-sectional studies of large numbers of 
individuals (e.g. 100 or more). The questionnaire can be self-administered, face-to-face 
interviewer administered or administered within a telephone interview; the questions are based 
around a given time period (e.g. in the past 6 months or 1 year) with the aim of capturing 
habitual intake [2]. 
Food frequency questionnaires are one of the most commonly used tools in epidemiologic 
studies to assess long-term nutritional exposure, they are less expensive than food records or 
diet recalls; can be easy for literate subjects to complete in a self-administered form and are 
suitable for very large studies and to examine the associations between diet and health or other 
variables. However, there are some disadvantages in the FFQs which are: the method relies 
upon the volunteer’s memory and is less sensitive to measures of absolute intake for specific 
nutrients [3]. However, it is worth noting that several studies have used FFQs, such as European 
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Prospective Investigation of Cancer (EPIC) [4], Scottish Collaborative Group-MRC Food 
Frequency Questionnaire (SCG-MRC/FFQ). There are several methods that can be used to 
determine the habitual intake such as diet history, diet recall typically 24-hours, 4-day food 
record and weighed food records. However, we did not use these methods because they are 
costly to administer, analyse and require a trained interviewer to ask the volunteer to remember 
in detail all the food and drink they consumed. They are, however, accurate and feasible method 
to measure food intake for small group of people [5]. 
 
2.2 Cobas C111 analyser 
 
The cobasc111 instrument is a continuous random-access analyser intended for determination 
of clinical chemical and electrolyte parameters in serum, plasma, urine or whole blood [6, 7]. 
It is optimised for small throughput workloads of approximately 50 samples per day, utilising 
photometric analysis with an optional unit for analysis with ion selective electrodes (ISE). This 
machine has been use for the blood biochemical analysis in the study; the advantages of this 
machine are as listed below: 
1. Flexible sampling and high analytical performance  
2. Efficient operation and the data management is good 
3. Disposable cuvette which allows for easy loading and removal 
4.  High reliability, low maintenance and has very high safety standards 
5. The touch screen process-driven software with reagent and sample 
barcode entry adapts to users of different skills and access levels 
6. It can accommodate about 50 samples at one run which enabling continuous sample 
placing and removal during operation. 
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2.3 Gas chromatography–mass spectrometry (GC-MS) 
Gas chromatography - mass spectrometry (GC/MS) is a core analytical method for 
metabolomics and has been used as a platform in non-targeted analysis, especially for 
hydrophilic metabolites Figure 2.1. The method is based on quantitative analysis of the 
concentration profile of free, low molecular mass metabolites, which can provide data relevant 
to metabolic disorders and colorectal cancer [8-10]. Volatile analysis was carried out by 
automated headspace solid-phase microextraction (SPME) (75 µm divinylbenzene/Carboxen 
on polydimethylsiloxane) followed by gas chromatography-mass spectrometry (GC-MS), 
using an Agilent 110 PAL injection system and Agilent 7890 gas chromatograph with 59705C 
mass spectrometer (Agilent, Santa Clara, CA). A 30m fused silica capillary column was used 
with helium as the carrier gas. The mass spectrometer operated in electron impact mode with 
an electron energy of 70 eV, scanning from m/z 20 to m/z 280 at 1.9 scans/s. 
 
Figure 2.1: Typical gas chromatography-mass spectrometry.  
 
GC/MS provides a highly efficient, highly sensitivity method with good peak resolution. The 
method is reproducible and there are extensive databases for identification of metabolites [11]. 
As such, this method was used within the thesis. 
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2.4 Gas chromatography (GC) 
Gas chromatography is a common method used in analytical chemistry for separation and 
analysis of compounds that can be vaporised without decomposition Figure 2.2. The principle 
of it, is to run volatile samples with gaseous mobile phase and a stationary phase [12]. Velocity 
of the compound through the column depends upon affinity for the stationary phase, and the 
interaction of partitioned components with the gas phase. These differences lead to different 
retention times between compounds. The advantages of this method are: high resolution power 
compared to the other methods High performance liquid chromatography (HPLC). The method 
is very sensitive and highly accurate allowing detection and quantification of hundreds to 
thousands of molecules in a single measurement [11]. The analysis of the samples is quick and 
only a small volume of sample is required. 
 
Figure 2.2: Fundamental of gas chromatography (GC). Figure adapted from [13] 
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2.5 The single cell gel electrophoresis (comet assay) 
The comet assay (single-cell gel electrophoresis) is a simple and sensitive method for 
measuring deoxyribonucleic acid (DNA) strand breaks and repair at individual cell level in 
eukaryotic and prokaryotic cells in low-melting point agarose [14].This assay has the potential 
to play an important role not only in the understanding of some of the fundamental aspects of 
human biology but also can be helpful in many practical ways Figure 2.3. 
 It was first described by Singh et al. in 1988 [15]. The idea was to combine DNA gel 
electrophoresis with fluorescence microscopy to visualise migration of DNA strands from 
individual agarose-embedded cells. Then the embedded cells on a microscope slide are lysed 
with electrophoresis buffer to form nucleoids containing supercoiled loops of DNA linked to 
the nuclear matrix. The DNA is allowed to unwind under alkaline conditions. Following the 
unwinding, the DNA undergoes electrophoresis, allowing the broken DNA to migrate away 
from the nucleus. After staining with a DNA-specific fluorescent ethidium bromide dye, the 
gel is read for amount of fluorescence in head and tail and length of tail. Negatively charged 
DNA breaks migrate toward the anode during electrophoresis; whilst undamaged DNA remains 
in a tightly wound ball, thus there would be no migration. The broken ends are called the comet 
tail, which is relative to the head reflects the extent of DNA that has migrated from the central 
cell mass. DNA repair can be monitored by incubating cells after treatment with damaging 
agents and measuring the damage remaining at intervals. This is one of the techniques used in 
the area of cancer research for the evaluation of genotoxicity [16]. 
Several exogenous and endogenous metabolites can induce DNA damage. Therefore, the 
investigator needs to consider the dose and the time of the exposure to samples in relation to 
which genotoxic aspect that he or she would like to study. 
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In this thesis, comet assay was used to measure the level of DNA damage in HT29 cell line, 
this type of cell is a commonly used colon cancer cell line. The cells were exposed to different 
concentrations of 4-cresol for 24 hours to give an idea of how much the different doses will 
affect the DNA damage.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: The process of the gel electrophoresis comet assay, to check DNA damage 
[17]. 
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2.6 pH controlled, in vitro, faecal fermentation (Batch culture) 
This is a closed bacterial batch culture system operated under anaerobic conditions with a 
specific temperature and pH. Nutrients to support microbial growth are supplied once before 
starting the fermentation process Figure 2.4. Although the batch model does lack biological 
brush boarder enzymes and intestinal epithelial cells, the models it does offer an environment 
where bacteria can grow under controlled conditions. This method can be used to assess how, 
within a mixed culture, microbes may behave with a specific treatment (e.g. substrate, 
pharmaceutic or a probiotic). The advantages of this method are that it is inexpensive and rapid. 
Finally it also aids assessment of the potential end products of the fermentation.  
 
Figure 2.4:  Batch culture fermentation setup. 
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2.7 Fluorescence in situ hybridisation (FISH) 
The human gut microbiota has become the subject of extensive research in recent years. The 
gut microbiota plays an important role in immunological, metabolic, and neurological diseases 
[18]. The most prominent in mammalian gut inhabitants are within the phyla Bacteroidetes and 
Firmicutes.  Individual bacterial species present unique pathological effects and, similarly, 
shifts in gut bacterial colonies can also prompt specific disease-inducing activity dysbiosis or 
disease-protective activity probiosis [19].  
The methods of bacterial quantification have changed dramatically in the past fifteen to twenty 
years. This is because not all bacteria can be cultured. It is estimated that up to 70% bacteria 
are unculturable in the colon. Therefore, microbiological culture techniques do not give a clear 
picture of the changes in microbial numbers [20]. Gut microbiota can be determined and 
quantified by different techniques that bypass the limitation of culturing of a complex anaerobic 
community. One of the technique is FLOW FISH, which involves hybridisation of a specific 
fluorescent probe to 16S r RNA with maintaining the structure of the cell. FISH has become 
one of the most powerful tools developed in microbiology field for direct detection of target 
microorganisms in their natural environments. This can then identified using fluorescent 
microscopy or flow cytometry [21] Figure 2.5.   FISH used to quantify the differences in 
bacterial populations with oligonucleotide probes designed to target specific diagnostic regions 
of 16S rRNA, can give an idea of broad phylogenetic changes in the gut microbiome.   
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Figure 2.5: Peaks that generate from flow cytometry machine during FLOW-FISH 
analysis  
In the first picture Flow-cytometry uses light scattering to assess and provide quantitative  data 
for the cell size or granularity of cells bound to the probes of interest, as such can provide a 
measure of the number of cells per mL of sample. The detection limit for FLOW FISH is about 
104 microbes/ ml. The second and third pictures show how differences in specific microbial 
groups, as compared to total bacteria. The final two images eanable background fluorescence 
to be measured.  
Classical microbiological techniques are still important for identifying organism 
characteristics, but FISH overcomes issues of cultivation. Other modern molecular techniques 
could include the use of 16S characterisation using sequencing facilities (miseq); these 
techniques can record the abundance of DNA present belonging to different microbial groups; 
however, the method cannot provide full quantification; issues in initial polymerase chain 
reaction stages and DNA extraction can result in bias in the end results. Sequencing can give a 
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broader idea of bacteria that are present, or changing due to a treatment; however for full 
quantification of bacterial groups of interest FISH provides an appropriate tool; moreover, 
when coupled with flow cytometry, some of the bias associated with counting cells through the 
microscope, are reduced. As such, FLOW-FISH was used within this thesis. 
 
2.8 Cell cycle  
The cell cycle is the process by which eukaryotic cells duplicate and divide. It consists of two 
specific and different phases (Figure 6). The first one is interphase which consists of G1 (Gap 
1), S (synthesis), and G2 (Gap 2). The second one is the mitotic phase which consists of M 
(mitosis). At each interphase, for instance, in G1, the cell grows, in S accumulates the energy 
necessary for duplication, finally in G2 prepares cell for division [22] Figure 2.6. There are 
several methods to assess the cell cycle, however, it is important to choose an appropriate 
method. The most common method for assessing the cell cycle is to use flow cytometry to 
measure cellular DNA content [23]. In this process, a fluorescent dye that binds to DNA is 
incubated with a single cell suspension of permeabilised or fixed cells. Then, the amount of 
fluorescence signal is directly proportional to the amount of DNA. There are several alterations 
that occur during the cell cycle, therefore, DNA content allows discrimination between G1, S, 
G2 and M phases. The value of the flow cytometry technique lies in the ability to take 
measurements of large numbers of single cells within a short period of time (tens of seconds to 
minutes). The heterogeneity of populations can be revealed and different subsets of cells 
identified and quantified. 
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Figure 2.6: Cell cycle pathways adapted from [24] 
 
 
 
 
 
 
 
 
 
DNA damage checkpoint Antephase checkpoint 
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The steps that the cells go through to be for cell cycle dynamics to be assessed by flow 
cytometry:  
Centrifuge the sample  
 
Cells fixed with 70% ethanol 
 
Permeabilise 
 
 Treated with RNase 
 
Allow the PI to enter the cell 
 
Staining the DNA  
 
DNA is measured by fluorescence 
 
 
Cell count vs propidium iodide 
 
Ensure only single cells are measured. 
 
 
Figure 2.7: Peaks generated by flow cytometry indicating the cell cycle dynamics, 
adapted from [24] 
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3.9  Cell viability and proliferation 
Cells can be distinct and characterised either by cell viability or/and proliferation. When 
measuring the number of living cells in a population, it is called cell viability [25]. Whereas, 
when measuring the cell division, then this is called cell proliferation. It should be noted that 
not all viable cells divide. Although proliferation can readily be interpreted as viability, absence 
of proliferation should not automatically be taken as a sign of cell death [26]. In this analysis 
several stains can be used such as 4',6-diamidino-2-phenylindole (DAPI), propidium iodide 
(PI), and others. PI and DAPI bind both RNA and DNA, and these can be assessed using a 
fluorescence microscope, flow cytometer or microplate reader. In this study, DAPI assay was 
used; with a microplate reader to analyse the data [27]. The advantages of cell viability and cell 
proliferation assays are easy, inexpensive, quick, accurate and good for initial screening. These 
assays are quick, allowing greater numbers of experiments to be performed within short 
timeframes [28]. However, the disadvantages are they all rely on the assumption that cell 
numbers remain in proportion to signal strength after treatments, an assumption that cannot be 
met. 
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3. The effect of macronutrient intake on the microbial metabolite 4-cresol in an Omani 
population 
 
3.1 Abstract 
Background: It has been proposed that dietary factors are responsible for 70-90% of colorectal 
cancer (CRC) cases. Evidence has indicated that metabolites from colonic microbial protein 
metabolism, such as 4-cresol, contribute to increased genotoxicity when combined with high 
meat intake. Arab and Gulf countries are becoming increasingly afflicted by these conditions. 
Several studies have shown that shifting to a Western diet and changing to a sedentary lifestyle 
has a negative impact on human health. The aim of this study was to identify the dietary intake 
of and physical activity levels of in Omani population and consider associations with CRC risk.  
Methods: A cross sectional study was carried out on 205 healthy study subjects (91 males and 
114 females). Participants were aged between 19-60 years. Validated semi-quantitative food 
frequency questionnaires were collected. Anthropometric measurements and physical activity 
were assessed. Blood pressure was recorded and serum analysed for biochemical analysis. 24 
hours urine samples were used to measure 4-cresol levels using nuclear magnetic resonance 
(NMR) analysis. Within faeces the microbial population of selected volunteers was ascertained 
using fluorescent in situ hybridisation attached to flow cytometry (flow FISH). Statistical 
analysis was performed using Statistical Analysis Software (SPSS) version 22. 
Results: Results of this study revealed the Omani population have high protein intake, more 
than the recommended dietary intake and similar to that of a Western diet. The protein intake 
and high BMI had a higher significant affected on the biochemical analysis creatinine, urea, 
total protein and cholesterol compared to the CHO intake (p=0.028, 0.008, 0.046 and 0.013 
respectively). Furthermore, there was a strong correlation in urine analysis, showing high 
protein consumers to have increased urinary 4-cresol (p=0.000). Moreover, the bacteriology 
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results indicated that diet impacted on the microbiota, with high protein and high carbohydrate 
consumers therefore, the results shows a  significant effect with high protein intake in total 
bacteria, Lactobacillus, Atopobium cluster, Clostridial cluster IX, Desulfovibrio and 
Clostridium histolyticum group  p = 0.000, 0.019, 0.014, 0.015, 0.017 and 0.031 respectively. 
Conclusion: The Omani dietary intake and results, which correlated with high amounts of 
creatinine, urea and 4-cresol, which may affect health negatively. Nutrition awareness and 
health education should emphasis the importance of healthy balanced diets and active lifestyles. 
 
Key words: dietary habits, lifestyle, colorectal cancer, dietary pattern, factor analysis, food 
frequency questionnaire, fluorescence in situ hybridisation and NMR.  
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3.2 Introduction 
Adequate and balanced macronutrient intake is necessary to maintain human health. There are 
few dietary population based studies conducted in the Middle East; these have reported high 
consumption of red meat, junk food, fat and a decreased consumption of fibre, vegetables and 
fruits [1, 2]. It is likely that dietary changes have an impact on health status of the population. 
There is growing evidence, that nutrition and activity levels are major factors affecting a range 
of chronic diseases such as CRC, obesity, cardiovascular diseases and others.  
The high incidence of sporadic CRC worldwide implies a role of environmental factors, 
specifically diet where 80% of colorectal cancer cases have been attributed to dietary factors, 
mainly animal protein consumption [3]. The highest rates of colorectal cancer are in some of 
the economically growing developed areas like United States, Europe and Australia; which are 
consuming a diet rich in animal products and fat content [4]. In addition, statistics have shown 
a 60% increase in cases in Africa, Asia and Central and South America [4]. Whilst in the Arab 
countries statistics have traditionally shown low incidence of colon cancer, however, more 
recently the incidence of CRC in people under 40 years of age has been found to be relatively 
high in the Gulf countries, such as Oman, Qatar, and Saudi Arabia [5].  
 The Gulf Centre for Cancer Registration (GCCR) reported that in the GCC states, CRC was 
the second most common cancer with overall age-standardised rate (ASRs) of 8ꞏ5 per 100,000 
for men and 7ꞏ2 per 100 000 for women. In Omani men the ASR ranged between 6ꞏ6 per 
100,000 men and 5ꞏ3 per 100,000 in women. The statistic showed increased incidence in both 
sexes between 1998 and 2009, with the total number of newly diagnosed colorectal cancer 
cases increasing by 3ꞏ4-times in men and 2ꞏ1-times in women [6]. Whereas in UK the age-
standardised rates of cancer registrations per 100,000 people were initially at much higher rates 
84.6 per 100,000 in males and 56.8 per 100,000 females and decreasing by less than 1% in 
2015[7]. 
78 
 
Indeed, the recent Oman World Health Survey reported a high prevalence of CRC with 
increased caloric, protein, fat and salt intake, tobacco use, combined with physical inactivity 
[7]. Such lifestyle changes are of importance, as eating less than five servings of fruits and 
vegetables and being physically inactive can increase the risk of obesity, CRC and 
cardiovascular diseases [8].  
The World Cancer Research Fund and the American Institute for Cancer Research concluded 
that there was convincing evidence that red meat and processed meat intake increases CRC risk 
[8]. Arab and Gulf countries have been undergoing a rapid change in lifestyle, with alterations 
to food consumption patterns and socioeconomic status during the last few decades [9, 10]. 
Several migrant studies of dietary intake support the concept that a shift to a Western diet 
results in increases in CRC incidence [6, 11]. Furthermore, other evidence suggests that long-
term consumption of red meat or processed meats may increase CRC risk. Therefore, a link 
has been hypothesed that high dietary intake of red and processed meats can influence all stages 
of carcinogenesis, starting from cell proliferation until differentiation and transformation to 
cancer [12-16]. 
 
Dietary impact on the colonic microbiota can mediate both changes in bacterial population and 
bacterial metabolic activity.  Moreover, several studies have shown a link between diet, 
lifestyle and the composition and metabolic activity of the human gut microbiota [17-19]. In 
fact, there is growing evidence that imbalances in gut microbial populations can be associated 
with several diseases including colon cancer. This is because microbial pathways in the colon 
can lead to production of carcinogenic and genotoxic compounds [20]. Not all colonic 
microbiota members result in negative effects, there are some bacteria within this consortium 
that have a positive impact on colonocytes; thus diet can influence these factors [21].  
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The main fermentable substrates in the large intestine are carbohydrates and protein [22]. The 
main products of CHO fermentation include short-chain fatty acids (SCFA) which, as well as 
having positive systemic effects, lower the colonic pH, making the environment of the colon 
less favorable to pathogenic bacteria [23]. 
 
On the contrary, protein metabolism (as in a high meat diet) can lead to detrimental metabolic 
end products [24-26] e.g. ammonia, amines, 4-cresol, phenol, indole, hydrogen sulphide [27]. 
Some of these end products are retained within the gut and absorbed into the circulation and 
eventually secreted in the urine; these compounds are well known as potential uremic toxins 
[28]. Furthermore, 4-cresol is produced from tyrosine or phenylalanine fermentation by 
intestinal bacteria, this metabolite has been found to be elevated in the urine of CRC patients 
[29]. Several studies have shown that, 4-cresol increases cell proliferation and production of 
reactive oxygen species production in endothelial and mononuclear cells; such transformations 
may aid initiation and progression of CRC [30].  
 
In contrast, several studies have shown that Bifidobacterium could inhibit ammonia production 
and enzymes such as beta-glucuronidase and tryptophanase that have been observed to be 
carcinogenic in rodents [31, 32]. Furthermore Lactobacillus, have also been observed to reduce 
the action of these enzyme in the colon. These genera have also been reported to possess 
anticancer potential by binding to amine, preventing its absorption from the colon [33]. As 
such, modulation of the microbiota to support the growth of lactobacilli and bifidobacteria 
could be of benefit to the host. 
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To date there are no studies in Gulf countries in general and in Oman specifically considering 
how current dietary intake influences metabolites, such as 4-cresol, and how these changes may 
impact on health. As such, this is the first study to address this issue. This will allow us to 
examine the potential metabolite production such as 4-cresol as a potential biomarker of CRC 
with respect to Omani diet.  
3.3 Materials and Methods 
A cross sectional study was carried out on 205 healthy study subjects (91 males and 114 
females). Participants were aged between 19-60 years, from different regions of the Sultanate 
of Oman. The inclusion criteria were healthy subjects free of any metabolic disorders or chronic 
diseases and had not consumed antibiotic medication in the last 6 months. Written consent form 
was obtained from all study subjects before their interview. The study protocol was approved 
by the Research and Ethics Committee of Ministry of Health, Sultanate of Oman. 
 
3.3.1 Semi-Quantitative Food Frequency Questionnaire 
Adapted modified semi-quantitative food frequency questionnaires were developed and 
validated by the nutrition section, Sultan Qaboos University-Oman. Qualified dietitians asked 
the study subjects questions in a face-to-face interview and filled out the questionnaires. The 
food listed in the FFQ consisted of 128 food items categorised into nine major groups: 20 of 
vegetables; 36 of meat (Traditional Omani food) such as red meat (lamb and beef), chicken, 
fish, cold meat, and others; 14 of fruits and juices; nine of milk and dairy products; 11 of breads; 
four of nuts; six of beverages; ten of fast food; 18 of snacks and sweets. The questionnaire used 
measures to determine portion size, e.g. ½ cup and 1 cup standard serving and also considered 
frequency of food consumption (never, a few times/year, 1–2/month, 1–2/week, 3–4/week, 5–
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6/week, 1/day, 1–3/day, 4–5/day, or 6/day). Dietary intake was analysed using NutriBase11 
software (NutriBase 11 version: 11.5, Phoenix Arizona, USA).  
 
2.3.2 Assessment Questionnaires 
Qualified trained nurses collected assessment questionnaires from the volunteers in Oman. 
These questionnaires were used to obtain information from the study subjects about socio-
demographic characteristics; including personal details, marital status and level of education, 
monthly income, permanent residential zone (urban, rural areas). The second section was about 
anthropometric measurements, third about blood pressure and fourth about lifestyle factors 
including physical activity, smoking and drinking habits.  
The anthropometric measurements including body weight, height, BMI and waist/hip ratio 
(W/H) were taken by qualified trained nurses. Body weight was measure to the nearest 0.1kg 
with minimal clothing, using Tanita digital scale. Height was measured to the nearest 0.5 cm 
with the subject in the full standing position without shoes and using a calibrated portable 
measuring rod. BMI is defined as the individual's body mass divided by the square of their 
height (Kg/m2). We used the cut-off points for adults (normal and overweight/obese) based on 
18–24.9, ≥25 Kg/m2, respectively). W/H was calculated as waist measurement divided by hip 
measurement using a non-stretchable measuring tape. The blood pressure was measured in the 
morning from the right arm of subjects while they were seat and at rest for at least 5 minutes, 
using an automatic blood pressure machine standardised daily against a mercury 
sphygmomanometer.  
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3.3.3 Global Physical Activity Questionnaire 
A WHO developed Global Physical Activity Questionnaire (GPAQ) was filled out by trained 
nurses and was used to assess the physical activity levels of the study subjects [34]. The 
questionnaire focused on intensity, duration, and type of activity. Then the number of hours 
spent in different activity levels was obtained and converted into Metabolic Equivalents 
(METs). Average METs for walking 60-90 minutes = 3.3 METs, for moderate activity = 4.0 
METs, for vigorous activity = 8.0 METs. Finally, the score expressed as MET-min/week; 
calculated as (MET level × minutes of activity / day × days per week). Total physical activity 
MET-min/week was obtained by METs summation and categorised as inactive (below 600 
MET-min/week), and above 600MET-min/week) as active.  
 
3.3.4 Urine and Faecal Collection 
Urine and faecal samples were obtained from healthy volunteers age ranging from (19-60) 
years old by trained nurses. Volunteers had no history of gastrointestinal diseases and had not 
consumed antibiotics within the previous 6 months. Urine was collected over the course of 24 
hours (all voids were within the collection container). Within the container, ascorbic acid was 
used as a preservative: 0.042 g. The urine container was stored within a cool bag. Following 
collection, 12.5 mL of urine specimen was taken into 25 mL falcon tube, this sample was stored 
at -80ºC for further analysis.  
Faecal samples were provided on site. About 20 g of fresh faeces was transferred into mayo 
stool containers with glycerol preservative (20 mL glycerol/tube). Samples were stored at -
80ºC for further analysis. 
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3.3.5 NMR spectroscopy 
Urine is a biofluid and has been considered to be highly appropriate amongst metabolomics 
researchers [46]. Urine is an easily accessible biological fluid  which can be obtained in large 
volumes, largely free from interfering proteins or lipids and other complex chemical [46]. 
Furthermore, it is known that urine contains significantly more metabolic end products and 
exhibits significantly more chemical diversity than other biofluids. More than 484 compounds 
have been identified in urine that were not previously reported to be in blood either 
experimentally or via literature review [48]. Therefore, in this study urine samples have been 
used.  Therefore, 205 urine samples were analysed by 1H nuclear magnetic resonance (NMR) 
spectroscopy. Jonathon Swann from Imperial College London carried out this analysis. The 
frozen samples were prepared by adding 400 µl of urine with 200 µl of phosphate buffer (pH 
7.4; 100% D2O) containing 1 mM of the internal standard, 3-trimethylsilyl-1-[2, 2, 3, 3-2H4] 
propionate (TSP).  Samples were mixed by vortex, before centrifuging (10,000 x g) for 10 
minutes before transfer to a 5 mm NMR tube.  Spectroscopic analysis was carry out on a 600 
MHz Bruker NMR spectrometer.  Standard one-dimensional 1H NMR spectra of the urine 
samples were acquired with water peak suppression using a standard pulse sequence.  For each 
sample, 8 dummy scans were followed by 32 scans and collected in 64K data points.  A recycle 
delay of 2 s, a mixing time of 10 µs and an acquisition time of 3.8 s was used.  The spectral 
width was set at 20 ppm.  Spectra were automatically phased and corrected for baseline 
distortions and the chemical shifts in the spectra were referenced to the TSP singlet at δ 0.0. 
1H NMR spectra (δ 0.2-10.0) were digitised into consecutive integrated spectral regions 
(~20,000) of equal width (0.00055 ppm).  The regions between δ 4.50 - 5.00 were removed to 
minimise the effect of baseline caused by imperfect water suppression. Each spectrum was then 
normalised using a probabilistic quotient-based approach. Here, 1H NMR spectroscopic 
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profiles were used as the descriptor matrix and class membership (e.g. control and infected) 
was used as the response variable.  Correlation coefficient plots were generated by back-scaling 
transformation to display the contribution of each metabolite to sample classification.  The 
colour scale represented the significance of correlation for each metabolite to class 
membership, with red indicating strong significance and blue indicating weak significance.  
The predictive performance (Q2Y) of the model was calculated using a 7-fold cross validation 
approach and model validity was established by permutation testing (1000 permutations). 
3.3.6 Faecal samples - Bacterial enumeration 
Faecal samples were obtained from 8 volunteers who consumed high protein, low CHO and 
another 8 volunteers who consumed high CHO, low protein. Bacteriological analyses 
performed in triplicate using standard published procedures. Differences in bacterial 
populations were assessed by fluorescence in situ hybridisation (FISH) coupled with flow 
cytometry, with oligonucleotide probes designed to target specific diagnostic regions of 16S 
rRNA. Probes for FISH were commercially synthesised and labelled at the 5′ end with the 
fluorescent dye Cy3 (Sigma Aldrich Ltd, Poole, Dorset, UK). The probes in Table 3.1 used 
were EUB 338 mixture as a positive control consisting of EUB338, EUB338II and EUB338III 
for total bacteria count and Non EUB as a negative control. Other probes used such as : Ato 
291 for Atopobium cluster (ATO), Lab 158 for Lactobacillus/Enterococcus (LAB), Bif 164 for 
Bifidobacterium (BIF), Erec 482 for Eubacterium rectale–Clostridium coccoides group 
(EREC) [47], Chis 150 for the Clostridium histolyticum group (CHIS), Bac 303 for 
Bacteroides—Prevotella spp. (BAC) and Fuso 664 for Fusobacterium nucleatum. 
Seven hundred and fifty microliters of the samples was centrifuged at 12,400 × g for 5 min. 
Afterwards, pellets were resuspended in 375 μL of filtered PBS (using a 0.22 μm PVDF 
filter) and fixed in 1125 μL of 4% (v/v) paraformaldehyde. After 4 h of incubation at 4°C, 
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samples were washed twice using 1 mL of PBS, resuspended in 500 μL (1:1, v/v) PBS- 99% 
ethanol and stored at –20◦C. To hybridise the samples 75 μL sample was added to 500 μL 
PBS and centrifuged at 12,400 × g for 3 min. Pellets were resuspended using 100 μL of 
filtered TE-FISH buffer (Tris/HCl 1 M pH 8, EDTA 0.5 M pH 8, distilled H2O, 0.22 μm 
filters). Then lysozyme was added (50 000 U) and incubated in the room temperature for 10 
min. The samples were then vortexed and centrifuged at 12,400 × g for 3 min. Pellets washed 
with 500 μL PBS and centrifuged (12,400 × g, 3 min). Afterwards, the hybridisation process 
was performed by resuspending the pellets in 150 μL of hybridisation buffer (5 M NaCl, 1 M 
Tris/HCl pH 8, 30% formamide, ddH2O, 10% SDS), vortexing and centrifuging (12,400 × g, 
3 min). Pellets were resuspended in 1 mL of hybridisation buffer and 50ng/ μL aliquoted into 
each Eppendorf tube containing the relevant probe (Table 3.1).  
The samples were read by flow cytometer, in a BD Accuri C6 flow cytometer. Scattered light 
and fluorescence of different wavelengths are then recorded to give number of cells per µL 
sample.  
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Table 3.1: Oligonucleotide probes used in this study for Flow- FISH analysis of bacterial 
populations.  
Probes 
name 
Sequences 5’ To 3’ Target genus Reference  
 
Non Eub 
(Negative 
control) 
ACTCCTACGGGAGGCAGC Control [35] 
Eub338 I + 
(Positive 
control) 
GCT GCC TCC CGT AGG AGT  Most bacteria [36] 
Eub338 II +  GCA GCC ACC CGT AGG TGT Planctomycetales [36] 
Eub338 III 
+  
GCT GCC ACC CGT AGG TGT Verrucomicrobiales [36] 
Bif164 CATCCGGCATTACCACCC 
 
Most Bifidobacterium 
spp. 
[37] 
Lab158 GGTATTAGCAYCTGTTTCCA Most Lactobacillus, 
Leuconostoc and 
Weissella spp. 
 
[38] 
Bac 303 CCAATGTGGGGGACCTT Most Bacteroidaceae 
and Prevotellaceae, 
some 
Porphyromonadaceae 
 
[39] 
Erec 482 GCTTCTTAGTCARGTACCG Most of the Clostridium 
coccoides-Eubacterium 
rectale group 
[40] 
Rrec 584 TCAGACTTGCCGYACCGC Roseburia subcluster [41] 
Chis150 TTATGCGGTATTAATCTYCCTTT Most of the Clostridium 
histolyticum group 
(Clostridium clusters I 
and II) 
[40] 
Prop 853 ATTGCGTTAACTCCGGCAC Clostridial cluster IX  
 
[41] 
Ato 291 GGTCGGTCTCTCAACCC Atopobium, Colinsella, 
Olsenella and 
Eggerthella spp. 
[42] 
Fprau 647 CGCCTACCTCTGCACTAC Faecalibacterium 
prausnitzii and related 
sequences 
[43] 
DSV 687 TACGGATTTCACTCC T Most 
Desulfovibrionales 
(excluding Lawsonia) 
and many 
Desulfuromonales
[44] 
Fuso 664 CTTGTAGTTCCGCYTACCTC Fusobacterium spp. [45] 
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3.3.7 Assay of serum lipids profile  
Fifteen mL of blood samples were collected from the subjects in the morning before breakfast 
after at least 12 hours of overnight fasting after dinner on the previous day of measurement. 
Fifteen mL of venous blood was collected into red cap plain vacutainer tube using vacuum 
blood collecting tube. Blood samples were centrifuged at 1500 g at 4oC for 10 minutes and 
stored at -80oC for subsequent analyses. The serum samples were thawed at room temperature 
(25 to 29°C) at Laboratories of food and nutrition department, Sultan Qaboos University, 
Oman, and using a COBAS C 111 analyser (Roche, Basel, Switzerland) analysed for levels of 
blood glucose, magnesium, creatinine, triglyceride, high-density lipoprotein (HDL), low-
density lipoprotein (LDL) and cholesterol using specific kits for each of these analysis. The 
COBAS C111 analyser uses a single point calibration for each analysis in which a calibration 
curve was created based on internal standard for the sample analysis. The internal quality 
control for the automatic analyser was performed using two levels of control materials 
purchased from manufacturer to calculate mean and standard deviation (SD). The results of 
lipid profile were expressed in mean ± SD. 
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3.4 Statistical analysis 
Statistical Package for Social Sciences (SPSS Version 22, IBM, Chicago, Illinois, USA) was 
used for statistical analysis. The data are presented as mean ±SEM. Categorical variables were 
tested by Chi-square test; continuous variables were tested by one-way ANOVA. For 
bacteriology, comparisons between high protein consumers (≥60 g) and high CHO consumer 
(≥300 g) were made by analysis of variance. The correlation between protein consumption and 
4-cresol production and the correlation between the biochemical analysis against 4-cresol 
production was assessed using a Pearson test. P values <0.05 were considered to be statistically 
significant. 
3.5 Results 
A total of 91 males and 114 females, with a mean of age 30.8±8.32 and 29.5±8.93 years 
respectively participated in this study. The general characteristics of the subjects are given in 
Table 3.2. Figure 3.1 shows the distribution of the study subject according to their weight 
within the category. There was no significant difference in the age or BMI between the study 
subjects. However, a significant difference in physical activity levels was observed, males 
tended to be more active than females, with 72% of active males whereas just 35.6% of females 
were active p=000. BMI was categorised into 2 groups (Normal=18-24.9 and overweight and 
obese =≥25). The average BMI for males was 25.76± 5.69 whereas, the average BMI for 
females was 25.88±6.55. 
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Table 3.2: General Characteristics of the study subject’s values are expressed by 
mean±SD 
 
 
Gender  Males 
N=(91) 
Females 
N=(114) 
 
AGE (years) 30.71 ± 8.32 
 
29.57 ± 8.93 
 
BMI (kg/m2) 25.767 ± 5.69 
 
25.881 ± 6.55 
 
Waist/hip ratio (WHR) 1.6 ± 7.1    0.8 ± 0.1 
 
 
Physical activity 
1. Active 
 
68 (72.3%) 42 (36.8%) 
 
       2.    Not active 26 (27.2%) 72 (63.2%) 
 
Characteristics of study volunteers P-vales for categorical variables have been assessed by Chi-
square test, where the continuous variables have been tested by one-way ANOVA. BMI = body 
mass index; WHR = waist-to-hip ratio. *Data collected using the Global Physical Activity 
Questionnaire (GPAQ).  
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Figure 3.1: Distribution the number of the study subjects total of 205-study subject included: 94 males and 114 females weight within 
categories, values are expressed by mean ± SD. 
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Table 3.3 indicates the impact of BMI on systolic (SBP) and diastolic (DBP) blood pressure. 
For normal BMI study subject the mean of systolic blood pressure was 121.05±15.151mmHg, 
whereas for the overweight/obese BMI study subjects it was 127.24±14.790kg/m2, which is 
increased significantly between the two groups (p= 0.003). Furthermore, the diastolic was also 
significantly higher in overweight/obese study subjects compared to the normal (72.73±10.539 
mmHg and 76.79±12.875mmHg respectively, p= 0.012).  
 
Table 3.3: Effect of BMI on the study subjects blood pressure, values are expressed by 
mean±SD 
Variables         Normal BMI Overweight/Obese  P-value 
Systolic SBP 121.05 ± 15.151 127.24 ± 14.790 
 
0.003** 
Diastolic DBP 72.73 ± 10.539 76.79 ± 12.875 
 
0.012* 
Values listed are mean ± SD: P-vale obtained by one-way ANOVA. Total of 205-study subject 
included: 94 males and 114 females 
 
Table 3.4 shows the macronutrient consumption for the study subjects by gender, along with 
the recommended intake. It can be seen from Table 3.4 that total energy and fat intake of the 
study subjects was within the recommended values; however, both protein and carbohydrate 
intake were above the daily recommendations. 
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Table 3.4: Macronutrient consumption by the study subjects values are expressed as mean±SD. In this, study 8 volunteers who consumed 
high CHO diet and anther 8 volunteers who consumed high protein diet were analysed to check how much 4-cresol was produce from 
each diet.   
Variables Males N=94 
Females 
N=114 
Male   & female, who 
consumed high CHO   
(n=8) 
Male   & female, who 
consumed high protein      
(n=8) 
RDI 
Males 
RDI 
Females 
Total energy 
(Calories) 2265.5 ± 546.8 1958.1 ± 527.5 
 
2134.862 ± 431.4 
 
 
2019.8 ± 542.8 
 2500 
 
2000 
 
Carbohydrate 
(g) 349.9 ± 158.3 348.3 ± 261.6 
 
349±157.1  215.7± 90.3 
 
300 
 
 
230 
Protein (g) 91.5 ± 30.2 77.2 ± 27.8 
 
48±10.5 84.3±30.9 
 
55 
 
45 
 
Fat (g) 75.0 ± 27.8 61.3 ± 20.9 
 
66.9 ± 30.6 
 
62.9 ± 29.8 
 
95 
 
70 
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When blood serum was tested and analysed against the biochemical analysis it was observed 
that creatinine (CRE), Total protein and cholesterol (CHOL) were significantly in the study 
subjects who consumed more protein than CHO (p=0.028,  0.046 and 0.013) respectively Table 
3.5. 
Table 3.5: Biochemical analysis of the study subjects who consumed high protein diet 
using blood serum, values are expressed by mean±SD 
Types           Participants n=18  
↑protein intake   ↑CHO intake 
        P-value 
Magnesium (mmol/L) 0.89±0.192            1.78±0.991 0.61       
Glucose (mmol/L) 5.06±1.990             3.02±1.621 0.16       
Calcium (mmol/L) 2.40±0.348             4.59±1.248   0.55        
Phosphorous (mmol/L) 1.29±0.171             2.10±0.634 0.77       
Creatinine (mmol/L) 63.67±14.261         6.67±0.546   0.02*    
Bile (mmol/L) 5.92±1.397             3.16±0.125 0.75        
Urea (mmol/L) 4.16±1.325            12.60±4.676           0.00*     
Total protein (mmol/L) 78.16±5.358          5.86±0.860     0.04*    
Albumin (mmol/L) 52.30±20.206        6.40±1.348  0.06       
Triglyceride  (mmol/L) 1.15±0.731            1.34±0.651  0.91      
High density lipoprotein (mmol/L) 1.51±0.403           2.43±0.563    0.98     
Low density lipoprotein (mmol/L) 3.10±0.844           1.10±0.967  0.46     
Cholesterol (mmol/L) 6.59±2.248           4.34±0.974    0.01*    
  
Values listed are mean ± SD; P-values for the continuous variables were obtain by 
correlation.* indicate significant correlation with 4-cresol production. This table shows 
the results of biochemical analysis between the volunteers who consumed high protein 
diet (≥60 g) and high carbohydrate diet (≥300) and their effect in the serum.  
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Urine and Faecal samples 
Urine results 
Urine samples of the study subjects were analysed by NMR to examine 4-cresol produced when 
levels, which was compared to protein intake.  
In Figure 3.2 A and B (top), the results of the full cohort did not show any significant 
correlation p= 0.250 as a full cohort. However, when the data  for CHO adjustment was carried 
out using the residual method Figure 3.1 B. Pearson correlation coefficients were calculated 
using CHO adjusted data for CHO intake it showed a strong correlation, highly significant p 
=0.000 between the high protein intake and the production of 4-cresol within the study subjects. 
Analysis was conducted considering the volunteers who were selected for faecal analysis; as 
such from all the study subjects 8 were selected who consumed high protein ( ≥60g and low 
CHO ≤300g per day) and another 8 from the study subjects who consumed high (CHO ≥300g 
per day) and low protein (≤ 60g per day). The results showed significant correlation between 
high protein intake who consumed 60 g/d or above and production of 4-cresol (r=0.571 and p= 
0.030) (Figure 3.2 C). However, for those study subjects who consumed high carbohydrate 
intake Figure 3.2 D, the result shows no significant correlation between the CHO intake and 
4-cresol levels (r=0.078 and p = 0.520). 
Moreover, high protein intake influences serum levels by generation of various metabolites 
such as urea and creatinine. The result also showed a strong correlation between urea and 
creatinine production and against 4-cresol (r= 0.718, p=0.000 and r =0.277, p =0.04 
respectively), whilst there was no correlation with the other biomarkers of protein. 
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Figure 3.2: A and B: A and B: A- the correlation of protein intake g and 4-cresol by the study subjects (n= 205). B- The correlation of 
protein intake in grams and 4-cresol Adjusted for CHO by the study subjects (n= 205) according to mean and SD.  C and D: C- (8 study 
subjects) the correlation of high protein intake (g/d) and 4-cresol (mM) by the study subjects. D- (8 study subjects) the correlation of low 
protein intake g and 4-cresol by the study subjects according to mean and SD.
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Figure 3.2: A and B: A and B: A- the correlation of protein intake g and 4-cresol by the study 
subjects (n= 205). B- The correlation of protein intake in grams and 4-cresol Adjusted for CHO 
by the study subjects (n= 205) according to mean and SD.  C and D: C- (8 study subjects) the 
correlation of high protein intake (g/d) and 4-cresol (mM) by the study subjects. D- (8 study 
subjects) the correlation of low protein intake g and 4-cresol by the study subjects according 
tomean and SD.  
 
Faecal microbiota  
The faecal samples were analysed by fluorescence in situ hybridisation to determine number 
of key bacterial groups. From all the study subjects 8 were selected from the study subjects  
who consumed high protein ( ≥60g and low CHO ≤300g per day) and another 8 from the study 
subjects who consumed high CHO ≥300g per day and low protein diet  ≤60g per day. The study 
subjects who consumed a high protein diet had significantly more total bacteria, Bacteriodes,  
Clostridium histolyticum group, Desulfovibrionales, and Fusobacterium p= 0.024, 0.042, 
0.007,0.022, 0.015 respectively when compared to high carbohydrate consumers Table 3.6. 
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Table 3.6: Microbial populations when comparing volunteers with protein and carbohydrate intake  
 
Bacterial numbers (log10/g faeces determined by flow cytometry: fluorescence in situ hybridisation) from volunteers consuming a diet of 
over 60 g of protein, with less than 300g carbohydrate and volunteers consuming over 300g carbohydrate and less than 60 g protein. 
Values listed are mean ± SD; P-values for the continuous variables were obtained by two-way ANOVA comparing the two dietary habits 
* Indicate significantly different P>0ꞏ05. n=8 for high protein and n=8 for high carbohydrate. Eub= Total bacteria, BIF= 
Bifidobacterium spp. LAB= Lactobacillus spp. BAC= Bacteriodes spp. EREC= Eubacterium rectal, RREC= Roseburia , ATO= Atopobium, 
PRO= Clostridial, FPRAU= Faecalibacterium prausnitzii, DSV= Desulfovibrio, CHIS= Clostridium histolyticum. 
Diet 
 
Total 
bacteria BIF  LAB BAC EREC RREC ATO PRO F-PRAU DSV CHIS FUSO 
  
 
 
7.93±0.44* 
 
 
6.96±00.49 
 
 
6.63±0.40 
 
 
6.41±0.41* 
 
 
7.32±0.47 
 
 
6.72±0.64 
 
 
6.69±0.62* 
 
 
6.84±0.56 
 
 
6.90±0.52 
 
 
6.21±0.41* 
 
 
6.40±0.36* 
 
 
6.79±0.45* 
 
 
 
7.25±0.53 
 
 
6.45±0.43 
 
 
5.77±0.71 
 
 
5.75±0.65 
 
 
6.61±0.63 
 
 
6.00±0.53 
 
 
5.89±0.48 
 
 
5.82±0.64 
 
 
6.28±0.74 
 
 
5.51±0.58 
 
 
5.59±0.67 
 
 
6.16±0.49 
High 
protein 
High 
Carbohydrate 
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3.6 Discussion 
Epidemiology studies have shown that a balanced diet and active lifestyle may play a crucial 
role in the prevention of non-communicable diseases. As such, changes in dietary patterns and 
lifestyle can lead to changes in health status [6, 49]. This study is a cross-sectional assessment 
of dietary regimes in the Omani population, with consideration of subsequent disease risk, and 
the microbial metabolite 4-cresol, associated with CRC. 
Decades ago, people in Gulf countries were known to consume more traditional food than now. 
Such diets included dates, rice, high fibre breads and fish; which have now been replaced with 
red meat and others. This has been reflected negatively in the nutrition status and health of the 
Gulf countries [50, 51]. Indeed, in the current study the average intake of CHO and protein was 
349.1g and 84.35g respectively, which is higher than the recommended dietary intakes (RDI) 
of 265g and 50g respectively [52]. This could highlight a dietary shift of Arab and Gulf 
countries to a more Western diet; containing higher levels of fast food, animal protein and 
sugary beverages as also reported by (Abdulrahman, et al, 1993) [53, 54]. 
 
The implications of these dietary patterns were explored, and it was observed that, study 
subjects who consumed combined high protein and high fat diets had higher serum creatinine, 
urea, total protein and cholesterol levels (Table 3.5). This result was expected because protein 
catabolism is known to lead to increased serum creatinine and therefore, the urea level will also 
increase. Furthermore, high creatinine and urea levels may affect renal function by decreasing 
in glomerular filtration rate (GFR); which could be a factor in promoting renal disease.  
It is well known that diet is a major factor driving the composition and metabolism of the 
colonic microbiota [55]. The amount, and  type of macronutrients such as: carbohydrates, 
proteins and fats have a great impact on the large intestinal community [56]. Therefore, the 
dietary changes that have occurred within the Omani population are likely to impact on the gut 
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microbiota [57]. Meat provides a rich source of protein and high consumption of  red and 
processed meats have been linked to microbial 4-cresol production and therefore, linked to 
colorectal cancer later in life [58]. Indeed, Tayyem et al, 2015 [59] observed an association 
between total energy intake, protein and fat intake and developing CRC. Whereas consumption 
of high amounts of vegetables, and fruit was seen to be protective against CRC development, 
this was attributed to their dietary fibre and antioxidant content [5]. The intake of animal source 
foods is indeed growing steadily; it replaced many typical diets in the region [8].The study 
subjects indicated they had a diet with a high frequency consumption of red meat and processed 
meat p = 0.000 and 0.000 respectively and a moderate consumption of fruits and vegetables. 
In the current study, it observed that those consuming higher protein levels, along with low 
CHO had significant differences in a range of microbial groups e.g. Bacteriodes, Clostridium 
histolyticum group, Desulfovibrionales, and Fusobacterium. These groups are known to contain 
some proteolytic bacteria. As such, diet can shift the gut microbiota community; therefore, it 
is possible that a high protein diet is leads to a shift in the microbiota that could be more 
favourable to production of genotoxic products. 
Microbial protein fermentation metabolites such as 4-cresol are potentially harmful, when 
occurring at high concentrations, e.g. above 3 mM in endothelial lines [60]. The results in the 
current study show that high protein consumption was correlated with 4-cresol levels in the 
study subjects urine p = 0.030 (Figure 3.1 A). This results is in line with Windey, et al., [61] 
who found that 2 weeks of high protein intake by healthy volunteers led to increases in 4-cresol. 
Moreover, a study by Geypens, et al. [38] found that increased supplementary protein in healthy 
volunteers, resulted in a significant increase in urinary p-cresol (p = 0.04). Thus, a high protein 
diet, as was seen within the Omani population, may have a negative impact on gut health, 
resulting in increased 4-cresol. O'Keefe and coworkers found that when the gut bacteria 
composition shifted due to animal protein, there was fewer bacteria that produce the short chain 
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fatty acid butyrate, and more potentially harmful bacteria such as Fusobacterium nucleatum, 
Rhodopseudomonas faecalis, Bacteroides vulgatus and Enterococcus faecalis, which produce 
4-cresol and that may damage epithelial DNA [62]. A study by Brinkworth et al., in obese 
individuals, found that urinary 4-cresol and phenol levels at baseline were considerably higher 
than those reported in normal weight adults (94ꞏ9 mg/d and 15ꞏ0 g/d for p-cresol and phenol, 
respectively) and decreased upon weight loss [63]. Within the gastrointestinal tract (GI), about 
60% of the bacteria belong to the Bacteroidetes or Firmicutes phyla. Gut microbes are able to 
produce a wide range of products, the generation of which can be dependent on several factors 
such as nutrient availability and the luminal environment, particularly pH [64]. Therefore, 
competition between bacteria for substrates has a significant influence on which products are 
generated. Therefore, high protein intake will increase putrefactive bacteria and their 
fermentation end products which may lead to increased CRC risk [65] 
On the other hand a high CHO diet, rich in fibre such as cereals, nuts, fruits and vegetables has 
been observed to have a positive effect, with  consumption related to decreased incidence of 
several diseases, in some cases this may be mediated by production of short chain fatty acids 
(SCFAs) by the gut microbiota [66]. Indeed, in the current study, correlations of 4-cresol levels 
and protein intake were only apparent when high carbohydrate consumers were not considered 
in the analysis. As such, fibre intake may offer a protective effect against a high protein diet. 
Asides from this a Western lifestyle involving decreased physical activity and 
overconsumption of energy-dense food leads to increased BMI. Indeed, several studies, along 
with our own, have found a positive association of BMI and blood pressure has been reported 
among different populations [67, 68]. Furthermore, the average waist/ hip ratio of the study 
subjects was 1.2, which is more than is recommended, [69]. This data is of interest as evidence 
indicates an association between elevated body weight, waist and hip ratio to cancer risk [70, 
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71].  All these factors are linked as several studies support the idea of an increased risk of 
adenomas and CRC in patients with obesity and metabolic syndrome [72, 73].  
 
Furthermore, the, present study showed that only about half of subjects reached the 
recommended levels of physical activity of 60-90 minutes per day. This could be partly due to 
the environmental culture of people living in Oman. These results are in line with the results 
from Hashem Kilani, et al. [5] and Al-Hazzaa, et al. [6] study who found a high prevalence of 
sedentary behaviours and low levels of physical activity in Omani and Saudi populations 
respectively. However, this is of concern as a low level of physical activity can affect the 
general health of study subjects. Several studies have indicated that physical activity for 60-90 
minutes practiced every day results in reduced incidence rates of cancer, cardiovascular 
disease, type 2 diabetes, and obesity [74]. As such, increased exercise could provide many 
benefits to the population. 
 
This study, in line with several studies found a positive association of BMI and blood pressure 
[67, 68]. Hypertension can lead to other complications and diseases including heart disease, 
eye damage and stroke [75]. Furthermore, several epidemiological studies have revealed that 
excess body weight is associated with increased risk of colorectal cancer especially in men 
[76].  It has been calculated that compared to people with a BMI <23.0, the risk of CRC is 
increased by 14% for individuals with a BMI of 23.0–24.9; 19% for a BMI of 25.0–27.4; 24% 
for BMI of 27.5–29.9; and 41% for BMI of ≥30.0 [77]. A study by Koolhaas, found that, the 
volunteers who are overweight and obese with low physical activity had a higher CVD risk 
than normal weight participants with high physical activity [78]. Furthermore, it has been 
observed that leptin in obese people is directly related to CRC risk. Whilst the risk of 
developing tumours in patients with K-RAS mutation and p53 has been seen to be lower with 
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increase of the physical activity level [79]. Therefore, those in the overweight and obese 
category of the current cohort considered to be at higher risk of CRC development and other 
chronic diseases.   
 
3.7 Conclusions 
The present study indicated that the Omani population were consuming diets with high protein 
levels, combined with inactive lifestyles. High protein intakes were associated with elevated 
urinary 4-cresol, which could be increasing risk factors associated with non-communicable 
diseases such as CRC. Furthermore, high levels of physical activity have identified as being 
associated with a reduced risk of colon cancer. Therefore, health promotion policy should focus 
and set general strategies for encouraging increased physical activity and protein restriction to 
the recommended level and maintenance of a healthy diet. More research in this field is needed 
to explore the impact of different protein sources on the microbiota and the metabolites 
produced and whether fibre can mediate these effects.  
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4. Modelling the potential role of microbial 4-cresol in colorectal carcinogenesis 
 
4.1 Abstract 
Background: A greater understanding of mechanisms explaining the interactions between diet 
and the gut microbiota in colorectal cancer is desirable. Genotoxic microbial metabolites 
present in the colon may be implicated in carcinogenesis and potentially ameliorated by diet.  
Aims: We hypothesised that microbial 4-cresol is a colonic carcinogen and set out to model 
potential exposures in the colon and the effects of these exposures on colonic cells.   
 
Methods: Batch culture fermentations with faecal inoculate were used to determine the 
synthesis of 4-cresol and other metabolites in response to various substrates. The microbiota 
was monitored and fermentation supernatants were evaluated for genotoxicity and the 
independent effects of 4-cresol on colonic cells were studied in vitro.  
 
Results: In batch culture fermentation supplementary protein increased the synthesis of 
phenols, indoles and 4-cresol, whereas supplementary fructooligosaccharide (FOS) increased 
the synthesis of short chain fatty acids. The 4-cresol was the greatest predictor of genotoxicity 
against colonocytes in the fermentation supernatants. Spiking fermentation supernatants with 
exogenous 4-cresol further increased DNA damage, and independently 4-cresol induced DNA 
damage in a dose dependent manner against HT29 and Caco-2 cells and influenced cell cycle 
kinetics. 
 
Conclusions: High concentrations of microbial 4-cresol may contribute to carcinogenicity in 
the human colon.  
Key wards: 4-cresol, tyrosine, colonic metabolites, microbiota, comet, cell proliferation, cell 
cycle, HT29, Caco-2, FOS, DAPI and PI. 
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4.2 Introduction  
 
The colon is a pro-carcinogenic environment [1] with microbial activity being implicated in 
increased susceptibility to neoplastic transformation [2]. Environmental factors, particularly 
diet, modulate composition and metabolic activity of the colonic microbiota with implications 
for cancer risk [3, 4]. Current mechanistic models implicating diet in CRC risk propose that 
dietary fibre favourably improves the balance of the microbiome, increasing the abundance of 
saccharolytic species relative to proteolytic microbes. The latter are associated with increased 
production of an assortment of genotoxic metabolites from meat based or endogenous 
substrates [4-6]. Epidemiological studies implicate red and processed meat in particular as 
being pro CRC formation. Genotoxicity associated with haem, N-nitroso compounds, and 
heterocyclic amines is the proffered mechanism underpinning this association [7]. However, 
these compounds are also present in white meats and fish; foods which are not implicated in 
CRC risk. A deeper understanding of the relationship of diet to the production of genotoxic 
and tumour promoting microbial by products in the colon is therefore desirable. 
Amongst proteolytic metabolites present in the colon, 4-cresol is a relatively under studied 
potential contributor to the genotoxic load [8]. 4-cresol is a methyl phenol produced via 
microbial degradation of tyrosine and phenylalanine [9, 10]. In situ, it is absorbed and 
metabolised in the liver, producing 4-cresol sulphate, which is excreted in the urine. Elevated 
urinary 4-cresol sulphate has been observed in patients with colorectal cancer [10], it may be 
associated with ageing [11] and more recently it has been suggested as a biomarker of protein 
intake [12].  
 
Due to the efficient intestinal uptake of 4-cresol, and other luminal genotoxins, genotoxicity 
and chemical composition of faecal samples may be poorly representative of colonic 
exposures; this has, in part, limited the use of faecal water sample genotoxicity as a diet-related 
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biomarker of colorectal cancer risk [13]. The presence of 4-cresol sulphate in urine and its 
association with both diet and the microbiome may make it a useful, modifiable diet-sensitive, 
biomarker of colorectal genotoxicity and therefore CRC risk which could be applied in human 
intervention studies, assuming it is causally linked to carcinogenesis [12]. 
Here the objectives of this study were three fold, a) to consider the microbial fermentation of 
dietary protein sources. b) to establish the potential luminal exposure to 4-cresol using a 
simulated gut fermentation system. c) to determine the genotoxicity, and potential 
carcinogenicity, of 4-cresol, as part of the colonic metabolome, at levels of exposure consistent 
with those achievable in vivo, using two separate cell based models of the colonic epithelium.     
 
4.3 Materials and methods 
 
4.3.1 Chemicals 
4-cresol, agarose, EDTA, Trizma base, Triton x100, hydrogen peroxide (H2O2), Hepes, BSA, ethidium 
bromide, propidium iodide (PI) and RNase A were purchased from Sigma-Aldrich  Ltd. (Dorset UK). 
Sodium chloride (NaCl) and potassium chloride (KCl) were supplied by Fisher Scientific 
(Loughborough, UK).  
Tyrosine, Fructooligosaccharide, Albumin, soybean protein peptone meat extracts were all 
purchased from Sigma-Aldrich Ltd. (Dorset UK). Bacteriological growth medium supplements 
were obtained from Oxoid Ltd. (Basingstoke, Hants, U.K.).  
Probes for fluorescence in situ hybridisation were commercially synthesised and labelled at the 
5′ end with the fluorescent dye Cy3 (Sigma Aldrich Ltd, Poole, Dorset, UK). The probes used 
were: EUB 338 mixture as a positive control consisting of EUB338, EUB338II and EUB338III 
for total bacteria count and Non EUB as a negative control. Other probes used such as : Ato 
291 for Atopobium cluster (ATO), Lab 158 for lactobacilli/enterococci (LAB), Bif 164 for 
bifidobacterium (BIF), Erec 482 for Eubacterium rectale–Clostridium coccoides group 
 117 
 
(EREC) [47], Chis 150 for the Clostridium histolyticum group (CHIS), Bac 303 for 
Bacteroides—Prevotella spp. (BAC) and Fuso 664 for Fusobacterium genus (Table 4.1). The 
HT29 and Caco-2 human colorectal cell lines were obtained from the European Collection of 
Animal Cell Cultures (ECACC) (Salisbury, UK) and used between passages 45 and 70. 
Essential Medium (MEM), McCoy’s 5A with L-gulatumate, Penicillin-Streptomycin and Fetal 
Bovine Serum (South America) were purchased from Biosera Ltd. (East Sussex, UK). Non-
essential Amino Acid (NEAA) (Lonza group Ltd. Basel, Switzerland). Phosphate Buffered 
Saline (PBS), Trypsin-Versene and Ethylenediaminetetraacetic acid (EDTA) were purchased 
from Lonza group Ltd. (Basel, Switzerland).   
 
4.3.2 Faecal inoculate for batch culture fermentation 
Faecal samples were collected from three individuals (over 60 years of age). This is conducted 
to a certain if the microbiota of different volunteers behave in the same way, increasing the 
number of volunteers under same conditions would increase the statistical power of any data 
generated. A pooled sample however would mask differences observed due to different 
functional groups within the volunteers. All volunteers self-reported as being healthy, 
antibiotic free for at least 6 months prior to sampling and free from gastrointestinal issues. 
Samples were collected on the day of the experiment and were used immediately. Upon 
collection, they were diluted 1:10 (w/v) with anaerobic phosphate buffered saline (PBS; 0.1 M; 
pH 7.4) and homogenised in a stomacher for 2 min (460-paddle beats/min). (15 ml) of the 
resulting faecal slurries from each individual were used to inoculate batch culture vessels in 
triplicate. 
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4.3.3 Batch culture fermentation 
Batch culture fermentation vessels were autoclaved and filled with 135 ml of basal nutrient 
medium (peptone water (2 g/L), yeast extract (2 g/ L), NaCl (0.1 g/ L), K2HPO4 (0.04 g/ L), 
KH2PO4 (0.04 g/ L), NaHCO3 (2 g/ L), MgSO47H2O (0.01 g/ L), CaCl26H2O (0.01 g/ L), tween 
80 (2 ml/ L), hemin (50 mg/ L), vitamin K1 (10 ml/ L), L-cysteine (0.5 g/l), bile salts (0.5 g/ 
L), resazurin (1 mg/ L) and distilled water (Sigma, Aldrich, UK). The vessels were gassed 
overnight with O2-free N2 (15 ml/min).  
 
Supplementary substrates: Alternative additional substrates were included to consider the 
influence of dietary substrate on cresol fermentation. These were prepared as a high tyrosine 
(supplementary tyrosine at 0.3:100 w/w), a low tyrosine treatment (supplementary tyrosine 
0.003:100 w/w), a high tyrosine with fructoligosaccharide (FOS) (0.3:100 w/w Tyr + FOS 
1.5:100 w/w), a low tyrosine with FOS (0.003:100 w/w Tyr + 1.5:100 w/w FOS), an albumin 
treatment (0.3:100 w/w), a soybean protein treatment (0.3:100 w/w) and a peptone meat extract 
treatment (0.3:100 w/w). 
 
15 ml of faecal inoculate was added to the cultures and the subsequent fermentation carried out 
under anaerobic conditions. The temperature was maintained at 37°C by use of a circulating 
water bath and pH was maintained at 6.8 using a pH controller (Electro lab, UK). At six time 
points (0, 4, 8, 24, 30 and 48 hours), 10 ml of fermentation supernatant was collected for 
analysis. Fermentation supernatants were filter sterilised through a 0.2 mm PVDF single use 
filter (Sartorius Ltd. Surrey UK) for use as microbe free treatments in cell culture experiments.  
All fermentation conditions were conducted in triplicate, each time with a different donor- then 
to prove reproducibility one donor experiment was repeated three times.  
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4.3.4 Bacterial enumeration 
4.3.4.1 Fluorescence in situ hybridisation 
Bacterial populations from the batch culture samples were enumerated using fluorescence in 
situ hybridisation and flow cytometry (Flow-FISH), with oligonucleotide probes targeting 
specific regions of 16S rRNA. Probes were commercially synthesised and coated with the 
fluorescent dye, Cy3. Seven hundred and fifty μL of batch culture samples were centrifuged at 
12,400 × g for 5 min.  The resultant pellets were re-suspended in 375 μL of filtered PBS (using 
a 0.22 μm filters) and fixed in 1125 μL of 4% (v/v) paraformaldehyde. After 4 h of incubation 
at 4◦C, samples were washed twice using 1 mL of PBS, re-suspended in 500 μL PBS- 99% 
ethanol (1:1, v/v) and stored at –20◦C. 75 μL of the sample was added to 500 μL PBS and 
centrifuged at 12,400 × g for 3 min for premeabilisation. Pellets were re-suspended using 100 
μL of filtered TE-FISH buffer (Tris/HCl 1 M pH 8, EDTA 0.5 M pH 8, distilled H2O, 0.22 μm 
filters). Then lysozyme added (50 000 U) and the mixture incubated at room temperature for 
10 min. The samples were then vortexed and centrifuged at 12,400 × g for 3 min. Pellets were 
washed with 500 μL PBS and centrifuged (12,400 × g, 3 min). The hybridisations process was 
completed by re-suspending the pellets in 150 μL of hybridisation buffer (5 M NaCl, 1 M 
Tris/HCl pH 8, 30% formamide, ddH2O, 10% SDS), the mixture was vortexed then centrifuged 
(12,400 × g, 3 min). Pellets were then resuspended in 1 mL of hybridisation buffer and 50ng/ 
μL aliquoted into Eppendorf tubes for analysis.  
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Table 4.1: Oligonucleotide probes used in this study for Flow- FISH analysis of 
bacterial populations. concentration is 50 ng/μL 
 
 
 
Probes 
name 
Sequences 5’ To 3’ Target genus Reference  
 
Non Eub 
(Negative 
control) 
ACTCCTACGGGAGGCAGC Control  [14] 
Eub338 I + 
(Positive 
control) 
GCT GCC TCC CGT AGG AGT  Most bacteria [15] 
Eub338 II +  GCA GCC ACC CGT AGG TGT Planctomycetales [15] 
 
Eub338 III 
+  
GCT GCC ACC CGT AGG TGT Verrucomicrobiales [15] 
Bif164 CATCCGGCATTACCACCC 
 
Most Bifidobacterium 
spp. 
[16] 
 
Lab158 GGTATTAGCAYCTGTTTCCA Most Lactobacillus, 
Leuconostoc and 
Weissella spp. 
 
[17] 
Bac 303 CCAATGTGGGGGACCTT Most Bacteroidaceae 
and Prevotellaceae, 
some 
Porphyromonadaceae  
 
[18] 
Erec 482 GCTTCTTAGTCARGTACCG Most of the Clostridium 
coccoides-Eubacterium 
rectale group 
[19] 
 
Rrec 584 TCAGACTTGCCGYACCGC Roseburia subcluster [20] 
 
Chis150 TTATGCGGTATTAATCTYCCTTT Most of the Clostridium 
histolyticum group 
(Clostridium clusters I 
and II) 
[19] 
 
Prop 853 ATTGCGTTAACTCCGGCAC Clostridial cluster IX   
 
[20] 
Ato 291 GGTCGGTCTCTCAACCC Atopobium, Colinsella, 
Olsenella and 
Eggerthella spp. 
[21] 
Fprau 647 CGCCTACCTCTGCACTAC Faecalibacterium 
prausnitzii and related 
sequences 
[22] 
DSV 687 TACGGATTTCACTCC T Most 
Desulfovibrionales 
(excluding Lawsonia) 
and many 
Desulfuromonales 
[23] 
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4.3.5 Metabolite characterisation 
Standards of 4-cresol, phenol and indole were prepared in distilled water at concentrations from 
(0.1-1600 mM)  and standard curves plotted following quantification via solid-phase 
microextraction (SPME) gas chromatography mass spectrometry (GC-MS) using an Agilent 
110 PAL injection system and Agilent 7890 gas chromatograph with 5975C mass spectrometer 
(Agilent, Santa Clara, CA). The SPME fiber stationary phase was composed of 75 µm 
divinylbenzene/Carboxen™ on polydimethylsiloxane; Supelco, Bellefonte, PA). Sample (0.1 
mL) was placed in a 20-mL headspace vial with magnetic screw cap and PTFE/silicone septum 
(Supelco). The samples were allowed to equilibrate for 10 minutes at 35 °C before being 
extracted for 30 min. Sample was agitated at 500 rpm (5 seconds on, 2 seconds off) during 
equilibration and extraction. After extraction, the contents of the fibre were desorbed onto the 
front of a Stabilwax-DA fused silica capillary column (30 min 0.25 mm i.e., 0.50 mm film 
thickness; Restek, Bellefonte PA). The GC temperature program and the fiber desorption step 
commenced at the same time. During the desorption period (45 s), the oven was held at 40 °C. 
After desorption, the oven was held at 40 °C for a further 255 s before incremental heating at 
4 °C/min to 260 °C, where the temperature was maintained for 5 min. Helium was used as the 
carrier gas at a constant flow rate of 0.9 mL/min. The mass spectrometer was operated in 
electron impact mode with an electron energy of 70 eV, scanning from m/z 20 to m/z 280 at 
1.9 scans/s. 
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4.3.6 Organic acid analysis 
Samples from batch culture fermentation were screened for the organic acid short-chain fatty 
acid (SCFA) concentration which were determined using an acidification method adapted from 
Zhao, G et al [24]. Briefly fermentation samples were defrosted, vortexed and centrifuged for 
5 minutes at 13,400 x g. The samples were filtered using a 0.22 μm filter and sulfuric acid was 
added to bring the pH down to 2. 200 µl of the resulting sample solution and 50 µl of internal 
standard was added to the vial. The internal standard used in this experiment was 2-ethylbutyric 
acid (Aldrich) made to concentration of 100 mM in HPLC grade water.  The GC apparatus was 
calibrated for detection of acetate, propionate, iso-butyrate, butyrate, iso-valeric, valeric and 
caproic acid using standards of a range of concentrations (5mM – 50mM).  
Analysis was conducted using a HP 5890 series II GC system (Hewlett Packard, Palo Alto, 
Calif) with an FFAP, capillary fused silica packed column 25 m by 0.32 mm; filter thickness, 
0.25µm (Macherey-Nagel, Düren, Gemany). Afterwards, the sample was injected into the 
column, which was maintained at 140°C for 5 minutes. Then the column temperature was 
increased over 5 minutes to 240°C. The calibrated organic acids were detected in the samples 
and the concentrations calculated. An external standard with known concentrations of SCFAs 
were injected after every 10 samples to maintain appropriate calibration. Finally, peaks were 
analysed and integrated using HP GC ChemStation Software, Hewlett Packard.  
 
4.3.7 Tissue culture  
The HT29 and Caco-2 human cell lines are derived from colonic epithelial adenocarcinoma 
cells and are widely used in the study of tumourgenicity. The cells were obtained from the 
European Collection of Animal Cell Cultures (ECACC) (Salisbury, UK) and used between 
passages 45 and 70. HT29 cells were cultured routinely in McCoy’s 5A with L-gulatumate 
supplemented with Penicillin-Streptomycin and 10% Fetal Bovine Serum (South America) 
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Biosera Ltd. (East Sussex, UK). Caco-2 cells were cultured in Minimal Essential Medium 
(MEM) supplemented Fetal Bovine Serum (Biosera Ltd. East Sussex, UK). Non-essential 
Amino Acid (NEAA) (Lonza group Ltd. Basel, Switzerland). Phosphate Buffered Saline 
(PBS), Trypsin-Versene and Ethylenediaminetetraacetic acid (EDTA) were purchased from 
Lonza group Ltd. (Basel, Switzerland).  Routine culture was carried out at 37C with 5% CO2 
and 95% humidity, the cell medium was changed every 2 days with trypsin mediated passage 
at 80-90% confluence.  
 
4.3.8 Cell viability 
The nuclear stain 4,6-diamidino-2-phenylindole, dihydrochloride (DAPI) was used to assess 
the cytotoxic effects of 4-cresol on HT29 and Caco-2 cells. HT29 and Caco-2 cells were seeded 
in each 96 well plate at 1×106 cells/ml concentration and incubated at 37oC with 5% CO2 and 
95% humidity for 24 hours. 4-cresol was dissolved in PBS, then HT29 and Caco-2 cells were 
treated with 50 µl of McCoy’s media and 50 µl of MEM media respectively containing serial 
dilutions of the test compounds. Concentrations used were 0-3 mM. The plates were then 
incubated at 37C for 24 hours before removing the treatment solutions via aspiration. Cells 
were permeabilised with 100 µl of ice-cold methanol and left for 5 minutes to incubate at room 
temperature. Methanol was removed by pipette and plates were allowed to dry in a hood for 15 
minutes, followed by addition of 100 µl of DAPI in PBS (70 µl of DAPI staining stock solution 
(3 mM) plus 10.43 ml of PBS per plate) and incubated in the dark for at least 30 minutes at 
37C prior to measurement. Absorption was measured using a GENios microplate reader 
(TECAN Group Ltd., Männedorf, Switzerland) with absorbance and emission at 340 nm and 
465 nm, respectively. 
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4.3.9 DNA damage  
DNA damage was assessed using the single strand comet assay which is widely used to detect 
single stranded breaks in cellular DNA. HT29 and Caco-2 cell lines were seeded into separate 
T75 flasks at a concentration of 1x106 and maintained at 37oC in an atmosphere of 5% CO2 and 
95% filtered air. Cells were treated in the tissue culture flasks at 80 % confluency; 4-cresol was 
made up in serial dilutions at 0, 0.5, 1.5 and 3.0 mM concentrations of growth media and 
applied directly to the cells for 24 hours. At 24 hours’ cells were washed and detached with 
trypsin, following centrifugation 13000 x g for 3 minutes and the supernatant was removed via 
aspiration, followed by washing with PBS for 1 minute. A positive control was prepared with 
untreated cells exposed to 7.5 mM hydrogen peroxide for 15 minutes prior to lysis. Cells were 
counted with trypan blue and adjusted to give a working concentration of 3x106 cells/m l20 µl 
of cells suspension re-suspended with 200µl of melted agarose were bedded on microscope 
slides, then left at 4C for 15 minutes. The slides were placed into lysis buffer (2.5M NaCl, 0.1 
EDTA, 0.01 M Tris and added 1% (v/v) Triton x100 prior to use) for 1 hour at 4C, and then 
washed 3 times with neutralising buffer (96.9 g Trizma base, 1 L water and adjusted PH 7.5 
with (6M HCl)) for 5 minutes before transfer into electrophoresis buffer (0.3M NaOH and 
1mM EDTA). After 20 min at 4oC the slides were placed horizontally in an electrophoresis 
tank containing electrophoresis alkaline buffer to allow the DNA to unwind. Electrophoresis 
was run at 26V, 300mA for 40 minutes in at 4C in the dark. The slides were then washed with 
neutralising buffer (0.4 M Trizma base, pH 7.5) three times for 5 minutes each and then left for 
5 minutes in 99% ethanol for 5 minutes, then left to dry overnight. Cells were stained with 
ethidium bromide (20µl/ml) and kept for 15minutes in the dark. Images of DNA integrity were 
captured by fluorescence microscopy using the Kinetic image software, Komet 4.0 UK. One 
hundred randomly selected cells from each replicate slides were evaluated for DNA tail damage 
by an analyst blinded to the treatment. 
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Fermentation supernatants: HT29 cells were prepared as described above. Filter sterilised 
fermentation supernatants were prepared at 10% (v/v) in McCoy’s carrier culture medium with 
inactivated at 56°C Fetal Bovine Serum (FBS) and antibiotics at 37°C with 5% CO2 and used 
to treat the cells for 24 hours, prior to the Comet assay as described.  
Spiked cell line: to check the sensitivity of the HT29 cell line 4-cresol was added in a growth 
culture media alone with different concentrations (0, 0.2, 0.5,1, 1.5 and 3) mM in HT29 cell 
line without any fermentation supernatants.  
 
4.3.10 Cell cycle assay 
Cell cycle progression was assessed considering the percentage of cells in phases Gap0/1 
(G0/1), Synthesis (S), Gap2/mitosis (G2/M) and apoptotic cells (sub G0/1) according to the 
fluorescence intensity of a PI nuclear stain, and based on the concentration of DNA within the 
cell. HT29 and Caco-2 cell cultures were treated at 2x105 cells/well into 6 well plates at 80% 
confluence. The cells were exposed to 4-cresol at 0.2, 0.5, 1.0, 1.5, 3.0 mM for 24 hours. After 
removing treatments, the cells were washed with ice cold PBS and collected following trypsin 
harvest of the monolayer and pelleting by centrifugation at 300 x g for 3 minutes. The 
supernatants were discarded and then the cell tissues were resuspended in 200 μl ice cold PBS 
and fixed with 2 ml of fresh ice cold 70% ethanol. The cell pellets were stored in freezer at -
20C until analysis.  
 
After chilling, the samples were centrifuged at 300 x g for 5 minutes and the supernatants 
discarded. The pellets were resuspended with 200 µl PBS before adding 25 µl of 1 mg/ml 
RNAse and the suspensions were then incubated at 37C for 30 minutes. 2.5 μl of 400 µg/ml 
of PI were added to bind DNA and were left to incubate for 30 min at room temperature in dark 
condition. Cells suspensions were adjusted to a final volume of 600 µl with PBS. The DNA 
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content of 15,000 cells were then measured immediately via flow cytometry (BD Accuri C6 
flow cytometer, Germany). Analysis was performed using the Flow Jo software (Tree star Inc, 
Oregon, USA). 
 
4.4 Statistical Analysis  
All statistical analyses were carried out using the Statistical Package for Social Sciences (SPSS) 
version 22. All data have been carried in three biological replicates for each analysis. The data 
are presented as mean ±SEM. Fermentation sample metabolites as predictors of genotoxicity 
were evaluated. Cell viability and cell cycle data were analysed using linear regression models. 
For bacteriology, comparisons between each volunteers made by analysis of variance. 
Similarly ANOVA was used to compare the effects of substrates on fermentation sample 
genotoxicity and cell cycle kinetics where appropriate comparison of individual treatments 
with negative control were performed using the Dunnett Post-hoc test.   
P values <0.05 were considered to be statistically significant between the treatments. 
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4.5 Results 
4.5.1 Characterisation of fermentation microbiota 
Three faecal donors supplied specimens for the inter-individual biological replication of batch 
culture fermentations. An analysis of the microbial composition of the fermentation inoculate, 
was performed using 16S rRNA adherent molecular probes. There were statistically significant 
differences in the starting microbial composition of the batch culture fermentation which fed 
through to inter-individual differences in metabolite production. Volunteer 1 had a greater 
relative abundance of Bifidobacterium (BIF164) P < 0.000, Atopobium cluster (ATO 291) P < 
0.000 and Desulfovibrio (DSV 687) P < 0.000 than volunteers 2 and 3. In contrast, volunteer 1 
had a lower relative abundance of Faecalibacterium (FPRAU 655) P < 0.000, 
Propionibacterium (Prop 853) P= 0.002, and Lactobacillus (Lab 158) P < 0.000 (Figure 4.1)   
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Figure 4.1: Differences in starting bacterial communities used within in vitro batch culture fermentation for all the three volunteers 1, 2 
and 3 at t=0. Values are presented of the bacterial numbers (log10/g faeces determined by flow cytometry: fluorescence in situ 
hybridisation) Values listed are mean ± SD. Eub= Total bacteria, BIF= Bifidobacterium spp. LAB= Lactobacillus, Leuconostoc and 
Weissella spp. BAC= Bacteriodes spp. EREC= Clostridium coccoides-Eubacterium rectale group, RREC= Roseburia subcluster, ATO= 
Atopobium, Colinsella, Olsenella and Eggerthella spp, PRO= clostridial cluster IX, FPRAU= Faecalibacterium prausnitzii and related 
sequences, DSV= Desulfovibrionales (excluding Lawsonia) and many Desulfuromonales, CHIS= (Clostridium clusters I and II). 
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Table 4.2: Microbial changes following fermentation of substrates in pH controlled 
batch cultures. Log10 number of bacterial cells/ml batch supernatant, +/- stdev. * 
indicated     significantly different to blank, a indicates significantly different to t0. 
TYR (L)  t0        t4        t8        t24        t30        t48       
EUB FL2  6.71  ±0.74     7.03  ±0.75     6.92  ±0.61     6.96  ±0.74     6.92  ±0.18     6.74  ±0.59    
 BIF  5.68  ±0.50    5.91  ±0.74    5.79  ±0.74  5.93  ±0.70  5.76  ±0.38    5.63  ±0.65 
LAB  5.15  ±0.98    5.69  ±0.73    5.33  ±0.67  5.64  ±0.71  5.67  ±0.36    5.60  ±0.79 
 BAC  5.30  ±0.71    5.69  ±0.72    5.66  ±0.57  5.79  ±0.72  5.78  ±0.23    5.78  ±0.65 
 EREC  6.19  ±0.73    6.51  ±0.77    6.32  ±0.65  6.15  ±0.84  5.88  ±0.43    5.81  ±0.55 
RREC  5.36  ±0.72    5.29  ±0.95    5.55  ±0.46  5.44  ±0.83  5.62  ±0.22    5.55  ±0.51 
ATO  5.41  ±0.43    5.69  ±0.37    5.53  ±0.39  5.88  ±0.53  5.72  ±0.40    5.70  ±0.46 
 PRO  5.82  ±0.83    5.88  ±0.92    6.05  ±0.68  6.03  ±0.94  6.17  ±0.31    5.88  ±0.67 
FPRAU  5.69  ±0.88    6.06  ±1.14    5.89  ±0.91  5.95  ±0.78  5.79  ±0.41    5.69  ±0.54 
 DSV  5.11  ±0.90    5.48  ±0.82    5.39  ±0.55  5.55  ±0.62  5.54  ±0.38    5.26  ±0.68 
 CHIS  5.27  ±0.77     5.55  ±0.56     5.29  ±0.65     5.64  ±0.48     5.61  ±0.33     5.50  ±0.61    
 
TYR (H)  t0        t4        t8        t24        t30        t48       
EUB FL1  6.99  ±0.70     7.19  ±0.69  a  7.13  ±0.46     7.07  ±0.81     7.16  ±0.20     6.85  ±1.00    
 BIF  5.87  ±0.61    5.85  ±0.79    5.94  ±0.47  6.04  ±0.71  5.82  ±0.34    5.78  ±0.90 
LAB  5.46  ±0.95    6.01  ±1.10    5.96  ±0.88  5.79  ±1.22  6.10  ±0.62    5.61  ±1.22 
 BAC  5.59  ±0.57    5.87  ±0.70    5.76  ±0.34  5.86  ±0.67  5.87  ±0.22    5.74  ±0.85 
 EREC  6.50  ±0.71    6.64  ±0.62    6.46  ±0.53  6.31  ±1.01  6.11  ±0.14    5.89  ±0.95 
RREC  5.66  ±0.39    5.52  ±0.36    5.67  ±0.34  5.69  ±0.74  5.75  ±0.14    5.48  ±1.08 
ATO  5.59  ±0.42    5.69  ±0.58    5.69  ±0.16  5.96  ±0.51  6.27  ±0.41    5.80  ±0.71 
 PRO  6.07  ±0.73    6.06  ±0.95    6.31  ±0.58  6.16  ±1.03  6.18  ±0.63    6.11  ±1.23 
FPRAU  5.98  ±1.01    6.13  ±0.96    6.10  ±0.67  5.94  ±0.77  5.89  ±0.02    5.63  ±0.94 
 DSV  5.40  ±0.87    5.51  ±0.58    5.50  ±0.40  5.56  ±0.78  5.67  ±0.22    5.31  ±0.99 
 CHIS  5.43  ±0.72     5.58  ±0.43     5.55  ±0.41     5.68  ±0.69     5.76  ±0.31     5.42  ±0.95    
 
TYR (L)+FOS  t0        t4        t8        t24        t30        t48       
EUB FL4  7.00  ±0.81    7.33  ±0.78    7.44  ±0.86  a  6.59  ±1.37  7.17  ±1.47    7.57  ±0.13 
 BIF  5.78  ±0.96    6.28  ±0.94  a  6.52  ±1.22  5.75  ±1.62  6.26  ±1.51    6.45  ±0.83 
LAB  5.53  ±0.91    6.22  ±0.89    6.22  ±0.92  4.99  ±1.18  5.71  ±1.53    6.31  ±0.43 
 BAC  5.33  ±1.21    5.93  ±0.86    6.20  ±1.15  5.62  ±1.45  6.26  ±1.64    6.52  ±0.22  * 
 EREC  6.38  ±0.98    6.62  ±0.82    6.48  ±0.77  5.55  ±1.38  6.00  ±1.22    6.21  ±0.17 
RREC  5.34  ±1.10    5.75  ±0.46    5.85  ±0.56  5.17  ±1.11  5.69  ±1.20    5.98  ±0.19 
ATO  5.55  ±0.64    5.82  ±0.16    6.12  ±0.65  5.56  ±1.67  5.98  ±1.76    6.38  ±0.44 
 PRO  6.28  ±0.44    6.17  ±1.04    6.15  ±1.09  5.52  ±1.45  6.05  ±2.03    6.80  ±0.57 
FPRAU  5.99  ±1.31    6.34  ±0.91    6.32  ±0.93  5.47  ±0.98  6.03  ±1.16    6.18  ±0.12 
 DSV  5.29  ±1.18    5.69  ±0.88    5.59  ±0.94  4.97  ±1.21  5.57  ±1.75    5.91  ±0.18 
 CHIS  5.31  ±1.16    5.89  ±1.00    6.16  ±1.05  a  5.14  ±1.02  5.83  ±1.14    6.15  ±0.16  
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ALBUMIN  t0        t4        t8        t24        t30        t48       
EUB FL5  7.07  ±0.44     7.00  ±0.47     7.13  ±0.52     7.02  ±0.36     7.09  ±0.05     6.73  ±0.28    
 BIF  5.90  ±0.47    5.79  ±0.59    5.94  ±0.73  6.02  ±0.35  5.90  ±0.37    5.68  ±0.47 
LAB  5.57  ±0.73    5.71  ±0.13    5.49  ±0.58  5.69  ±0.43  5.85  ±0.05  *  5.59  ±0.23 
 BAC  5.75  ±0.36    5.70  ±0.38    6.03  ±0.30  a  5.75  ±0.09  5.84  ±0.26    5.70  ±0.28 
 EREC  6.56  ±0.39    6.44  ±0.53    6.46  ±0.67  6.02  ±0.25  6.11  ±0.15    5.62  ±0.48 
RREC  5.63  ±0.47    5.36  ±0.54    5.68  ±0.50  5.64  ±0.29  5.51  ±0.33    5.56  ±0.23 
ATO  5.72  ±0.26    5.63  ±0.71    5.67  ±0.37  6.04  ±0.60  6.09  ±0.23  a  5.60  ±0.41 
 PRO  6.13  ±0.59    5.99  ±0.61  a  6.31  ±0.52  6.03  ±0.64  6.28  ±0.46    5.87  ±0.43 
FPRAU  6.12  ±0.69    6.03  ±0.78    6.12  ±0.89  6.03  ±0.51  5.97  ±0.20    5.62  ±0.46 
 DSV  5.54  ±0.65    5.33  ±0.52    5.40  ±0.63  5.60  ±0.17  5.66  ±0.37    5.20  ±0.29  * 
 CHIS  5.60  ±0.52     5.22  ±0.61     5.53  ±0.59     5.56  ±0.27     5.57  ±0.10     5.49  ±0.21    
 
SOYBEAN  t0        t4        t8        t24        t30        t48       
EUB FL6  7.10  ±0.60     7.12  ±0.41     7.13  ±0.66     6.88  ±0.87     6.84  ±0.80     6.97  ±0.67    
 BIF  5.94  ±0.62    5.99  ±0.63    6.00  ±0.55  5.94  ±0.63  5.84  ±0.68    5.96  ±0.73 
LAB  5.68  ±0.49    6.18  ±0.44    5.96  ±1.29  5.76  ±1.34  5.90  ±1.16    5.96  ±0.97 
 BAC  5.58  ±0.53    5.87  ±0.36    5.83  ±0.69  5.64  ±0.94  5.58  ±0.89    5.84  ±0.88 
 EREC  6.52  ±0.71    6.52  ±0.44    6.31  ±0.73  5.83  ±0.97  5.78  ±0.95    5.97  ±0.66 
RREC  5.64  ±0.31    5.63  ±0.57    5.70  ±0.32  5.58  ±0.86  5.59  ±0.72    5.78  ±0.61 
ATO  5.59  ±0.29    5.59  ±0.25    5.59  ±0.19  5.65  ±0.69  5.61  ±0.80    5.67  ±0.77 
 PRO  6.29  ±0.73    5.97  ±0.52    6.21  ±0.88  5.99  ±1.12  5.58  ±0.79    6.04  ±0.50 
FPRAU  6.19  ±0.83    6.08  ±0.66    5.98  ±0.74  5.56  ±0.84  5.57  ±0.93    5.65  ±0.72 
 DSV  5.59  ±0.58    5.46  ±0.46    5.59  ±0.44  5.37  ±0.98  5.41  ±0.86    5.49  ±1.05 
 CHIS  5.53  ±0.58     5.46  ±0.63     5.57  ±0.44     5.44  ±0.97     5.68  ±0.75     5.65  ±0.71    
 
 
 
 
 
TYR 
(H)+FOS  t0        t4        t8        t24        t30        t48       
EUB FL3  6.98  ±0.83    7.42  ±0.98    7.33  ±1.01  7.31  ±0.54  7.93  ±0.32  *  7.59  ±0.30    
 BIF  5.89  ±0.68    6.45  ±1.06    6.42  ±1.26  6.53  ±0.84  6.84  ±0.77    6.58  ±0.75 
LAB  5.45  ±0.97    6.30  ±1.31    5.97  ±1.06  a  5.93  ±0.85  6.62  ±0.79    6.30  ±1.04 
 BAC  5.54  ±0.73    6.07  ±1.04    6.16  ±0.89  5.64  ±0.18  6.58  ±0.73    6.24  ±0.21 
 EREC  6.41  ±0.90    6.68  ±0.89  a  6.55  ±1.14  6.28  ±0.81  6.70  ±0.04    6.30  ±0.53 
RREC  5.65  ±0.63    5.74  ±0.60    5.44  ±0.66  5.41  ±0.57  a  6.08  ±0.49    5.88  ±0.37 
ATO  5.66  ±0.48    5.97  ±0.74    5.69  ±0.77  5.96  ±0.72  6.60  ±0.45  *  6.34  ±0.43 
 PRO  6.05  ±0.87    6.17  ±1.12    6.42  ±0.75  6.16  ±0.63  6.73  ±1.09    6.61  ±0.87 
FPRAU  6.09  ±1.05    6.37  ±1.04    6.28  ±1.24  6.18  ±0.50  6.60  ±0.18  *  6.11  ±0.29 
 DSV  5.56  ±0.93    5.84  ±0.87    5.56  ±0.78  5.35  ±0.32  6.14  ±0.44    5.71  ±0.56 
 CHIS  5.56  ±0.79    5.84  ±0.91    5.83  ±1.08  5.49  ±0.23  6.21  ±0.62    5.92  ±0.50    
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FOS  t0        t4        t8        t24        t30        t48       
EUB FL6  6.81  ±0.57     7.39  ±0.60     7.82  ±0.15  *  7.36  ±0.80     7.71  ±0.16  *  7.83  ±0.19  *a 
 BIF  5.62  ±0.60    6.21  ±1.03    6.61  ±1.12  6.42  ±1.07  7.37  ±0.17  *a  6.73  ±0.79 
LAB  5.41  ±0.69    6.00  ±1.02    6.49  ±0.88  6.05  ±1.42  6.68  ±0.93    6.61  ±0.98 
 BAC  5.43  ±0.57    6.21  ±0.56  a  6.36  ±0.38  5.86  ±0.86  6.32  ±0.38  a  6.56  ±0.70 
 EREC  6.32  ±0.56    6.29  ±0.40    6.49  ±0.05  6.34  ±0.33  6.36  ±0.15    6.30  ±0.40 
RREC  5.44  ±0.62    5.59  ±0.36    5.76  ±0.48  5.68  ±0.57  5.97  ±0.31    6.03  ±0.73 
ATO  5.42  ±0.45    5.92  ±0.78    6.02  ±1.02  6.28  ±0.87  6.22  ±0.50    6.54  ±0.26  * 
 PRO  5.79  ±0.71    6.40  ±0.78    6.83  ±0.84  6.05  ±0.81  6.17  ±0.30    6.72  ±1.14 
FPRAU  5.89  ±0.65    5.93  ±0.62    6.18  ±0.18  5.91  ±0.60  6.20  ±0.21    6.11  ±0.49 
 DSV  5.40  ±0.68    5.38  ±0.32    5.61  ±0.59  5.60  ±0.69  5.83  ±0.15    5.82  ±0.80 
 CHIS  5.34  ±0.60     5.99  ±1.13     6.31  ±0.23  *  5.74  ±0.81     5.91  ±0.26     5.94  ±0.71    
 
PEPTONE 
MEAT  t0        t4        t8        t24        t30        t48       
EUB FL6  6.71  ±0.66     6.89  ±0.43     7.20  ±0.47     7.01  ±0.55  a  7.08  ±0.13     7.00  ±0.53    
 BIF  5.45  ±0.70    5.74  ±0.50    5.99  ±0.54  5.97  ±0.40  5.97  ±0.32    5.91  ±0.45 
LAB  5.37  ±0.66    5.24  ±0.26    5.59  ±0.82  5.76  ±0.98  5.58  ±0.26    5.76  ±0.57 
 BAC  5.36  ±0.60    5.63  ±0.39    5.74  ±0.97  5.82  ±0.26  5.95  ±0.34    6.11  ±0.52 
 EREC  6.13  ±0.64    6.34  ±0.51    6.52  ±0.48  a  6.34  ±0.46  6.09  ±0.15    6.10  ±0.50 
RREC  5.38  ±0.53    5.34  ±0.33    5.83  ±0.44  5.58  ±0.52  a  5.76  ±0.29    5.72  ±0.52 
ATO  5.43  ±0.38    5.47  ±0.54    5.58  ±0.38  5.77  ±0.55  5.90  ±0.08    5.80  ±0.41 
 PRO  5.91  ±0.70    6.00  ±0.59    6.30  ±1.12  5.99  ±0.69  6.18  ±0.58    6.16  ±0.64 
FPRAU  5.63  ±0.89    5.97  ±0.61    6.02  ±0.71  5.93  ±0.66  6.15  ±0.41    5.91  ±0.61 
 DSV  5.25  ±0.84    5.28  ±0.24    5.56  ±0.62  5.47  ±0.60  5.49  ±0.29    5.54  ±0.64 
 CHIS  5.25  ±0.68     5.25  ±0.33     5.51  ±0.57     5.55  ±0.60     5.53  ±0.19     5.65  ±0.58    
 
Blank  t0        t4        t8        t24        t30        t48       
EUB FL6  6.73  ±0.65     6.95  ±0.65     6.92  ±0.52     6.78  ±0.53     6.83  ±0.16     7.03  ±0.29    
 BIF  5.42  ±0.68    5.85  ±0.48    5.75  ±0.27  5.63  ±0.28  5.84  ±0.22    5.94  ±0.17 
LAB  5.23  ±0.80    5.41  ±0.52    5.53  ±0.41  5.96  ±0.97  5.50  ±0.16    5.81  ±0.19 
 BAC  5.33  ±0.71    5.73  ±0.70    5.73  ±0.55  5.62  ±0.59  5.67  ±0.24    6.00  ±0.24 
 EREC  6.25  ±0.66    6.21  ±0.86    6.12  ±0.65  5.80  ±0.53  6.04  ±0.44    6.01  ±0.34 
RREC  5.40  ±0.48    5.67  ±0.24    5.66  ±0.27  5.46  ±0.19  5.63  ±0.09    5.92  ±0.19 
ATO  5.28  ±0.47    5.56  ±0.38    5.50  ±0.29  5.67  ±0.33  5.71  ±0.14    5.90  ±0.23 
 PRO  5.74  ±0.69    6.07  ±0.99    6.18  ±0.92  5.72  ±0.71  5.88  ±0.32    6.13  ±0.53 
FPRAU  5.83  ±0.86    5.93  ±0.71    5.81  ±0.54  5.69  ±0.51  5.71  ±0.26    5.95  ±0.28 
 DSV  5.28  ±0.78    5.60  ±0.65    5.55  ±0.36  5.38  ±0.36  5.47  ±0.05    5.84  ±0.24 
 CHIS  5.24  ±0.66     5.48  ±0.45     5.52  ±0.22     5.53  ±0.55     5.54  ±0.19     5.83  ±0.23    
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Fermentation of the substrates resulted in changes in bacterial groups as observed using 
FLOW-FISH. Low tyrosine lead to no significant bacteriological changes whilst high tyrosine 
lead to an increase in total bacteria after 4h fermentation compared to baseline. The addition of 
FOS to low tyrosine resulted in significant increases in Bifidobacterium at t4 and of total 
bacteria and bacteria within the C. histolyticum group following 8 h fermentation when 
compared to t0. At time 48 h in the low tyrosine with FOS treatment there were more 
Bacteroides, compared to the blank vessel. 
 
In the presence of FOS, the fermentation of high tyrosine resulted in significant increases in 
bacteria within the E. rectale group at t4; lactobacilli at t8 and Roseburia at t 24 as compared 
to t0. When compared to the blank vessel fermentation of high tyrosine with FOS resulted in 
more total bacteria, bacteria in the Atopobium group and members of the Faecalibacterium 
prausnitzii group. 
 
Albumin treatment resulted in reduced clostridial cluster IX at t4, increased Bacteroides at t8 
and increased Atopobium at t30 as compared to t0. Compared to the blank vessel, albumin lead 
to enhanced lactobacilli at t30 and reduced DSV following 48 hours fermentation. 
Fermentation of soybean protein resulted in no significant changes of the groups monitored. 
 
Fermentation of FOS resulted in increases in Bacteroides at t4, Bifidobacterium and 
Bacteroides at time 30 h and total bacteria at time 48 h as compared to t0. When compared to 
the blank vessel FOS resulted in significant increases in Bifidobacterium after 30 hours, 
enhanced total bacteria after 8 hours and enhance Atopobium after 48 hours fermentation. 
Fermentation of peptone resulted in increases in E. rectale group after 8 hours fermentation 
and total bacteria and Roseburia after 24 hours. 
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4.5.2 Indole and Phenols 
There was considerable inter-individual variation in the synthesis of organic metabolites in the 
batch culture fermentation supernatants according to the donor inoculum used; for the purposes 
of clarity, Figure 4.2 shows metabolites produced with inoculae from volunteer 1 only, and 
shows variance in the production of proteolytic metabolites in fermentation supernatants, there 
was higher concentration of these metabolites at 30 hours, hence this data has been used. Data 
obtained using different fermentation substrates (three replicates within the same faecal donor) 
is in supplementary Figure 4.1 for a comparison of inter-individual metabolite production. 4-
cresol was produced in the highest concentrations using a basal media supplemented with a 
mixture of FOS (1.5:100 w/w) and tyrosine (0.3:100 w/w), reaching a concentration of 17.2 
mM. Modest concentrations of 4-cresol were also observed in batch cultures supplemented 
with tyrosine at high concentration (0.3:100 w/w) reaching a concentration of 12 mM or low 
doses (0.003:100 w/w). Lower concentrations of 4-cresol were produced in fermentations 
where the media was supplemented with meat peptone (0.3:100 w/w), soy protein (0.3:100 
w/w) or albumin (0.3:100 w/w). Using supplementary FOS alone in the media did not lead to 
appreciable production of 4-cresol (0.2 mM).   
The highest concentrations of phenol (9.3 mM) were observed in the fermentation supernatant 
where the culture media was supplemented both tyrosine and FOS (0.3:100 w/w and 1.5:100 
w/w). With all other substrates phenol concentrations were much lower. Indole production was 
also greatest (0.8 mM) in the fermentation supplemented with the combination of high tyrosine 
and fructo-oligosaccharide. It was produced in the lowest concentrations in fermentations 
supplemented with FOS alone (1.5:100 w/w)  (0.06 mM), but was relatively abundant in 
fermentations with increasing concentrations of high tyrosine (0.3:100 w/w) tyrosine and FOS 
(0.3:100 w/w 1.5:100 w/w) and peptone meat ( 0.3:100 w/w) 
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 Figure 4.2: Concentrations of 4-cresol (A), phenol (B), indole (C) and total organic acid (D) using from mixed culture fermentation 
supernatants at 30 hours using faecal innoculate from volunteer 1; High tyrosine (HT) (0.3:100 w/w), Low tyrosine (LT) (0.003:100 
w/w), High tyrosine with FOS (HT with FOS) (0.3:100 w/w and 1.5:100 w/w), Low tyrosine with FOS (LT with FOS) (0.003:100 w/w and 
1.5:100 w/w), Soybean (SB) (0.3:100 w/w),, Peptone meat extract (PM) (0.3:100 w/w),  and fructo-oligosaccharide (FOS) (1.5:100 w/w) 
after 30hrs incubation. The data presented as mean (±SEM) comparable to the control (n=3).
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4.5.3 Short Chain Fatty Acids  
Inter-individual variation in the synthesis of SCFA in batch culture fermentation was observed 
according to the inoculum used; again for the purposes of clarity, data are presented here for 
volunteer 1 only (see supplementary Figure 2 for comparisons with volunteers 2 and 3). Figure 
4.3 shows the SCFA concentrations of fermentation supernatants at 30 hours with different 
supplementary substrates (three replicates within the same faecal inoculum). The highest 
production of SCFA was observed using a basal media supplemented with a mixture of tyrosine 
(0.3:100 w/w) and FOS (1.5:100 w/w), reaching concentrations of, 33 mM of acetate, 9 mM 
propionate and 6 mM butyrate. As anticipated, the presence of supplemental FOS led to higher 
SCFA concentrations with or without sources of supplemental nitrogen. The lowest 
concentrations of SCFA were produced in the negative control, indicating the baseline potential 
of the microbiota to produce SCFAs without the additional of substrates to the media.  
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Figure 4.3: Concentration of SCFA from mixed culture fermentation supernatants at 30 hours using faecal inoculate from volunteer 1; 
High tyrosine (HT) (0.3:100 w/w), Low tyrosine (LT) (0.003:100 w/w), High tyrosine with FOS (HT with FOS) (0.3:100 w/w and 1.5:100 
w/w), Low tyrosine with FOS (LT with FOS) (0.003:100 w/w and 1.5:100 w/w), Soybean (SB), Peptone meat extract (PM) and fructo-
oligosaccharide (FOS) (1.5:100 w/w) after 30 hrs incubation. The data presented as mean (±SEM) comparable to the control (n=3). 
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4.5.4 Genotoxicity of fermentation supernatants 
For clarity, in Figure 4.4 data presented show the induction of DNA damage in HT29 cells by 
fermentation supernatants by supplementary regime for volunteer 1. DNA damage was 
assessed via the COMET assay following a 24 hour exposure to the filter sterilised supernatant 
at 10% of the carrier media. The highest observed levels of DNA damage were reported for the 
fermentation supernatant with the high tyrosine supplementation (with and without FOS), they 
were lowest in the fermentations supplemented with FOS alone. The low tyrosine, low tyrosine 
with FOS, albumin, soybean and peptone meat fermentations all produced moderately 
genotoxic fermentation samples.  
Using the genotoxicity and metabolite data from all three volunteers the study were able to 
regress the measured metabolites for individual fermentation supernatants against the reported 
genotoxicity. The best predictors of genotoxicity were 4-cresol, acetate and iso-valerate. Of 
note however, acetate and iso-valerate are independently strong correlates of 4-cresol (p= 0.001 
and < 0.000 respectively).  
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Figure 4.4: Effect of different fermentation supernatants (High tyrosine (HT), High tyrosine with FOS (HT with FOS), Soybean (SB) 
and Peptone meat (PM) on DNA damage for 24 hrs exposure on HT29 cell line. The data presented as mean (±SEM) percentage of DNA 
damage comparable to the control (n=3). * indicate a significant difference compared to the untreated control (Dunnett test; *p<0.05).  
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Table 4.3: Regression liner model test shows the effect of the metabolites from 
fermentation supernatants; 4-cresol, phenol, indole and SCFA and BSCFA in 
genotoxicity. Values are log10 biological replicates.  
 Metabolite 
predictor 
r P value 
 
Model 1 
4-cresol  
0.775 
0.002 
Phenol 0.317 
indole 0.708 
 
Model 2 
 
4-cresol 
 
0.681 
 
0.005 
 
 
 
 
Model 3 
SCFA  
Acetate 0.759 0.001 
Iso-valerate 0.995 0.000 
Propionate  
 
0.477 
0.407 
Butyrate 0.820 
Iso-butyrate 0.199 
Valerate  0.249 
Caproic 0.241 
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4.5.5 4-cresol genotoxicity and cytotoxicity  
The independent genotoxic effects of increasing concentrations of 4-cresol against both HT29 
and Caco-2 cells, following a 24 hr treatment in carrier cell culture media, are shown in Figure 
4.5. In the top pane of the figure cell viability established via DAPI assay with equivalent 
exposures is displayed. Cell viability was maintained above 85 % at each of the doses used 
although there was a trend towards increasing cytotoxicity at 3 mM (Figure 4.5).  
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Figure 4.5: The top figure shows the cytotoxicity of 4-cresol (cell viability) present as mean (±SEM ) percentage (n=4-6). Cells were 
incubated with different concentration of 4-cresol at 0, 0.2, 0.5, 1.0, 1.5 and 3 mM for 24 hours on HT29 and Caco-2. The data presented 
as mean (±SEM) percentage of viable cells comparable to the control (n=4-6).* indicate a significant difference compared to the 
untreated control (Dunnett test; *p<0.05). The lower figure shows the DNA strand breaks on HT29 and Caco-2 cells with different 4-
cresol concentration 0,0.5,1.5 and 3.0mM for 24 hours. Values are means ±SEM biological replicates. * indicate a significant difference 
compared to the untreated control (correlation coefficient). 
 142 
 
There was a dose dependent increase in DNA damage with increasing concentrations of 4 
cresol reaching statistical significance at concentrations of 3 mM for both cells lines (p= <0.05) 
the observed DNA damage was slightly higher in the HT29 cells.  
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Internally spiked fermentation supernatants: To consider the effects of increasing 4-cresol 
concentrations within the context of the gut microbial environment the study spiked selected 
fermentation supernatants, post-fermentation with either low (0.2mM) or high (3mM) doses of 
exogenous 4-cresol and assessed genotoxicity against the HT29 cells Figure 4.6 with the 
higher 4-cresol spike significant increase in DNA strand breaks was observed.  
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Figure 4.6: Spiked cell with low dose 0.2mM and high dose 3mM of 4-cresol in high production of 4-cresol from fermentation supernatants 
High tyrosine (HT), High tyrosine with FOS (HT with FOS), and low production of 4-cresol from Soybean (SB) and FOS alone on DNA 
damage for 24 hrs on HT29 cell line. The data presented as mean (±SEM) percentage of DNA damage comparable to the control (n=3). 
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4.5.6 4-cresol and cell cycle kinetics 
Both the HT29 (A) and Caco-2 (B) cells treated with 4 cresol for 24 hours, before observing 
disruptions to cell cycle behaviour Figure 4.7. There was a non-linear dose response to 4-
cresol, with the changes observed perhaps relating to levels of DNA damage. At lower 
exposures of up to 0.5 mM 4-cresol, the study observed decreases in the abundance of cells in 
G0/G1 with a compensatory increase in the proportion of cells in S phase, however at higher 
concentrations the proportion of cells in G0/G1 increased significantly relative to the proportion 
of cells in S phase in both cell lines, suggesting a slight growth promoting effect at lower doses 
and G0/G1 growth arrest in response to genotoxic insult at higher doses.  
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Figure 4.7: Cell cycle progression of HT29 (A) and Caco-2 (B) cell line treated with 0.2, 0.5, 1.0, 1.5 and 3mM of 4-cresol for 24hours. 
The percentage of cells in each phase of the cell cycle was determined using flow cytometry to quantify DNA content (n= 4). Asterisks 
indicate a significant difference compare to the untreated control (Dunnett test; * p<0.05, ** p <0.01, ***p<0.001)
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4.6 Discussion and conclusions 
Here, the synthesis of 4-cresol in a batch culture model of the human colon and assessed its 
effects on cultured human colonocytes has been evaluated. In this model, it was first observed 
that the resident microbiota influences the subsequent metabolic profile of gut fermentation 
supernatants given the, same dietary substrate. Then demonstrated that the genotoxicity of gut 
fermentation supernatants may be influenced by dietary fermentation substrates, and that this 
genotoxicity may, in part, be predicted by the concentrations of the metabolite 4-cresol. This 
study observed that 4-cresol induces genotoxic insult in colorectal cell lines, both 
independently, and as a supplementary component of faecal fermentation supernatants. Finally, 
the study show that 4-cresol interferes with normal cell cycle kinetics in two separate human 
colorectal cancer cell lines, stimulating DNA synthesis at low doses, and cell cycle arrest at 
genotoxic concentrations. The fluctuation of 4-cresol toxicity suggests a slight growth 
promoting effect at lower doses and G0/G1 growth arrest in response to genotoxic insult at 
higher doses.Changes in cell kinetics are a hallmark of carcinogenesis, and may be considered 
tumour promoting. These results support our original hypothesis that 4-cresol may contribute 
to a pro-carcinogenic colonic environment.  
At baseline, the faecal inoculate from volunteer 1 was characterised by a higher relative 
proportion of Bifidobacterium (BIF164 ), Atopobium cluster (ATO 291) and Desulfovibrio 
(DSV 687) than volunteers 2 and 3; and a lower relative abundance of bacteria staining positive 
for Faecalibacterium (FPRAU 655) and Propionibacterium (Prop 853) and Lactobacillus (Lab 
158) . The microbial composition of the faecal inoculate from volunteers 2 and 3 were more 
closely aligned and were associated with a lower production of 4-cresol and other metabolites. 
Importantly, the study also show that fermentation substrates can influence both composition 
of the microbiota and the subsequent production of beneficial and detrimental metabolites.   
The total bacteria count was increased in particular following fermentation with broths 
supplemented with high levels of tyrosine, high levels tyrosine with FOS or with peptone meat 
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extract. Furthermore, the high tyrosine broth and the high tyrosine with FOS broths induced 
increases in the proportion of the proteolytic Clostridium histolyticum group (Chis 150) 
following fermentation. However, soybean and FOS supplemented broths favoured the growth 
of the saccharrolytic genera with observed increases in the proportions of bacteria staining for 
BIF, LAB and BAC.  
According to the fermentation results in this study, microbial changes observed following 
fermentation indicated limited impact of tyrosine on the microbiota, however, enhanced 
activities were observed with the addition of FOS (Table 4.2). Such changes impacted on a 
range of groups, including Roseburia, a key butyrate producing group; but also Atopobium 
and Faecalibacterium prausnitzii. Whether these changes are of benefit are difficult to 
determine based on the bacterial changes, although alteration in a wide range of microbial 
groups points to reduced selectivity - this conclusion is further supported by the increased 
genotoxicity observed. A large increase in total bacteria was observed at 30 hours, this 
change implies a microbial group that was not monitored also increased at this time point and 
may account for some of the potentially negative changes seen. This result was not expected 
as a positive impact of the prebiotic was expected; however, in an in vitro environment with 
limited substrate availability the bacteria are competing in a different way as to how they 
would in vivo [25-27]. These results were in line with a study results by Vipperla  O'Keefe 
who found that  when the gut bacteria composition was shifted by animal protein diet  and 
contained fewer bacteria that produce the short chain fatty acid butyrate, and more potentially 
harmful bacteria such as Fusobacterium nucleatum, Rhodopseudomonas faecalis, 
Bacteroides vulgatus and Enterococcus faecalis, the latter being a superoxide producer that 
may damage epithelial DNA [28]. Furthermore, a results from Hildebrandt et al, study found 
that  Sulfate reducing bacteria is considered harmful for the gut epithelium and can damage 
the DNA through production of free radicals [29]. In the present study it was seen that several 
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bacterial groups, that include proteolytic genera, such as Bacteroides, Clostridium and 
Fusobacterium increased, along with genotoxicity after 24 hours. These observation are 
associated with high proteolytic activities and thus DNA damage [30].  
In this study, it was selectively measured the concentration of several known faecal metabolites 
in the fermentation supernatants. The short chain fatty acids are generally seen as beneficial 
products of both the proteolytic and saccharolytic fermentation; whereas indoles, phenols and 
cresol might be viewed as potential toxins produced during proteolytic fermentation. As 
expected, supplementing fermentation broth with the prebiotic FOS led to enhanced synthesis 
of the saccharolytic metabolites (SCFA) with little effect on the production of cresol, indole or 
phenol, whereas supplementing broths with tyrosine or sources of protein induced increases in 
the production of the proteolytic metabolites but also increased the production of acetate and 
butyrate. Furthermore, combining prebiotic FOS with supplemental tyrosine in the 
fermentation broth led to the highest concentrations of the measured fermentation supernatants. 
This was a surprising result, as a rescuing effect of FOS may have been expected in terms of 
protein fermentation end-products. However, enhanced SCFA produced when FOS is 
additionally present may offer benefits to the host [31]. 4-cresol can be found in human faeces 
at concentrations of up to 0.5 mM; in vivo 4-cresol is largely absorbed and metabolised to 4-
cresol sulphate appearing in urine at concentrations of up to 0.3 mM [32]. Therefore faecal 4-
cresol poorly reflects colonic concentrations, and further the normal range of concentrations 
through the colon remains uncertain. In this study, in vitro batch culture fermentation system 
were flawed, in that there is no absorptive, or flow through, clearance of 4-cresol from the 
system and no replenishment of substrate, as would occur in vivo; nevertheless, by experiencing 
this build up 4-cresol production can be observed; and as the study observed 4-cresol at 
concentrations of up to 17 mM, suggesting that the 0.5 mM concentrations reported in faeces 
may significantly under represent potential intestinal epithelial exposures.  
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The study assessed the genotoxicity of our fermentation supernatants against HT29 cells using 
the Comet assay. The post fermentation supernatant resulting from broth supplemented with 
high tyrosine plus FOS was observed to be the most genotoxic. Regressing genotoxicity against 
the metabolites measured in the fermentation samples from all three volunteers, it was found 
that the best independent predictor of genotoxicity was the concentration of 4-cresol (Table 
4.3). The study observed considerable co-linearity in the concentrations of the metabolites in 
our fermentation samples, and further, the study was uncertain of the potential for collinearity 
between 4-cresol and other un-characterised potential genotoxins in our fermentation 
supernatants. Therefore in a follow up experiment the study spiked a selection of fermentation 
supernatants with 0.2 or 3 mM of 4-cresol and observed a consistent dose-dependent increase 
in supernatant genotoxicity.           
Having established that 4-cresol contributes to the observed genotoxicity in the fermentation 
samples from this gut model, the next phase was to establish the independent effects of 4-cresol 
against two separate colonic cell lines. 4-cresol was observed to be cytotoxic at doses 3 mM 
and up for both HT29 and Caco-2 cells; HT29 cells appeared more sensitive to 4-cresol 
mediated genotoxicity than the Caco-2 cells, however in both cell lines this study observed a 
linear dose dependent increase in DNA damage up to 3 mM. The study observations are 
consistent with previous work by Andriamihaja et al, who used the γH2AX assay and observed 
genotoxicity against both HT29 Glc-/+ and LS-174T human colonic cell lines at concentrations 
of >1.5 mM [33]. 
 Then proceeded to study the effects of exposure to this genotoxin on cell cycle activity. At 
lower concentrations the abundance of cells in S phase was increased in both cell lines with a 
subsequent decrease in the abundance of cells in G0/G1. This observation of a mitogenic 
response to low dose 4 cresol might explain the tumour promotion demonstrated by Boutwell 
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and Bosch [34] for 4-cresol in a classical murine papilloma study following tumour initiation 
with 9,10-dimethyl-l-benzanthracene.  
 
At higher doses the study observed a reduction in the proportion of cells in S phase and an 
increase in proportion of cells in G0/G1 and in G2/M, perhaps indicating cell cycle arrest in 
response to DNA damage. The observed genotoxicity and mitogenicity therefore represent two 
separate, and complimentary, potential pro-carcinogenic properties of colonic 4-cresol. The 
models have employed in this study are widely used and accepted in mechanistic studies of 
dietary exposures related to colorectal cancer; they represent different aspects of the 
carcinogenic process, and so it is interesting that 4-cresol exerts effects on each of these models. 
Having said that, these are in vitro systems, the anti-cancer defence mechanisms of the colonic 
epithelium are potentially very different in vivo, and the complexity of the microbiota and the 
environment of the gut lumen confounds the ability to draw firm conclusions regarding the 
potential carcinogenic effects of 4-cresol in vivo. One human randomised crossover trial with 
high and low protein diets reported a weak correlation between urinary 4-cresol excretion and 
FW genotoxicity [35].  
Carcinogenicity in humans has not yet been proven for 4-cresol; based on a very small (n=6 
cases) case control study by Bone and Tamm [36] argued that comparable urinary 
concentrations of 4-cresol in from volunteers with bowel cancer to that from the urine of 
healthy controls was evidence that this metabolite is not affecting CRC risk; ours and other 
emerging data would challenge this. Evaluation of 4-cresol in stored urinary samples from 
existing prospective cohort studies may help establish the strength of any relationship with 
cancer risk and further validate the use of urinary 4-cresol as a biomarker of risk for 
intervention studies.       
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5. Genotoxicity of culture supernatants derived from intestinal tumour associated 
fusobacteria. 
 
5.1 Abstract 
 
Background:   Fusobacterium nucleatum are typically present in oral mucosa but not in 
healthy gastrointestinal mucosa; several groups now report the adherence of fusobacteria to 
inflammatory bowel specimens as well as to colorectal adenoma and tumour tissues. It remains 
unclear as to whether fusobacteria act as a driver or a passenger in colorectal cancer.  
Aim: Here, we assess the genotoxicity of culture supernatants from F. nucleatum samples 
isolated from CRC tissue and further, we assess the influence of these supernatants on the cell 
cycle activity of the intestinal HT29 cell line. 
Methods: 18 F. nucleatum strains were isolated from tumour tissue and anaerobically cultured 
in a modified tryptic soy broth for 24 hrs. For the purity of these strains, these were isolated on 
selective agars, and strain type identified. The isolated fermentation supernatants were analysed 
for metabolite composition, and then used to treat HT29 cells, with assessment for DNA 
damage via comet assay, cells proliferation via DAPI, and cell cycle kinetics via propidium 
iodide staining with flow cytometry.  
 
Results: All 18 F. nucleatum specimens produced supernatants which induced DNA damage 
at levels above those observed for the carrier control. The range in associated DNA damage 
correlated most positively with the concentration of 4-cresol in the culture supernatant. The F. 
nucleatum supernatants increased the rate of cell proliferation after a 24-hour incubation in 
some strains, however, with strain specific effects observed on cell cycle kinetics.  
Conclusions: We demonstrate that supernatants from the fermentation of F. nucleatum contain 
metabolites which may be both genotoxic and growth promoting to intestinal tumour cells, this 
work potentially implicates tumour associated F. nucleatum in carcinogenic process, although 
further studies are needed. 
 
Key words:   F. nucleatum, IBD, colorectal cancer, HT29 cell line, DNA damage, cell 
proliferation and cell cycle. 
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5.2 Introduction  
Understanding passenger-driver relationships in relation to the colonic tumor-adherent 
microbiome is of interest. The emergence of culture independent techniques in microbiology 
has revealed an enriched presence of adherent F. nucleatum in colorectal carcinoma tissues [1, 
2]. Normally identified as an oral-commensal bacteria, the presence of F. nucleatum in tumour 
tissue raises questions about disease causality. The tumour microenvironment is characterised 
by a dysplastic mucosa, inflammation, occult blood and disruption to the colonic flow, it may 
therefore provide an ecological niche for adaptable bacteria [3, 4]. Alternatively, commensals 
from within the intestinal microbiota are implicated in inflammation, the production of 
genotoxins, and of metabolites which influence host cell behaviour through epigenetic 
mechanisms [5]. The role of individual members of the gut microbial community remains 
poorly defined, whilst developing an understanding of optimal microbiota composition for 
colon cancer prevention might allow for nutritional or pharmaceutical strategies which 
beneficially attenuate the microbiome [6]. Here, we focus on the specific role of F. nucleatum 
in colorectal cancer. Several studies have shown that the adherence of F. nucleatum in tumour 
samples may be specifically associated with a high level of microsatellite instability and the 
CPG island methylator phenotypes (CIMP) [9]. This association with a molecular sub type of 
intestinal tumour favours the causation/driver hypothesis, although a mechanistic explanation 
is needed.  
In the present study, we have obtained F. nucleatum strains previously isolated from tumour 
mucosa and kindly donated by Dr Alasdair Scott of Imperial College London to generate 
fermentation supernatants which were characterised for the presence of genotoxic and other 
metabolites, we then took these supernatants and applied them to the HT29 cell line to evaluate 
their influence on cell behaviour. Colonic genotoxicity is implicated as an exposure which may 
initiate the tumour process through the induction of loss or gain of function in tumour 
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suppressor or oncogenes respectively [7]. On the other hand, mitogenic exposures which lead 
to enhanced cell cycle kinetics may be considered tumour promoting [8, 9]. Thus our models 
were selected to represent different phases of the cancer process. 
 
5.3 Materials and methods 
28 F. nucleatum strains isolated from human tumour mucosa were gifted by Dr Alasdair Scott 
St Mary's Hospital, London, UK. Since F. nucleatum are often present in mixed cultures with 
other obligate anaerobes and with facultative species, the use of a selective medium is often 
necessary for their isolation. 18 F. nucleatum strains were isolated from tumour tissue and 
anaerobically cultured in a modified tryptic soy broth for 24 hrs. For purity of these strains, 
they were isolated on selective agars, and strain the type strain were identified through 
amplicon sequencing. The strains in this study were transferred into modified tryptic soy broth 
(tryptic soy broth with hemin (5mg/L), menadione (0.5mg/L) and, L-cysteine HCl 0.25mg). 18 
of the received strains proved culturable. These were transferred from broth into modified 
tryptic soya agar and incubated for several days anaerobically. Plates were inspected every day 
for growth.  From the agar plates individual colonies were aseptically transferred into hungate 
tubes (modified tryptic soya media) and incubated for 24 hours at 37 oC. After that, in a new 
fresh hungate tubes containing 10 mL of basal media (chapter 5-has the recipe of basal media) 
with peptone meat added as a protein source, the strain was transferred and incubated again for 
24 hrs at 37°C.   After 24 hours’ incubation, 1 mL of fermentation supernatant was transferred 
into an Eppendorf and stored in -20°C for further analysis. The remaining 9 mL transferred 
into a falcon tube, centrifuged (13,000 x g) for 10 minutes; the resulting supernatant was filter 
sterilised (0.22 mm filter Milipore) and transferred into 1 mL Eppendorf tubes. This experiment 
was conducted in triplicate. The fermentation supernatants of the strains were analysed by GC 
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MS to determine the concentrations of 4-cresol, phenol and indole and the short chain fatty 
acids (SCFAs), acetate, propionate, butyrate, isobutyrate, valerate, isovalerate and caproic acid.  
 
5.3.1 Chemicals 
4-cresol (CH3C6H4OH), Phenol (C6H6OH), indole (C8H7N), McCoy’s 5 A with L-glutamate, 
Trizma base, agarose, EDTA, Triton x100, hydrogen peroxide (H2O2), Fructooligosaccharides 
(FOS), ethidium bromide, propidium iodide (PI) and RNase A were purchased from Sigma-
Aldrich Ltd. (Dorset UK). Sodium chloride (NaCl) and potassium chloride (KCl) were supplied 
by Fisher Scientific (Loughborough, UK).  The HT29 colorectal adenocarcinoma cells line was 
obtained from the European Collection of Animal Cell Cultures (ECACC) (Salisbury, UK) and 
used between passages 70 and 85. Essential Medium (MEM), McCoy’s 5A with L-gulatumate, 
penicillin-streptomycin and fetal Bovine Serum (South America) were purchased from Biosera 
Ltd. (East Sussex, UK). Non-essential Amino Acid (NEAA) (Lonza group Ltd. Basel, 
Switzerland). Phosphate Buffered Saline (PBS), Trypsin-Versene and 
Ethylenediaminetetraacetic acid (EDTA) were purchased from Lonza group Ltd. (Basel, 
Switzerland). Non-essential Amino Acid (NEAA). Bacteriological growth medium 
supplements were obtained from Oxoid Ltd. (Basingstoke, Hants, U.K.). 
 
5.3.2 GC MS Analysis 
4-Cresol, phenol and indole analyses were carried out by automated headspace solid-phase 
microextraction (SPME). Then followed by gas chromatography-mass spectrometry (GC-MS), 
using an Agilent 110 PAL injection system and Agilent 7890 gas chromatograph with 59705C 
mass spectrometer (Agilent, Santa Clara, CA). The SPME fibre stationary phase was composed 
of 75 µm divinylbenzene/Carboxen™ on polydimethylsiloxane; Supelco, Bellefonte, PA). 
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Sample (0.1 mL) was placed in a 20-mL headspace vial with magnetic screw cap and 
PTFE/silicone septum (Supelco). The samples were then equilibrated for 10 minutes at 35 °C 
before being extracted for 30 min. Sample was agitated at 500 rpm (5 s on, 2 s off) during 
equilibration and extraction. After extraction, the contents of the fibre were desorbed onto the 
front of a Stabilwax-DA fused silica capillary column (30 m ´ 0.25 mm i.d, 0.50 mm film 
thickness; Restek, Bellefonte PA). The GC temperature program and the fibre desorption step 
commenced at the same time. During the desorption period of 45 s, the oven was held at 40 °C. 
After desorption, the oven was held at 40 °C for a further 255 s before heating at 4°C/min to 
260°C, where the temperature was maintained for 5 min. Helium was used as the carrier gas at 
a constant flow rate of 0.9 mL/min. The mass spectrometer operated in electron impact mode 
with an electron energy of 70 eV, scanning from m/z 20 to m/z 280 at 1.9 scans/s. 
 
5.3.3 Organic acid analysis (SCFAs)  
The main organic acid production was determined by Gas Chromatography (GC) (Hewlett 
Packard, UK). Samples from F.nucleatum fermentation were screened for the short-chain fatty 
acid (SCFA) concentrations using an acidification method adapted from Zhao, G et al [10]. 
Briefly fermentation samples were defrosted, vortexed and centrifuged for 5 minutes at 13,400 
x g. The samples were filtered using a 0.22 μm filter and sulfuric acid was added to bring the 
pH down to 2. 200 µl of the resulting sample solution and 50 µl of internal standard was added 
to the vial. The internal standard used in this experiment was 2-ethylbutyric acid (Aldrich) 
made to concentration of 100 mM in HPLC grade water.  The GC apparatus was calibrated for 
detection of acetate, propionate, iso-butyrate, butyrate, iso-valeric, valeric and caproic acid 
using standards of a range of concentrations (5mM – 50mM).  
Analysis was conducted using a HP 5890 series II GC system (Hewlett Packard, Palo Alto, 
Calif) with an FFAP, capillary fused silica packed column 25 m by 0.32 mm; filter thickness, 
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0.25µm (Macherey-Nagel, Düren, Gemany). Afterwards, the sample was injected into the 
column, which was maintained at 140°C for 5 minutes. Then the column temperature was 
increased over 5 minutes to 240°C. The calibrated organic acids were detected in the samples 
and the concentrations calculated. An external standard with known concentrations of SCFAs 
were injected after every 10 samples to maintain appropriate calibration. Finally, peaks were 
analysed and integrated using HP GC ChemStation Software, Hewlett Packard.  
 
5.3.4 Tissue culture  
The HT29 colorectal adenocarcinoma cell line was obtained from the European Collection of 
Animal Cell Cultures (ECACC) (Salisbury, UK). Cells were cultured in McCoy’s 5A media 
with L- gulatumate, 10% FBS 1% Pen Strep (Biosera Ltd. East Sussex, UK) and 1% NEAA 
(Lonza Ltd, Basel) The HT29 colorectal adenocarcinoma cell line was used to model the 
intestinal epithelium. Assays were performed between passages 45-55 with routine culture at 
37°C with 5% CO2 and 95% humidity and passage via trypsin-versene and PBS supplied by 
Lonza (Basel) McCoy’s 5A with L-gulatumate was used for HT29 and. The rest of the chemical 
has been used for HT29 cells line such as: Penicillin-Streptomycin and Fetal Bovine Serum 
(South America) (FBS) were purchased from Biosera Ltd. (East Sussex, UK). Phosphate 
Buffered Saline (PBS), Non-essential Amino Acid (NEAA), Trypsin-Versene and 
Ethylenediaminetetraacetic acid (EDTA) were purchased from Lonza group Ltd. (Basel, 
Switzerland). HT29 cells was cultured into tissue culture flasks as monolayers in the growth 
medium (containing 10% FBS, 1% Penicillin-Streptomycin and 1% NEAA).  
 
 
 
 
 164 
 
5.3.5 Comet Assay 
DNA damage was assessed using the single strand comet assay which is widely used to detect 
(SB) in single cells. HT29  cells line were seeded into separate T75 flasks at a concentration of 
1x106and maintained at 37oC in an atmosphere of 5% CO2 and 95% filtered air. Cells were 
treated, in tissue culture flasks at 80 % confluency, with filter sterilised supernatants from the 
F. nucleatum fermentations at 10% (v/v) in McCoy’s carrier culture medium with inactivated 
at 56°C Fetal Bovine Serum (FBS) and antibiotics at 37°C and 5% CO2 and applied directly to 
the cells for 24 hours. The negative control was composed of 10% v/v unfermented modified 
tryptic soy broth in carrier media. The carrier control was McCoy’s carrier culture medium (as 
described above). The positive control was additional H2O2 (75mM) applied in carrier media 5 
minutes before cell harvest. At 24 hours’ cells were washed and detached with trypsin, 
following centrifugation 300 x g for 3 minutes the supernatant was removed via aspiration, 
followed by washing with PBS for 1 minute. A positive control was prepared with untreated 
cells exposed to 7.5 mM hydrogen peroxide for 15 minutes prior to lysis. Cells were counted 
with trypan blue and adjusted to give a working concentration of 3x106 cells/ml, 20 µl of the 
cell suspension was re-suspended in 200µl of melted agarose and coated on to microscope 
slides, then left at 4C for 15 minutes. The slides were placed into lysis buffer (2.5M NaCl, 0.1 
EDTA, 0.01 M Tris and 1% (v/v) Triton x100) for 1 hour at 4C, and then washed 3 times with 
neutralising buffer (96.9 g Trizma base, 1 L water, adjusted to PH 7.5 with 6M HCl) for 5 
minutes before transfer to electrophoresis buffer (0.3M NaOH and 1mM EDTA). After 20 min 
at 4oC the slides were placed horizontally in an electrophoresis tank containing electrophoresis 
alkaline buffer to allow the DNA to unwind. Electrophoresis was run at 26V, 300mA for 40 
minutes in at 4C in the dark. The slides were then washed with neutralizing buffer (0.4 M 
Trizma base, pH 7.5) three times for 5 minutes each and then left for 5 minutes in 99% ethanol 
for 5 minutes, then left to dry overnight. Cells were stained with ethidium bromide (20ul/ml) 
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and kept for 15minutes in the dark. Images of DNA integrity were captured by fluorescence 
microscopy using the Kinetic image software, Komet 4.0 UK. One hundred randomly selected 
cells from each replicate slides were evaluated for DNA tail damage by an analyst blinded to 
the treatment. 
 
5.3.6 Cell Proliferation Assays 
HT29 cells were seeded into 96-well microplates (Thermo Fisher Scientific Inc., Roskilde, 
Denmark) at 1.5×104 cells/well and incubated at 37oC with 5% CO2 and 95% humidity for 24-
hours. Then the different F. nucleatum strain supernatants were removed via aspiration. Cells 
were permeabilised with 100 µl of ice-cold methanol and left to incubate at room temperature 
for 5 minutes. Methanol was removed carefully by pipette and plates were allowed to dry in a 
hood for 15 minutes. Afterwards, 100 µl of DAPI in PBS (70 µl of DAPI staining stock solution 
(3 mM) plus 10.43 ml of PBS) was added. Finally, cells were incubated in the dark for 30 
minutes at 37°C prior to measurement using a GENios microplate reader (TECAN Group Ltd., 
Männedorf, Switzerland) with absorbance and emission at 340 nm and 465 nm, respectively. 
 
5.3.7 Cell Cycle Assays 
Cell cycle progression was assessed considering the percentage of cells in phases Gap0/1 
(G0/1), Synthesis (S), Gap2/mitosis (G2/M) and apoptotic cells (sub G0/1) according to the 
fluorescent intensity of a PI nuclear stain, and based on the concentration of DNA within the 
cell [25]. HT29 cell cultures were treated at 2 x105 cells/well in two different 6 well plates at 
80% confluence. Each cell suspension was exposed to different F. nucleatum supernatant 10% 
v/v for 24 hours where the negative control was only cell suspension and the carrier control 
was added McCoy’s carrier culture medium. After removing treatments, the cells were washed 
with ice cold PBS and collected following the trypsin harvest of the monolayer and pelleting 
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by centrifugation at 377 x g for 3 minutes. The supernatants were discarded and then the cell 
tissues were resuspended in 200 μl ice cold PBS and fixed with 2 mL of fresh ice cold 70% 
ethanol. The cell pellets were stored in freezer at -20C until analysis.  
After chilling, the samples were centrifuged at 277 x g for 5 minutes and the supernatants 
discarded. The pellets were resuspended with 200 µl PBS before adding 25 µl of 1 mg/ml 
RNAse and the suspensions were then incubated at 37C for 30 minutes. 2.5 μl of 400 µg/ml 
of PI were added to bind DNA and were left to incubate for 30 min at room temperature in dark 
condition. Cells suspensions were adjusted to a final volume of 600 µl with PBS. The DNA 
content of 15,000 cells were then measured immediately via flow cytometry (BD Accuri C6 
flow cytometer, Germany). Analysis was performed using the Flow Jo software (Tree star Inc, 
Oregon, USA). 
 
5.4 Statistical Analysis  
All statistical analyses were carried out using the Statistical Package for Social Sciences (SPSS) 
version 22. All data have been carried in three biological replicates for each analysis. The data 
are presented as mean ±SEM. Gc Ms analysis for 4-cresol, phenol and indole and GC analysis 
for SCFA and BSCFA were analysed by LSD one-way ANOVA. Correlation coefficient runs 
for total SCFAs versus total metabolites of 4-cresol, phenol and indole. F. nucleatum stains 
supernatants as predictors of genotoxicity, cell proliferation and cell cycle were evaluated using 
linear regression models. P values <0.05 were considered to be statistically significant between 
the treatments. 
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5.5 Results 
 
5.5.1 Metabolite production: The production of proteolytic metabolites varied between the 
Fusobacterium isolates, although generally it remained low, with phenol reaching maximal 
observed concentrations of ~0.05 mM for one strain. This same strain produced the highest 
concentrations of 4-cresol and indole, each also in the 0.02-0.05 mM range. Most other 
fermentation supernatants were characterised by very low concentrations of these metabolites 
>0.01 mM (Figure 5.1). 
 There was similar variability in the production of SCFAs with a predominance of acetate 
observed in most but not all the fermentations. This was produced at concentrations between 0 
and 7 mM (Figure 5.2). There was no apparent correlation between the production of 
proteolytic and saccharolytic metabolites r = -0.25 and p = 0.35. 
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Figure 5.1: Proteolytic metabolite production, 4-cresol, phenol and indole (mM) from F. nucleatum fermentation supernatants. Values 
are means ±SEM with three replicates per sample. P values are calculated using one-way ANOVA, * indicate significant difference 
compare to carrier control with P<0.05
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 Figure 5.2: The production of SCFA and BSCFA (mM) by different F. nucleatum strains supernatants detected by gas chromatography 
(GC). Values are means ±SEM with three replicates per samples. P values are calculated using one-way ANOVA, * indicate significant 
difference compare to carrier control with P<0.05 
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5.5.2 Genotoxicity 
 
HT29 cell viability was maintained above 85 % after 24 hour exposure to fermentation 
supernatants at a 10% v/v concentration as assessed via DAPI staining. DNA damage was then 
assessed in HT29 cells via the COMET assay following a 24 hour exposure to the filter 
sterilised fermentation supernatant at 10% of the carrier media. The highest observed levels of 
DNA damage were reported for F. nucleatum isolates 7, 8, 9 and 10) Figure 5.4. However, 
fermentation supernatants from other F. nucleatum isolates were either only moderately or not 
at all more genotoxic than the negative control. The strongest metabolic correlate of 
fermentation genotoxicity was the 4-cresol concentration of the supernatant (r = 0.54, p = 
0.001), whereas phenol and indole concentrations did not significantly correlate with 
genotoxicity (r= 0.19, p = 0.074 and r = 0.117, p = 0.165 respectively). 
   
5.5.3 Cell proliferation and cell cycle kinetics 
HT29 cells were incubated with filter sterilised supernatants from the fermentations of the F. 
nucleatum isolates at 10% v/v of carrier medium for 24 hours, with cell cycle kinetics assessed 
via PI staining. Some of the fermentations, notably isolates # 4 and 5 that at lower exposures 
of up to 0.5 mM 4-cresol induced decreases in the abundance of cells in G0/G1 with a relative 
increase in the proportion of cells in S phase. In contrast the fermentation supernatants from 
isolates # 2, 6 and 14 induced increases in the proportion of cells in G0/G1 relative to the 
proportion of cells in S phase in cell line. This suggests a slight growth promoting effect at 
lower doses and G0/G1 growth arrest in response to genotoxic insult at higher doses. 
Changes in cell kinetics are a hallmark of carcinogenesis and may be considered tumour 
promoting.  
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Taken together we therefore report both the induction DNA damage and the encouragement of 
a more carcinogenic phenotype in cells cultured in vitro when exposed to 4-cresol. These 
observations were not deemed significant after adjustment for multiple testing p> 0.05.   
Figure 5.5. The strongest metabolite predictors of the abundance of cells in S phase were total 
metabolites (4-cresol, phenol and indole) r=0.162, p=0.243 
Neither the abundance of cells in G0/G1 or the abundance of cells in the S phase were correlated 
with genotoxicity r=0.083, p=0.763 
There were significant differences in the growth curves of the HT29 cells post exposure to the 
fermentation supernatants. Isolates # 9, 10, 12, 15 and 16 induced increases in total HT29 cell 
numbers to a much greater extent than the negative and the carrier control. The strongest 
metabolite predictors of cell proliferation were 4-cresol r= 0.630 p= 0.000. However, cell 
proliferation was not correlated with DNA damage-genotoxicity r= 0.066, p=0.290. 
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Figure 5.3: Genotoxic effect of different F. nucleatum strains supernatants for 24-hour incubation on the DNA strand breaks in HT29 
cells. Data shown represent the average of three independent experiment. Values are means ±SEM with three replicates per samples. P 
values are calculated using one-way ANOVA, * indicate significant difference compare to carrier control with P<0.05 
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 Figure 5.4:  Effect of F. nucleatum supernatants on HT29 cell proliferation after 24-hour incubation. Data shown represent the average 
of three independent experiment ±SEM with three replicates per sample. P values are calculated using one-way ANOVA, * indicate 
significant difference compare to carrier control with P<0.05 
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Figure 5.5: Cell cycle analysis of HT29 cells exposed with different types of Fusobacterium supernatant for 24-hour incubation. The 
percentage of cells in each phase of the cell cycle was determined using flow cytometry to quantify DNA content. Values are present in 
percentage with three replicates per sample. 
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5.6 Discussion 
Recent attention has turned to look at the role of F. nucleatum as a key microorganism in CRC. 
F. nucleatum is an invasive anaerobe linked to periodontitis, appendicitis and more recently 
inflammatory bowel conditions and CRC [11]. F. nucleatum strains have been isolated from 
the mucosa in colon tumours where they are shown to be present at much higher densities than 
in normal mucosa. Here, we have sought to address the potential influence these bacteria may 
have on tumour promotion and or initiation. Previous studies have used a single/isolate of F. 
nucleatum, to do similar work [12]. In this study, 18 different F. nucleatum CRC isolates used 
and assessed their potential influence on established in vitro models of carcinogenesis. 
First, we performed monoculture fermentations using modified basal media, to establish the 
typical end products of F. nucleatum metabolism. Then identified the production of 4-cresol, 
phenol, indole and SCFAs in these fermentation supernatants and demonstrated the 
genotoxicity and cytotoxicity of the fermentation supernatants from these isolates. The study 
observed that the isolates producing the highest concentrations of the metabolite, 4-cresol, 
induced the highest levels of genotoxic insult in colorectal cell lines. However, there may be 
other non-identified metabolites and small molecules with the potential to influence host 
physiology in our supernatants HT29. 
The average concentrations of the proteolytic metabolites 4-cresol, phenol and indole were 
0.0075 mM, 0.0063 mM and 0.0058 mM respectively, there were significant unexplained 
differences in the concentration of these metabolites between the isolates. In vivo proteins 
which escape digestion or absorption in the small intestine reach the colon [13] and are 
metabolised by the dominant proteolytic bacteria which can lead to the production of harmful 
metabolites [14, 15]. The presence of proteolytic products in our media, albeit at low levels, 
demonstrates usage of amino acids as substrate by the fusobacteria; additional amino acids may 
be available within the tumour environment in the form of blood. 
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Phenol and cresol are commonly identified in colonic fermentations and have been previously 
implicated as potential toxins. Indole is seen in faecal samples of healthy individuals and in 
patients with inflammatory bowel disease (IBD) [16].  The fusobacteria did produce SCFAs 
which are considered beneficial to host physiology,  and which  may enhance the mucosal 
barrier, improve immunity and provide metabolic fuel for the colonic epithelia [17]. Depending 
on the diet, the total concentration of SCFAs typically range between 70 to 140 mM in the 
proximal colon to 20 to 70 mM in the distal colon [18, 19]. This gradient in concentrations may 
account for anatomical differences in susceptibility to bowel diseases. The average 
concentration of SCFA produced by our isolates was acetate 2.1 mM, propionate is 0.43 mM, 
butyrate 0.46 mM, valerate 0.51 mM and caproic 0.9 mM .  However, in general it can be seen 
that most of the isolates produced SCFAs at levels not significantly different to that observed 
in unfermented media. Although some F. nucleatum isolates produced significant amounts of 
acetate when compared to the control, this was below what would be expected in a mixed gut 
culture fermentation with saccharolytic substrates [20] [21]. This is because in mixed culture 
fermentation (previous chapter) several bacteria are involved in metabolising the substrates 
whereas in the current chapter only one type of bacteria is involved. Yu et al., found that oral 
F. nucleatum were producing SCFAs as metabolic by-products, from saliva of patients with 
severe periodontal disease, which they argued increased histone acetylation and eventually 
contributed to the development of oral Kaposi's sarcoma in herpes patients [22]. In the gut less 
production of SCFA may lead to imbalance of the T regulatory and T effector cell, which are 
the function of control gut inflammatory response and diseases [12, 23].  
In the current study, SCFA were present in higher concentrations than 4-cresol, indole and 
phenol. The proteolytic metabolites were produced in relatively low concentration but may still 
be genotoxic as the samples with higher levels of these proteolytic metabolites led to greater 
DNA damage in the HT29 cell line (Figure 5.3). Indeed, there were isolate dependent 
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differences in supernatant genotoxicity which correlated most strongly with the concentration 
of 4-cresol, r = 0.54 and p< 0.001. However, phenol and indole were not significantly correlated 
with genotoxicity (r = 0.19 and p= 0.074, r = 0.12 and p= 0.165 respectively).   
Furthermore, there were significant differences in the growth curves of HT29 cells post 
exposure to the fermentation supernatants. Some isolates induced increases in total HT29 cell 
numbers to a much greater extent than the negative and the carrier control. The regression 
results showed a significant correlation between the 4-cresol and cell proliferation after 24-
hour incubation (r = 0.63, p < 0.000). But, cell proliferation was not correlated with 
genotoxicity r=0.066, p=0.290. Previously Yang, et al, found that F. nucleatum increased 
proliferation and invasive activities of CRC cell lines compared with control cells. Further, 
CRC cell lines pre-treated with F. nucleatum formed larger tumours, more rapidly, in mice than 
untreated cells [24].  
Several epidemiological studies have shown that F. nucleatum, is implicated as a pro-
inflammatory pathogen and has been found at higher abundance within IBD patients  and may 
be implicated in human colorectal cancer [25]. A study conducted by Castellarin et al. found 
F. nucleatum within a frozen tumour specimen was at a very high abundance compared with 
normal controls and therefore, they confirmed it as invasive bacteria [2]. Several other studies 
have found higher numbers of F. nucleatum in faeces of CRC patients compared to healthy 
controls [26] [27]. Whereas Kostic et al. [28] observed that F. nucleatum is enriched in 
colorectal adenomas and therefore may be involved in early tumorigenesis. However, they also 
showed that inflammation was not enhanced in F. nucleatum colonised Il10-/- mice compared 
to controls. The result from the current study showed some strains of F. nucleatum are not 
involved in increasing the genotoxic environment, whist others seemed capable of promoting 
a more genotoxic environment. More information on the location and the stage of the tumour 
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that the isolates were from could allow us to see if these differences had occurred for a reason; 
e.g. are Fusobacterium from advanced tumours more likely to produce genotoxins? 
Considering mechanisms that may be at play, Rubinstein et al., [29] found that FadA stimulates 
CRC cell growth by binding to E-cadherin and activating Wnt/ß-catenin signaling and 
differentially regulates the inflammatory and oncogenic responses. However, this stimulation 
is occurring in colorectal carcinoma cells because FadA binding to other types of cells does not 
stimulate cell growth. 
 
Importantly the results observed that F. nucleatum fermentation products can cause DNA 
damage and may induce human colonocytes to proliferate. However, these findings are not 
unique to F. nucleatum, and this work would be strengthened by evaluating other bacteria for 
their metabolic profiles and looking at other colorectal cell lines. Furthermore, the study 
performed a targeted analysis of fermentation supernatant metabolites, these may simply be 
correlates of other potential genotoxic, or cell cycle regulating, microbial products, a fuller 
interrogation of the microbial metabolome would therefore be welcome. 
Important questions remain to be answered about the host microbe relationship for F. 
nucleatum in CRC. Notably, the competitive performance of  F. nucleatum in mixed gut culture 
conditions with a medium representative of the tumour environment still needs to be 
established. Additionally research focussing on epigenetic interactions might help explain the 
observed selective preference of F. nucleatum for CIMP phenotype tumours.   
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5.7 Conclusions 
In summary, the study indicated that routine fermentation of F. nucleatum, isolated from the 
surface of colorectal tumours, produce several proteolytic end products, albeit in low 
concentrations. These have the capacity to influence mammalian cell physiology, either 
through inducing direct DNA damage, or by influencing cell proliferation. There are 
inconsistencies in the metabolic behaviour of the F. nucleatum isolates studied, and these need 
further investigation, however the results are intriguing and suggest potential mechanisms of 
Fusobacterium spp. involvement in colorectal carcinogenesis. From this work thus far we are 
unable to determine whether these isolates are likely to be acting as a driving or a passenger in 
CRC.  
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6. General Discussion and Conclusions 
6.1 Discussion 
The human intestines are home to billions of bacteria and their fermentation end products, 
including the genotoxic agent 4-cresol. Variation in microbiome functionality is modifiable by 
dietary substrates; as such it is likely that diet can be used to modulate host exposure to  
genotoxins, such as 4-cresol and therefore influence the risk of CRC [1-3]. There are few 
studies indicating a potential role of 4-cresol to colonic carcinogenesis [4], most previous 
studies exploring the role of the microbiota focus on sulphate or bile acid faecal-genotoxicity 
[5, 6], or butyrate-dependent mechanisms using saccharolytic fermentation to protect against 
cancer [7]. Thus, it seems that genotoxic microbial metabolites present in the colon may be 
implicated in carcinogenesis, can increase intestinal cell proliferation and or induce DNA 
damage in the epithelium [8-11]. Importantly, these factors could be impacted on by diet. In 
the current thesis the role 4-cresol plays in genotoxicty and factors influencing it’s production 
have been considered. The novelty of the current study focuses on less well characterised 
microbial metabolites present within the faecal stream, whilst considering their production in 
relation to the activity of an established tumour associated bacterial species.  
 
Within this thesis 4-cresol has been explored across a range of systems; to begin with, an 
intervention study was performed on a reasonably large cross-section of Omani adults (205).  
It was found that total self-reported protein intake was positively correlated with urinary 4-
cresol excretion (r=0.571, p = 0.030) described in Chapter 3. It is well known in the literature 
that colonic 4-cresol is absorbed and sulphated by the host prior to excretion. The current study 
therefore, hypothesised that its excretion in urine would reflect intestinal synthesis, and that 
this would be dependent on dietary protein intake. As such, the study results confirmed there 
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to be a correlation between total protein intake and production of 4-cresol this results is 
consistent with previous findings [12-14]. Several epidemiological studies, and case-control 
studies and others have tested similar hypotheses, however, the work in this thesis is the first 
to study these parameters in an Omani population. This study evaluates  the macronutrient 
intake of a large group (205) of study volunteers, monitoring BMI, blood pressure, physical 
activity along with blood biochemical analysis in (mmol/L) Magnesium, Glucose, Calcium, 
Phosphorous, Creatinine, Bile, Urea, Total protein, Albumin, Triglyceride, High density 
lipoprotein, Low density lipoprotein and Cholesterol. 
The majority of the studies agreed that there is a positive correlation between high protein 
intake and production of 4-cresol and risk of having colorectal cancer; whilst other failed to 
establish a definite conclusion. As the microbiota are producers of 4-cresol faecal microbial 
composition on a subset from within this cohort (n= 16) showed study subjects who reported 
consuming a higher protein diet, were found to have higher counts of total bacteria, 
Bacteriodes, Clostridium histolyticum group, Desulfovibrionales and Fusobacterium (p= 
0.024, 0.042, 0.007 and 0.022 respectively) when compared to high carbohydrate consumers. 
Therefore, competition between bacteria for substrates has a significant influence on the 
population within and the products that are generated. Thus a high protein intake will increase 
putrefactive bacteria and their fermentation products such as 4-cresol which may lead to 
increased CRC risk. This is the first study that has directly linked protein intake with the 
microbial community and 4-cresol, and as such helps to generate more information on the 
microbial groups modulated by a high protein diet and the link of these to 4-cresol. Such 
information is useful for determining the impact of large dietary-style choices of the 
microbiota, particularly when considering a high protein (meat) intake has been associated with 
elevated CRC risk.  
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In previous work by Moore, et al. on faecal specimens which obtained from 22 healthy 
Japanese from a rural, Japan, and 16 African (both low risk of colon cancer) and 15 Japanese-
Hawaiians and 17 Hawaiian and continental U.S. who consumed a western-type diet (both 
moderate to high risk of colon cancer). They found that the abundance of Bacteroides and 
Bifidobacterium was associated with increased risk of colon polyps, whereas Lactobacillus and 
Eubacterium aerofaciens were protective [15]. In contrast, in previous case-control studies the 
abundance of Clostridium, Roseburia, and other butyrate-producing bacteria and Eubacteria 
spp., may be reduced amongst cancer patients. The results of the current study support this 
notion that the microbial consortium is important in terms of risk factors of CRC – a factor that 
can be modulated by diet. As such this highlighting the potential to consider microbial 
modulation as a way of modulating cancer risk; as well as microbial groups that might be 
associated with negative effects of high protein consumption. 
 
The absolute production of 4-cresol was explored in faecal culture models of the human colon 
in order to evaluate potential in vivo exposures. The resultant in vitro gut fermentation 
supernatants were used to treat human colorectal cell line based models of carcinogenesis.  
 
In the second part of this thesis, the study focus was to understand the impact of protein on 4-
cresol production by the human microbiota and to evaluate its potential contribution to colonic 
genotoxicity. The novelty of this study in is that 4-cresol is less well characterised in the 
literature, thus this research focusses on the activities of this lesser studied metabolite. Many 
studies have looked to the phenols in general and have a very few works about 4-cresol 
genotoxicity and cytotoxicity. Within this chapter different protein sources were used to 
investigate their potential to be broken down to yield 4-cresol; this helps to identify whether 
all proteins are equal when considering dietary risks associated with CRC. Furthermore, in this 
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chapter two cell lines were used to detect the genotoxicity of 4-cresol on them. Followed by 
testing the cytotoxicity in cell proliferation and its effect on cell cycle; therefore generating end 
point data associated with CRC, linking, fermentation metabolites with cancer risk factors.  
 
 4-cresol is produced through the microbial metabolism of the amino acid tyrosine which, in 
the colon, may derive from exogenous or endogenous protein [16]. The batch culture results 
indicated the highest concentrations of 4-cresol were observed upon fermentation of high 
tyrosine with FOS (17 mM). This is well in excess of the 4-cresol concentrations reported in 
faecal samples (58ꞏ86 μmol/g) [17]. It is also in excess of the concentrations of 4-cresol which 
this study found to be cytotoxic. The batch culture fermentation models are limited by the lack 
of clearance of fermentation metabolites. In vivo 4-cresol would be cleared from the colonic 
lumen through either excretion in faeces or through absorption, they are also limited in that 
there is no replacement of substrate, thus the supply of tyrosine is quickly exhausted. To 
overcome that, in this model used perhaps artificially high levels of tyrosine. For these reasons, 
the study cautiously predict that these very high concentrations are not achievable in the colon 
of man. Nevertheless, the current data suggest a higher potential exposure to 4-cresol in the 
colon than previously considered. The other non-animal protein sources tested did not lead to 
as greater production levels of 4-cresol, indicating the source of protein is important when 
considering CRC risk. 
The optimal media for 4-cresol production contained tyrosine (0.3:100 w/w) and FOS (1.5:100 
w/w). This surprisingly produced more 4-cresol than tyrosine alone (0.3:100 w/w), it was 
hypothesised that the FOS would favour the growth of saccharolytic bacteria and inhibit 
proteolysis, however the additional substrate may have favoured total bacterial growth and 
consequently led to more 4-cresol. Furthermore, the high tyrosine diet and high tyrosine diet 
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with FOS media led to increases in the abundance of Clostridium histolyticum group at 24 
hours, a group often associated with proteolysis and negative effects. Therefore, mixed 
substrates somehow led to increased enhancement of this group – this data was not supported 
by the human study, whereby high carbohydrate was more protective of a high protein diet – 
i.e. leading to lower 4-cresol that high protein alone. As such, more in vitro work to explore 
how the microbiota are interacting is warranted.   
In vivo, high protein intake has previously been shown to stimulate the growth of proteolytic 
species such as Clostridium perfringens, and to reduce faecal counts of beneficial 
Bifidobacterium Anaerobes known to ferment aromatic amino acids include Bacteroides, 
Lactobacillus, Bifidobacterium, Clostridium and Peptostreptococcus [18]. The study utilised 
the fermentation supernatants from this model as treatments applied to cultured colonocytes to 
assess genotoxicity in the first instance, and influences on cell behaviour in the second instance. 
These supernatants were applied to cultured cells at a concentration of 10% v/v in carrier 
media; there was therefore a significant dilution of their metabolic load, nevertheless they 
showed a range of genotoxicities. In regression analysis the metabolite within these 
fermentation supernatants that best predicted genotoxicity was indeed 4-cresol (r= 0.775, p = 
0.002).    
Importantly the results showed that spiking of weakly genotoxic fermentation supernatants 
with 4-cresol enhanced their genotoxic potential. This strongly suggests that the 4-cresol within 
the fermentation supernatant is acting as a direct genotoxin rather than presenting as a proxy 
for unidentified metabolites. The results confirmed this genotoxicity using 4-cresol as a direct 
challenge in two different colonic cell lines and using two separate analysts (Grateful for the 
contribution of Piyarach Kullamathee who made the assessment of Genotoxicity in the Caco-
2  model).  There was a dose dependent increase in DNA damage with increasing 
191 
 
concentrations of 4-cresol reaching statistical significance at concentrations of 3 mM in both 
cells line (p= <0.05). 
Further, the 4-cresol was shown to influence cell cycle kinetics consistently across both cell 
lines in a dose dependent manner at lower exposures of up to 0.5 mM 4-cresol, the study results 
observed decreases in the abundance of cells in G0/G1 with a compensatory increase in the 
proportion of cells in S phase. Where at higher concentrations the proportion of cells in 
G0/G1increased significantly relative to the proportion of cells in S phase in both cell lines, 
suggesting a slight growth promoting effect at lower doses and G0/G1growth arrest in response 
to genotoxic insult at higher doses. 
As such, importantly this thesis highlights the importance of 4-cresol in impacting on the cell 
cycle, and being a major, protein fermentation contributor, to negatively impacting on cell 
cycle. 4-cresol has not been studied at length in this way, however, this research highlights 4-
cresol as a very important component for future investigation in CRC studies. 
Finally, this PhD thesis tested the ability of human tumour mucosa derived Fusobacterium 
nucleatem isolates for their ability to both synthesise 4-cresol and to influence in vitro models 
of carcinogenesis. F. nucleatum, which was particularly interesting as it is normally considered 
an oral commensal and not frequently observed in the healthy colon. F. nucleatum has begun 
to attract wider attention as several groups now report its presence on intestinal tumours [19]. 
This raises the question about its potential role in disease causation. The results suspected that 
it is perhaps present due to its competitive ability to colonise the environmental niche that is a 
colonic tumour, therefore, the study was conducted to assess its ability to produce potentially 
genotoxic metabolites and influence DNA damage.  
The 18 isolates were fermented in monoculture using a modified tryptic soy broth. The 
fermentation supernatants of these strains were analysed by GC-MS to determine the 
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concentrations of metabolites as in Chapter 5, the fermentation supernatants were used to treat 
HT29 cells line to assess their genotoxicity) via comet assays and their influence on cells 
proliferation and cell cycle kinetics.  
The results of this study found that the isolates were differentially genotoxic, again in a 
regression analysis; 4-cresol emerged as the biggest predictor of supernatant genotoxicity; 
however, the absolute concentrations of 4- cresol in these supernatants were much lower than 
in the mixed culture fermentations described in Chapter 4. Some of the F. nucleatum isolates 
produced supernatants, which increased HT29 cell proliferation after 24-hour incubation. 
There were considerable differences in activity between the isolates studied. Due to a lack of 
time and resources we were unable to confirm that all of the isolates were indeed F. nucleatum, 
for that we relied on the reporting of our clinical collaborators, given the different metabolite 
profiles to take this work further we need to address this.  This is a highly topical area of 
research, in an APC mouse model, F. nucleatum increased the tumour burden and infiltration 
of myeloid immune cells and pro-inflammatory markers [20], data which do suggest a role in 
disease causality.  
To take this work forward it is important to next establish whether there are aspects of the 
tumour environment that favour F. nucleatum growth, it would be good to assess this in mixed 
gut culture models using media enriched to represent the tumour condition. From observations 
whilst 4-cresol is produced in the isolates studied, there may be other unidentified genotoxins 
being produced, and therefore a fuller -omic based analysis would be beneficial. 
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6.2 Conclusions  
This work has considered potentially detrimental effects of diet on the metabolic activity of 
the gut microbiota; from the Omani study, the results found that high protein intakes were 
associated with elevated urinary 4-cresol, which could be increasing risk factors associated 
with non-communicable diseases such as CRC. The population described as undergoing the 
nutrition transition and the study therefore were intended to better understand nutritional 
issues in that community. Therefore, future nutrition awareness and health education should 
emphasise in the importance of healthy balanced diets (e.g. including RDA levels of fibre) 
and active lifestyles 
Furthermore, this thesis has increased the knowledge of the activity of 4-cresol in the gut, 
particularly in relation to DNA damage. This is a unique finding and emphasises the 
importance of this low concentration microbial metabolite may have a key role in the CRC 
process. The consumption of protein, specifically of meat origin, has been seen to be a key 
factor in 4-cresol production; microbial modulation; whilst also being linked to increased 
genotoxicity. Therefore, this thesis opens the door nicely to further dietary intervention and 
microbial manipulation studies to reduce 4-cresol levels and potential impact on markers 
associated with CRC. 
 
Finally, the preliminary work on F. nucleatum is topical, at this stage the results are uncertain 
as to why some but not all of the strains were genotoxic, whether or not they are passengers 
or drivers of the disease process remains unclear, but it is an exciting avenue of future 
research. In the immediate future we would hope to explore whether there are aspects of the 
tumour environment that favour F. nucleatum growth. 
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This work was funded by the Omani Ministry of Health. The Ministry of Health is in an 
excellent position to use this work to inform dietary intervention programs and guidelines for 
public health.   
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6.7 Future work 
The bigger picture is one of further development of data surrounding the relationship of 4-
cresol production with high protein intake and CRC.  
The results from this thesis showed that meat protein enhanced 4-cresol levels, which was seen 
to be genotoxic. Further exploration of this in an intervention study could explore the faecal 
microbiota and urinary metabolites of those on a high meat intervention; verses those on a 
vegetarian, high protein diet; to see the importance of the protein source within a population 
group. Additional intervention could be to then add a prebiotic to the diet to see if any changes 
observed, attributable to the diet were then adjusted by a food known to have a positive impact 
on the microbiota.   
The Fusobacterium work could be continued to look into if any specific substrates need to be 
present to increase genotoxic potential of these microorganisms. Furthermore, determining if 
Fusobacterium from different sites of the body and from different cancer stages behave in the 
same way. This would help to determine if this microbe actually has a role to play in CRC 
development. 
The human observational work described has established an important diet linked biobank for 
future work, and has helped characterise current food intake in Oman. The study generated a 
total of, 205 faecal, blood and urine samples stored in -80 °C.  These samples require a much 
more extensive look to investigate different correlations. For example, following on from this 
thesis a correlation could be sought between microbial populations and 4-cresol levels and 
dietary patterns from the whole cohort. Indeed, there is great potential for these samples to be 
used in a variety of ways to explore how different dietary patterns impact on human blood 
parameters and also microbial metabolites. This thesis is just the beginning and generates many 
new avenues for future research.  
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CONSENT FORM 
 
 
Title: Protein Fermentation, Gut Microbiota and Colorectal Cancer 
 
 
Name of Researchers: Eiman Al Hinai, Dr. Gemma Walton and Dr. Daniel Commane   
 
 
o I confirm that I have read and understood the information sheet for the above study 
o I understand that my participation is voluntary and I am free to withdraw at any time without 
my medical care being affected 
o I agree to take part in the study 
 
Name of the participant:……………………………………………………. 
 
Age:……………………………………. 
 
DOB:……………………………........... 
 
Gender: ……………………………….. 
 
Study #:……………………………….. 
 
Address:………………………………... 
 
Mobile #:………………………………. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature                                             date    
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PATIENT INFORMATION SHEET 
 
Background:  
Researchers have suggested that today the global leading causes of death are non-communicable 
diseases (NCDs) such as Colorectal cancer (CRC), which are rapidly becoming the leading causes 
of morbidity, and mortality among people. This increased burden of NCDs is could be prevented 
through primary prevention and early intervention strategies. The increase prevalence of NCDs in 
the Middle East countries, including Oman, is considered as an alarming phenomenon during 
adolescence, especially if synergized by adopting a sedentary lifestyle.  There is a need to explore 
the impact of diet and production of 4-cresol in the etiology of CRC among Omani population.  
 
What does it involve?  
We would ask you fill in a questionnaire, and if there were any queries, we would ask you to clarify. 
We would also collect blood, urine and faecal samples from you for preforming clinical, and 
biochemical analyses 
Is it harmful?  
Other a simple pin-prick for a blood test – no 
 
Is there any benefit for me?  
If we diagnose you with any chronic disease, you will be informed. The results of the study will be 
published and all the study participants will be acknowledged. Of course your identity would not be 
disclosed, however, should the study suggest a strong association, positive or negative, with any 
food / food content, you would be able to discuss the information with your doctor 
 
Is there any benefit for others?  
It would help us to work out the causes of non-communicable diseases in Oman  
 
What if I don’t want to take part?  
It will make no difference to the way we treat you. You will always get the best available 
treatment 
 
Who can I discuss this with further?  
You can discuss it further with Mrs. Eiman Al Hinai by email (alhinaie@yahoo.com ) 
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Protein Fermentation, Gut Microbiota and Colorectal Cancer 
 
Section 1: Personal Details 
 1.1 Name:……………………… 
 1.2 Date of Birth: …../…../…….      Age:…………..Years 
 1.3 Gender:  M………              F……..  
 1.4 Student number:……………………..Study number………………………………… 
 1.5 Date:…. /…… /2015   Mobile#:…………………Email:…………………………….. 
 1.6 Demographics Questions 
From which Governorate you are (circle the appropriate letter): 
1.6.1 Muscat              1.6.5 Al Batinah South          1.6.9 Al Batinah North  
1.6.2 Dhofar             1.6.6 Al Sharqiah South          1.6.10 Al Sharqiah North  
  1.6.3 Al Dakheliah          1.6.7 Al wusta            1.6.11 Al Dhaherah  
 1.6.4 Al Buraimi               1.6.8 Musandam  
 
 1.7 Marital status: 
(1) Single    (2) Married  
(3) Widowed   (4) Divorced 
 1.8 Work: 
(1) Working    (2) not working 
 1.9 Level of education:  
(1) Illiterate   (2) read and writes 
(3) Primary   (4) Preparatory 
(5) Secondary  (6) University 
 1.10 Income  level of the family (Omani Riyals):  
(1) 400 or less             (2) 400-800 
(3) 800-1200               (4) More than 1200 
 Are you related to any in the Institute? 
            (1) Yes                         (2) No 
 
Who is it?................................................ 
 
Section 2:  Anthropometric Measurements 
 2.1 Height  ….…………cm 
 2.2 Weight: …………...Kg 
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 2.3 Body Mass Index (BMI) = kg/m2 ………………………. 
 2.4 Waist circumference (WC): …………cm 
 2.5 Hip Circumference:……………cm 
 2.6 Waist/Hip ratio (WHR):……………… (>1 or < 1 or = 1) 
 2.7  Body Fat distribution: 
 2.7.1 Visceral fat (using TANITA scale)………………….. 
 2.7.2 Subcutaneous fat (using skin fold caliper)…………... 
 2.7.3 Body fat % (using TANITA scale)………………….. 
Section 3: Blood pressure measurement: 
           3.1 Systolic and Diastolic blood pressure…………………….. 
Section 4: Life Style Factors:  
4.1 Please tick those boxes that relate to your present diet: 
4.1.1 Mixed food diet (animal and vegetable sources)                
4.1.2  Vegetarian                                                                          
4.1.3  Salt restriction                                                                    
4.1.4  Fat restriction                                                                     
4.1.5  Starch/carbohydrate restriction                                                  
4.1.6  Calorie restriction                                                              
4.1.7  Other dietary plans, please                                                                     
    Detail :
………………………………………………………………………………………………………
……………………………………………………………………………………………………… 
 
4.2 Physical activity-related energy expenditure: 
4.2.1 (P2):  In a typical week, on how many days do you do vigorous intensity activities as 
part of your work? 
 
4.2.2 (P3): How much time do you spend doing vigorous-intensity activities at work on a 
typical day? 
 
4.2.3 (P5): In a typical week, on how many days do you do moderate intensity activities as 
part of your work? 
 
4.2.4 (P6): How much time do you spend doing moderate-intensity activities at work on a 
typical day? 
 
4.2.5 (P8): In a typical week, on how many days do you walk or bicycle for at least 10       
minutes continuously to get to and from places? 
4.2.6 (P9): How much time do you spend walking or bicycling for travel on a typical day? 
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4.2.7 (P11): In a typical week, on how many days do you do vigorous intensity sports, fitness 
or recreational (leisure) activities? 
 
4.2.8 (P12): How much time do you spend doing vigorous-intensity sports, fitness or 
recreational activities on a typical day? 
 
4.2.9 (P14): In a typical week, on how many days do you do moderate intensity sports, fitness 
or recreational (leisure) activities? 
 
4.2.10 (P15): How much time do you spend doing moderate-intensity sports, fitness or 
recreational (leisure) activities on a typical day? 
 
       4.3 Smoking: 
       (1) Smoking    (2) not smoking 
     If yes:  
 Smoking duration: …………………………………….. 
 Types of smoking: …………………………………….. 
 
 4.4 Drinking: 
         (1) Drinking   (2) not Drinking 
      If yes:  
 Drinking quantity: ………………………………………. 
 Types of Drinks: ………………………………………… 
Section 5: History of Intake of Vitamins and Minerals Supplementation:  
5.1 Iron  
                (1) Yes                         (2) No 
If yes: 
5.1.1 What supplementation you are taking? Iron or Iron with other combination  
5.1.2 What is the dose of the supplementation?................../ day? 
5.1.3 How long you have been taking the supplementation?............................................ 
5.1.4 Reasons for taking the 
supplemenation?................................................................................................................ 
5.2 Calcium  
                (1) Yes                         (2) No 
If yes: 
5.2.1 What supplementation you are taking? Calcium  or Calcium with other combination  
5.2.2 What is the dose of the supplementation?................../ day? 
5.2.3 How long you have been taking the supplementation?............................................ 
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5.2.4 Reasons for taking the 
supplemenation?................................................................................................................ 
 
5.3 Vitamin D 
                (1) Yes                         (2) No 
If yes: 
5.3.1 What supplementation you are taking? Vitamin D  or with other combination  
5.3.2 What is the dose of the supplementation?................../ day 
5.3.3 How long you have been taking the supplementation?............................................ 
5.3.4 Reasons for taking the 
supplemenation?................................................................................................................ 
5.4 Vitamin B12 
                (1) Yes                         (2) No 
 
5.4.1 What supplementation you are taking? Vitamin B12  or with other combination  
5.4.2 What is the dose of the supplementation?................../ day? 
5.4.3 How long you have been taking the supplementation?............................................ 
5.4.4 Reasons for taking the 
supplemenation?............................................................................................................... 
 
5.5 Multivitamin intake 
                (1) Yes                         (2) No 
If yes: 
5.5.1 What supplementation you are taking? …………………………………………… 
5.5.2 What is the dose of the supplementation?................../ day 
5.5.3 How long you have been taking the supplementation?............................................ 
5.5.4 Reasons for taking the 
supplemenation?................................................................................................................ 
 
5.6 Folate intake 
            (1) Yes                         (2) No 
If yes: 
5.6.1 What supplementation you are taking? Vitamin D  or with other combination  
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5.6.2 What is the dose of the supplementation?................../ day 
5.6.3 How long you have been taking the supplementation?............................................ 
5.6.4 Reasons for taking the 
supplemenation?................................................................................................................ 
               (1)< 1 month                (2) 1- 2 months 
               (3)   > 2 months            (4) Irregular supplementation] 
               (5)   Didn’t take supplementation 
 
5.7 Over counter nutritional supplements (Men and Women) 
            (1) Yes                         (2) No 
If yes: 
5.7.1 What supplementation you are taking?.....................................................................  
5.7.2 What is the dose of the supplementation?................../ day? 
5.7.3 How long you have been taking the supplementation?............................................ 
5.7.4 Reasons for taking the supplemenation?................................................................... 
 
5.8 Fish Oil 
                (1) Yes                         (2) No 
If yes: 
5.8.1 What type of fish oil you are taking? Alone  or fish oil with other combination  
5.8.2 What is the dose of the supplementation?................../ day? 
5.8.3 How long you have been taking the supplementation?............................................ 
5.8.4 Reasons for taking thesupplemenation?................................................................... 
Dietary supplements are vitamins, minerals, herbs, and many other products. They can come as 
pills, capsules, powders, drinks, and energy bars. Some supplements may help to assure that you 
get an adequate dietary intake of essential nutrients 
 
Section 6: Disease Status: 
6.1   Have you been diagnosed for diabetes? 
         1. Yes                                          2. No                                                          
6.2   Are you diabetic?  
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         1. Yes                                          2. No                                                          
   If yes:  
What type of medication you are taking?.......................................................................................... 
  
6. 3 Do you have any cardiovascular diseases? 
         1. Yes                                          2. No   
   If yes:  
What type of medication you are taking?.......................................................................................... 
 
Section 7: Family History: 
7.1 Family history of Diabetes: 
            1. Yes                                          2. No   
 
7.2 Family history of Hypertension:  
             1. Yes                                        2. No  
    
7.3 Family history of Cardiovascular Diseases (CVD): 
          1. Yes                                             2. No 
   If yes:  
 Types of CVD: 
7.3.1 Ischemic Heart Disease:  1. Yes                                          2. No   
7.3.2 Coronary Heart Disease: 1. Yes                                          2. No   
7.3.3 Stroke:                             1. Yes                                          2. No   
 
7.4 Family history of Obesity: 
          1. Yes                                             2. No 
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 Food Frequency Questionnaire 
  Vegetables  Serving size Never A few 
times  
1-2 / 
month 
1-2 /wk 3-4 /wk 5-6 
/wk 
1-3/ 
day 
4-5/ 
day 
6+/ 
day 
Quantity 
1 Broccoli (ﻂﻴﺒﻧﺮﻘﻟﺍ) 1/2 cup (40g)                    
2 Cabbage (ﻑﻮﻔﻠﻣ) 1/2 cup (40g)                    
3 Carrot (ﺭﺰﺟ) 1/2 cup(40g)                    
4 Cauliflower (ﻂﻴﺑﺎﻧﺮﻗ) 1/2 cup(40g)                    
5 Chili (ﻞﻔﻠﻓ) 1/2 cup(40g)                    
6 Cucumber (ﺭﺎﻴﺧ) 1/2 cup(40g)                    
7 Eggplant (ﻥﺎﺠﻧﺫﺎﺑ) 1/2 cup(40g)                    
8 Garlic (ﻡﻮﺛ) yes/ No                    
9 Green onion (ﺮﻀﺧﺃ ﻞﺼﺑ) 1/2cup(40g)                    
10 Green pepper (ﻮﻠﺣ ﻞﻔﻠﻓ) 1/2cup(40g)                    
11 Okra  (ﺔﻴﻣﺎﺑ) 1/2cup(40g)                    
12 Lettuce (ﺲﺧ) 1 cup(40g)                    
13 Mixed vegetables, raw, 
cooked (ﺔﻠﻜﺸﻣ ﺓﺮﻀﺧ) 
1/2 cup(40g)                    
14 Onions (raw or cooked) 
(ﻞﺼﺑ) 
1/2 cup(40g)                    
15 Potato, mashed, boiled or 
baked French fries (ﺎﻁﺎﻄﺑ) 
1/2 cup(40g)                    
16 Spinach (ﺦﻧﺎﺒﺴﻟﺍ) 1 cup(40g)                    
17 Sweet potatoes (ﻝﺍﺪﻨﻓ) 1/2 cup(40g)                    
18 Olive (green-Black) (ﻥﻮﺘﻳﺯ) 1/2 cup(40g)                    
19 Tomatoes (ﻢﻁﺎﻤﻁ) 1/2 cup(40g)                    
20 (Sweet) Corn 1/2 cup(40g)                    
Fruits
21 Apple (ﺡﺎﻔﺗ) 1/2 cup(40g)                    
22 Banana (ﺯﻮﻤﻟﺍ) 1/2 cup(40g)                    
23 Dates 
(Ratab/tamar)(ﺮﻤﺗ/ﺐﻁﺭ) 
1/4 cup(20g)                    
24 Grapes (ﺐﻨﻋ) 1/2 cup(40g)                    
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  Serving size Never A few 
times  
1-2 / 
month 
1-2 /wk 3-4 /wk 5-6 
/wk 
1-3/ 
day 
4-5/ 
day 
6+/ day Quantity 
25 Guava (ﺔﻓﺍﻮﺟ) 1/2 cup(40g)           
26 Kiwi (ﻱﻮﻴﻛ) 1/2 cup(40g)           
27 Mango (ﻮﺠﻧﺎﻣ) 1/2 cup(40g)           
28 Melon (ﻡﺎﻤﺷ) 1/2 cup(40g)           
29 Orange (ﻝﺎﻘﺗﺮﺑ) 1/2 cup(40g)           
30 papaya (ﻱﺎﻔﻴﻓ) 1/2 cup(40g)           
31 Peach (ﺥﻮﺧ) 1/2 cup(40g)           
32 Pears (ﻯﺮﺜﻤﻛ) 1/2 cup(40g)           
33 Pomegranate (ﻥﺎﻣﺭ) 1/2 cup(40g)           
34 Watermelon (ﺦﻴﻄﺑ) 1 piece 
/(40g)3-4 cm 
          
Traditional Omani Dishes 
 
35 Arsiya chicken (ﺝﺎﺟﺩ ﺔﻴﺳﺮﻋ) 1/2 cup(40g)           
36 Arsiya meat (ﻢﺤﻟ ﺔﻴﺳﺮﻋ) 1/2 cup(40g)           
37 Beans 1/2 cup(40g)           
38 Beriani chicken (ﺝﺎﺟﺩ ﻲﻧﺎﻳﺮﺑ) 1/2 cup(40g)           
39 Beriani fish (ﻚﻤﺳ ﻲﻧﺎﻳﺮﺑ) 1/2 cup(40g)           
40 Beriani meat (ﻢﺤﻟ ﻲﻧﺎﻳﺮﺑ) 1/2 cup(40g)           
41 Chicken Soup (ﺝﺎﺟﺩ ﺏﻮﺳ) 1/2 cup(40g)           
42 Chickpeas (hummus) (ﺺﻤﺣ) 1/2 cup(40g)           
43 Harees chicken (ﺝﺎﺟﺩ ﺲﻳﺮﻫ) 1/2 cup(40g)           
44 Harees meat (ﻢﺤﻟ ﺲﻳﺮﻫ) 1/2 cup(40g)           
45 Kidney beans (ﻝﻮﻓ) 1/2 cup(40g)           
46 Lentils (ﺱﺪﻋ) 1/2 cup(40g)           
47 Pasta (spaghetti, macaroni, 
noodles,  
(ﺔﻧﻭﺮﻜﻌﻣ) 
1/2 cup(40g)           
48 Makboos chicken ( ﺱﻮﺒﻜﻣ
ﺝﺎﺟﺩ) 
 1/2 cup(40g)           
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  Serving size Never A few 
times  
1-2 / 
month 
1-2 /wk 3-4 /wk 5-6 
/wk 
1-3/ 
day 
4-5/ 
day 
6+/ 
day 
Quantity 
49 Makboos meat (ﻢﺤﻟ ﺱﻮﺒﻜﻣ) 1/2 cup(40g)           
50 Meat Soup (ﻢﺤﻟ ﺏﻮﺳ) 1/2 cup(40g)           
51 Pizza 1 pc           
52 Qabooli chicken ( ﻲﻟﻮﺒﻗ
ﺝﺎﺟﺩ) 
1/2 cup(40g)           
53 Qabooli fish (ﻚﻤﺳ ﻲﻟﻮﺒﻗ) 1/2 cup(40g)           
54 Qabooli meat (ﻢﺤﻟ ﻲﻟﻮﺒﻗ) 1/2 cup(40g)           
55 Saloona chicken ( ﺔﻧﻮﻟﺎﺻ
ﺝﺎﺟﺩ) 
1/2 cup(40g)           
56 Saloona fish(ﻚﻤﺳ ﺔﻧﻮﻟﺎﺻ) 1/2 cup(40g)           
57 Saloona meat(ﻢﺤﻟ ﺔﻧﻮﻟﺎﺻ) 1/2 cup(40g)           
58 Samosa (ﺔﺳﻮﺒﻤﺳ)    2 small / 1 
big piece(60g) 
          
59 Thareed chicken (ﺝﺎﺟﺩ ﺪﻳﺮﺛ) 1/2 cup(40g)           
60 Thareed meat (ﻢﺤﻟ ﺪﻳﺮﺛ) 1/2 cup(40g)           
61 White Rice (boiled or 
cooked w fat) (ﺾﻴﺑﺃ ﺯﺭ ) 
 
1/2 cup(40g)           
62 Grains (wheat, oats, etc…) 1/2 cup(40g)           
Breads 
 
63 Brown Toast bread( ﺖﺳﻮﺗ
ﺮﻤﺳﺃ) 
  1 pc /25g           
64 Burger bread (ﺮﺟﺮﺑ ﺰﺒﺧ) 1/2 bun(40g)           
65 Chapati bread (ﻲﺗﺎﺒﺷ ﺰﺒﺧ) 1slice(40g)           
66 Lebnani bread -brown( ﺰﺒﺧ
ﺮﻤﺳﺃ ﻲﻧﺎﻨﺒﻟ) 
1slice(40g)           
67 Lebnani bread-white ( ﺰﺒﺧ
ﺾﻴﺑﺃ ﻲﻧﺎﻨﺒﻟ) 
1slice(40g)           
68 Parata (ﺎﺗﺍﺭﺎﺑ)  1/2 slice(40g)           
69 Rekhal (ﻝﺎﺧﺭ) 1 slice(40g)           
70 Salalah bread (ﺔﻟﻼﺻ ﺰﺒﺧ) 1 slice(40g)           
71 Tanoor Bread (ﺭﻮﻨﺗ ﺰﺒﺧ) 1/2 slice(40g)           
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  Serving size Never A few 
times  
1-2 / 
month 
1-2 /wk 3-4 /wk 5-6 
/wk 
1-3/ 
day 
4-5/ 
day 
6+/ 
day 
Quantity 
72 Unspecified bread (ﻉﺍﻮﻧﺃ 
ﻯﺮﺧﺃ) 
1 slice (40g)           
73 White Toast bread(ﺖﺳﻮﺗ 
ﺾﻴﺑﺃ) 
1 slice(40g)           
Meats, Milk, Dairy products and Nuts 
 
74 Almonds (ﺯﻮﻟ) 1/2 oz (14g)           
75 Cashew (ﻭﺯﺎﻛ) 1/2 oz (14g)           
76 Peanuts (ﻲﻧﺍﺩﻮﺴﻟﺍ ﻝﻮﻔﻟﺍ) 1/2 oz (14g)           
77 Pistachio (ﻖﺘﺴﻓ) 1/2 oz(14g)           
  78 Fish (cooked) (ﺥﻮﺒﻄﻣ ﻚﻤﺳ) 
 
     2oz (56g)           
79 Sea foods (squid, prawn,  
etc…) 
½ cup (40g)           
80 Tuna (canned) (ﺔﺒﻠﻌﻣ ﺔﻧﻮﺗ) 2 oz(56g)           
81 Meat (lamb) (Mutton)( ﻢﺤﻟ
ﻥﺄﻀﻟﺍ) 
2 oz(56g)           
82 Luncheon meats: salami, 
turkey, mortadella 
1 slice(40g)           
83 Saudages, not dogs….. 1 item (30g)           
84 Chicken  (ﺝﺎﺟﺩ) 2 oz(56g)           
85 Cheddar (ﺭﺪﻴﺷ ﺔﻨﺒﺟ)  2 oz(56g)           
86 Cream cheese(ﺓﺪﺸﻘﻟﺍ ﻦﺒﺟ) 2 oz(56g)           
87 Sliced cheese (ﻦﺒﺠﻟﺍ ﺢﺋﺍﺮﺷ) 2 oz(56g)           
88 Milk (whole milk) ( ﺐﻴﻠﺣ
ﻢﺳﺪﻟﺍ ﻞﻣﺎﻛ) 
1 cup (120g)           
89 Low fat or skimmed milk 1 cup (120g)           
90 Milk w chocolate ( ﺐﻴﻠﺣ
ﻪﺗﻼﻛﻮﺸﻟﺎﺑ) 
1 cup(120g)           
91 Milk w fruits (ﻪﻛﺍﻮﻔﻟﺎﺑ ﺐﻴﻠﺣ) 1 cup(120g)           
92 Yogurt (plain) (ﺏﻭﺭ) 1 cup(120g)           
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  Serving size Never A few 
times  
1-2 / 
month 
1-2 /wk 3-4 /wk 5-6 
/wk 
1-3/ 
day 
4-5/ 
day 
6+/ 
day 
Quantity 
93 Labneh 2 oz(56g)           
94 Egg (scrambled, boiled, 
omelet)(ﺾﻴﺑ) 
1 egg (50g)           
Beverages 
 
95 Coffee (Omani) (brewed) (ﺓﻮﻬﻗ) 1 cup(120g)           
96 Instant coffee (Nescafe) (ﻩﻮﻬﻗ 
ﺔﻌﻳﺮﺳ ﺮﻴﻀﺤﺘﻟﺍ) 
1 cup(120g)           
97 Tea w milk (ﻱﺎﺷ ﺐﻴﻠﺤﻟﺎﺑ) 1 cup(120g)  
 
         
98 Tea w/o milk (ﻱﺎﺷ ﻥﻭﺪﺑ ﺐﻴﻠﺣ) 1 cup(120g)  
 
         
99 Soft Drinks  1 cup(120g)  
 
         
100 bottled or canned fruit juices  1 cup(250g)  
 
         
Sandwiches 
 
101 Egg sandwich (ﺔﺸﻳﻭﺪﺳ ﺾﻴﺑ)  1 sandwich  
 
         
102 Cheese sandwich (ﺔﺸﻳﻭﺪﻨﺳ ﻦﺒﺟ)  1 sandwich           
103 Chicken sandwich (ﺔﺸﻳﻭﺪﻨﺳ ﺝﺎﺟﺩ)  1 sandwich           
104 Falafel sandwich (ﺔﺸﻳﻭﺪﻨﺳ ﻞﻓﻼﻓ)  1 sandwich           
105 Cheese burger (ﺔﺸﻳﻭﺪﻨﺳ ﺮﺟﺮﺑ 
ﻦﺒﺠﻟﺎﺑ) 
 1 sandwich           
106 Chicken fillet (ﺔﺸﻳﻭﺪﻨﺳ ﻪﻴﻠﻴﻓ ﺝﺎﺟﺩ)  1 sandwich           
107 Fish fillet (ﺔﺸﻳﻭﺪﻨﺳ ﻪﻴﻠﻴﻓ ﻚﻤﺳ)  1 sandwich           
Dessert & snacks 
 
108 Apple pie (ﺓﺮﻴﻄﻓ ﺡﺎﻔﺗ)  2 oz (56g)           
109 Popcorn ½ cup (40g)           
110 Biscuit (ﺖﻳﻮﻜﺴﺑ)  15g (piece)           
214 
 
 
    Serving size Never A few 
times  
1-2 / 
month 
1-2 /wk 3-4 /wk 5-6 
/wk 
1-3/ 
day 
4-5/ 
day 
6+/ 
day 
Quantity 
111 Cake (sponge) (ﻲﺠﻨﻔﺳﺍ ﻚﻌﻛ) 2 oz(56g)                    
112 Cheese cake (ﻦﺒﺠﻟﺍ ﺔﻜﻌﻛ) 80g                    
113 Croissant (ﻥﻮﺳﻭﺮﻛ) 
1 
croissant(120g) 
                   
114 Custard (ﺮﺘﺴﻛ) 150g                    
115 Date pi (ﺮﻤﺗ ﺓﺮﻴﻄﻓ) 80g                    
116 Donuts (ﺖﻧﻭﺩ) 2 oz(56g)                    
117 Luqaimat (ﺕﺎﻤﻴﻘﻟ) 2 oz(56g)                    
118 Omani Halwa (ﺔﻴﻧﺎﻤﻋ ﻯﻮﻠﺣ) 
1 oz=3TAS 
(28g) 
                   
119 Pancake (ﺓﺮﻴﻄﻓ) 40g                    
120 Potato chips (  ﺢﺋﺍﺮﺷﺎﻁﺎﻄﺒﻟﺍ ) 30g                    
121 Pudding (ﻎﻨﻳﺩﻮﺑ) 150g                    
122 Sweets/ chocolate/ candy (ﺕﺎﻳﻮﻠﺣ) 46g                    
123 
Arabic sweet, baklawah, 
konafah,mamaol…. 1 items (40g) 
                   
124 Honey and Jam 1 TES (5g)                    
125 
Breakfast Cereals, cornfleks, 
suger coated cereal….etc ½ cup (40g) 
                   
Fast Food 
 
126 Pizza (ﺍﺰﺘﻴﺑ) 1 pc                    
127 KFC/ Pizza Hut/ McDonald's 1 sandwich                    
128 fatiyer 1 pc                    
